Unnamed: 0,title,date,stock,sentiment
175345.0,"UbiVac Reports Trial Collaboration With Bristol Myers To Evaluate Safety, Tolerability, Prelim. Efficacy Of Co.'s DPV-001 Cancer Vaccine",2020-06-09 11:01:00-04:00,BMY,negative
175346.0,Jounce Therapeutics Regains Worldwide Rights To JTX-8064 From Bristol Myers Squibb,2020-06-04 08:06:00-04:00,BMY,neutral
175347.0,Traders Share Their Health Care Picks,2020-06-03 17:17:00-04:00,BMY,positive
175348.0,"The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study",2020-06-03 07:39:00-04:00,BMY,negative
175349.0,Bristol Myers Squibb Highlights New Data Reinforcing 'Improved and Durable Clinical Responses of Orencia in Moderate-to-Severe Early Rheumatoid Arthritis Patients with Autoantibodies Linked to More Severe Disease ',2020-06-03 07:00:00-04:00,BMY,positive
175350.0,l Myers Squibb Announces Topline Results From Pivotal Phase 3 True North Trial Evaluating Zeposia In Moderate to Severe Ulcerative Colitis; Study Met Primary Endpoint,2020-06-02 07:00:00-04:00,BMY,positive
175351.0,Compugen Announces FDA Clearance Of IND Application For Phase 1/2 Triple Combination Study Of COM701 With Bristol Myers Squibb's Opdivo (Nivolumab) And TIGIT Inhibitor,2020-06-01 07:11:00-04:00,BMY,negative
175352.0,"Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA, an Oral Treatment for Relapsing Forms of Multiple Sclerosis",2020-06-01 07:01:00-04:00,BMY,neutral
175353.0,"Benzinga's Bulls And Bears Of The Week: Amazon, Disney, Netflix And More",2020-05-30 13:47:00-04:00,BMY,positive
175354.0,"The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight",2020-05-30 09:25:00-04:00,BMY,neutral
175355.0,Bristol Myers CEO To Appear On CNBC's 'Squawk On The Street' At 9:45 a.m. EDT,2020-05-29 09:14:00-04:00,BMY,neutral
175356.0,"Cramer Shares His Thoughts On Teva, Oxford Industries And More",2020-05-29 06:40:00-04:00,BMY,positive
175357.0,"'metformin recalls are expected as early as this week. The carcinogen found in the diabetes drug is NDMA, the same one that forced recalls of millions of blood pressure pills and Zantac' -Tweet From Bloomberg Health Policy Reporter",2020-05-27 17:24:00-04:00,BMY,negative
175358.0,Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold $15B In Peak Sales Potential,2020-05-27 11:45:00-04:00,BMY,positive
175359.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,BMY,positive
175360.0,Bristol Myers Squibb Receives European Commission Approval For Zeposia (ozanimod) For Treatment Of Adult Patients With Relapsing Remitting Multiple Sclerosis With Active Disease,2020-05-27 06:59:00-04:00,BMY,positive
175361.0,Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb; BMS Will Make $65M Upfront Payment Including $15M In Equity Investment,2020-05-26 16:33:00-04:00,BMY,neutral
175362.0,"European Medicines Agency Validates Bristol Myers Squibb's Applications For Idecabtagene Vicleucel (Ide-cel, bb2121) And CC-486",2020-05-22 06:59:00-04:00,BMY,positive
175363.0,Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market,2020-05-20 08:33:00-04:00,BMY,negative
175364.0,Telemedicine A COVID-19 Winner,2020-05-19 16:46:00-04:00,BMY,positive
175365.0,Bristol Myers Squibb Press Release Confirms FDA Approval Of  Opdivo+ Yervoy,2020-05-15 15:57:00-04:00,BMY,positive
175366.0,"Bristol Myers Shares At Session High, Up 2.5%; Hearing FDA Okayed Opdivo, Yervoy Combo For Metastatic Non Small Cell Lung Cancer",2020-05-15 14:28:00-04:00,BMY,negative
175367.0,FDA  Approves Bristol Myers Squibb's Pomalyst (pomalidomide) For AIDS-Related And HIV-Negative Kaposi Sarcoma,2020-05-15 08:53:00-04:00,BMY,positive
175368.0,"Bristol Myers Reports 3-Year Data From CheckMate -277 Confirm Durable, Long-Term Survival Benefits For Opdivo Plus Yervoy vs Chemo",2020-05-13 17:04:00-04:00,BMY,positive
175369.0,"Bristol Myers, bluebird bio Will Present Updated Results From Pivotal KarMMa Study Of Ide-cel In Relapsed and Refractory Multiple Myeloma Patients at ASCO On May 29",2020-05-13 17:03:00-04:00,BMY,neutral
175370.0,Bristol Myers Reports Opdivo Plus Yervoy With Limited Chemo Significantly Improves Overall Survival vs Chemo Alone,2020-05-13 17:01:00-04:00,BMY,neutral
175371.0,"AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst",2020-05-13 12:03:00-04:00,BMY,neutral
175372.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,BMY,neutral
175373.0,"Bristol Myers Squibb And  bluebird bio Say Upon Preliminary Review, FDA Determined That The Chemistry, Manufacturing And Control Module Of The BLA For Idecabtagene Vicleucel Requires Further Detail To Complete The Review",2020-05-13 07:00:00-04:00,BMY,positive
175374.0,Bluebird Bio Announces Amended BCMA CAR-T Collaboration Agreement; Bristol Myers Squibb To Buy Out Its Ex-US Milestone And Royalty Obligations To Bluebird Bio For $200 Million,2020-05-11 07:44:00-04:00,BMY,positive
175375.0,5 Biopharmas Where BofA Would Put Its Money To Work,2020-05-08 11:23:00-04:00,BMY,neutral
175376.0,Mid-Afternoon Market Update: Dow Jumps 270 Points; Twilio Shares Rise On Upbeat Results,2020-05-07 14:36:00-04:00,BMY,positive
175377.0,"CFRA Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $70",2020-05-07 13:50:00-04:00,BMY,neutral
175378.0,Mid-Day Market Update: Crude Oil Rises 8%; Vista Outdoor Shares Plunge,2020-05-07 12:00:00-04:00,BMY,negative
175379.0,Mid-Morning Market Update: Markets Open Higher; Bristol-Myers Squibb Tops Q1 Estimates,2020-05-07 10:22:00-04:00,BMY,positive
175380.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,BMY,negative
175381.0,Bristol-Myers Squibb shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2020-05-07 07:06:00-04:00,BMY,positive
175382.0,"Bristol Myers Reaffirms FY20, FY21 Adj. EPS Guidance",2020-05-07 07:00:00-04:00,BMY,neutral
175383.0,"Bristol-Myers Squibb Q1 Adj. EPS $1.720 Beats $1.490 Estimate, Sales $10.800B Beat $10.020B Estimate",2020-05-07 06:59:00-04:00,BMY,neutral
175384.0,"A Peek Into The Markets: US Stock Futures Climb Ahead Of Earnings, Initial Jobless Claims Data",2020-05-07 06:06:00-04:00,BMY,neutral
175385.0,"8 Stocks To Watch For May 7, 2020",2020-05-07 05:15:00-04:00,BMY,neutral
175386.0,"Earnings Scheduled For May 7, 2020",2020-05-07 05:02:00-04:00,BMY,neutral
175387.0,"Bristol Myers Squibb Reports FDA Extended Action Date By 3 Months For Biologics License Application for Lisocabtagene Maraleucel; New PDUFA Date Set as Nov. 16, 2020",2020-05-06 07:11:00-04:00,BMY,neutral
175388.0,Why Shares Of Gene Therapy Company Genprex Are Surging Higher,2020-05-05 12:38:00-04:00,BMY,positive
175389.0,What You Should Know About Alexion's $1.4B Proposed Buyout Of Portola Pharma,2020-05-05 09:10:00-04:00,BMY,neutral
175390.0,3 Keros Analysts On Why Biopharma Is A Compelling Investment Opportunity,2020-05-04 14:41:00-04:00,BMY,positive
175391.0,"Benzinga Pro's Top 5 Stocks To Watch For Mon., May 4, 2020: DIS, BMY, PTON, QTNT, TBIO",2020-05-04 08:30:00-04:00,BMY,positive
175392.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,2020-05-03 09:25:00-04:00,BMY,neutral
175393.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,BMY,neutral
175394.0,Shares of several healthcare companies are trading lower as markets dip following recent strength. Markets have sold off as investors weigh recent earnings and amid concerns of renewed US-China trade frictions.,2020-05-01 12:35:00-04:00,BMY,positive
175395.0,"UPDATE: Bristol Myers Sets FDA PDUFA Date As Sep. 3, 2020",2020-05-01 07:04:00-04:00,BMY,neutral
175396.0,Bristol Myers Reports FDA Accepted For Priority Review Co.'s Application For CC-486 For Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia,2020-05-01 07:04:00-04:00,BMY,positive
175397.0,Bristol Myers Squibb And Acceleron Receive Positive CHMP Opinion For The Treatment Of Adults With Anemia In Beta Thalassemia And Myelodysplastic Syndromes,2020-04-30 16:27:00-04:00,BMY,positive
175398.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,BMY,negative
175399.0,Fast Money Picks For April 27,2020-04-25 16:24:00-04:00,BMY,neutral
175400.0,WindMIL Therapeutics Opens Combination Therapy Portion Of Its Phase 2a Clinical Trial Of Marrow-Infiltrating Lymphocytes (MILs) For Treatment Of Patients With Non-Small Cell Lung Cancer,2020-04-21 07:13:00-04:00,BMY,negative
175401.0,Bristol-Myers Squibb shares are trading higher after the company announced the results from its Phase 3 CheckMate -9ER Trial met the primary endpoint.,2020-04-20 11:05:00-04:00,BMY,positive
175402.0,Bristol Myers Squibb And Exelixis Announce Topline Results From Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo In Combination With CABOMETYX In Previously Untreated Advanced Renal Cell Carcinoma; Study Met Primary Endpoint,2020-04-20 07:01:00-04:00,BMY,positive
175403.0,Intensity Therapeutics Signs Clinical Collaboration Agreement With Bristol Myers Squibb For Advanced Solid Tumors,2020-04-14 07:39:00-04:00,BMY,positive
175404.0,"Cramer Weighs In On Uber, Yelp And More",2020-04-09 08:08:00-04:00,BMY,neutral
175405.0,"The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO",2020-04-08 07:53:00-04:00,BMY,neutral
175406.0,Bristol Myers Squibb Announces Acceptance Of US And EU Regulatory Filings For Opdivo Plus Yervoy Combined With Limited Chemotherapy In First-Line Lung Cancer,2020-04-08 06:59:00-04:00,BMY,negative
175407.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 09:42:00-04:00,BMY,positive
175408.0,Credit Suisse Compiles List Of Corporations With Most And Least Cash,2020-04-02 06:57:00-04:00,BMY,positive
175409.0,"CLARIFICATION: B of A Securities Yesterday Maintained Buy on Bristol-Myers Squibb, Announced $75 Price Target",2020-04-01 10:50:00-04:00,BMY,positive
175410.0,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,2020-04-01 09:20:00-04:00,BMY,negative
175411.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2020-03-31 17:15:00-04:00,BMY,neutral
175412.0,"Shares of several healthcare companies are trading higher amid market strength. NOTE: The coronavirus pandemic has potentially benefited the sector due to demand for medical supplies, testing and treatment candidates",2020-03-31 12:00:00-04:00,BMY,positive
175413.0,"The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions",2020-03-31 08:26:00-04:00,BMY,negative
175414.0,Bristol Myers Squibb And Bluebird Bio Announce Submission Of Biologics License Application For Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel To FDA,2020-03-31 07:00:00-04:00,BMY,neutral
175415.0,Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak.,2020-03-30 10:17:00-04:00,BMY,positive
175416.0,"The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty",2020-03-29 12:10:00-04:00,BMY,negative
175417.0,Bristol Myers Reports Receives Positive CHMP Opinion Recommending Approval Of ZEPOSIA For Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease,2020-03-27 11:06:00-04:00,BMY,positive
175418.0,Why Bristol-Myers Squibb's Stock is Trading Higher Today,2020-03-26 14:08:00-04:00,BMY,neutral
175419.0,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",2020-03-26 11:49:00-04:00,BMY,positive
175420.0,"Bristol-Myers Squibb shares are trading higher after the company announced the FDA has approved ZEPOSIA, its new oral treatment for relapsing forms of multiple sclerosis.",2020-03-26 11:34:00-04:00,BMY,positive
175421.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger",2020-03-26 08:23:00-04:00,BMY,negative
175422.0,Bristol-Myers Reports FDA Approval For ZEPOSIA 0.92 mg For Treatment Of Adults With Relapsing Forms Of Multiple Sclerosis,2020-03-26 06:32:00-04:00,BMY,positive
175423.0,'Bristol-Myers Zeposia appears to be approved. Drug is listed on Bristol's website. Here is the label: https://packageinserts.bms.com/pi/pi_zeposia.pdf' -Tweet From STAT News' Adam Feuerstein,2020-03-26 06:23:00-04:00,BMY,positive
175424.0,Bristol-Myers Says No Sites For New Studies Will Be Initiated Or Activated Until Apr. 13,2020-03-25 09:25:00-04:00,BMY,negative
175425.0,"UPDATE: BeiGene Sees Disruption In ABRAXANE Supply In China, Is Working With Partner Bristol Myers To Restore Supply As Soon As Possible",2020-03-25 09:06:00-04:00,BMY,negative
175426.0,"BeiGene Reports China National Medical Products Admin. Suspended Import, Sale, Use Of ABRAXANE Supply In China, Suspension Based On 'inspection findings at Bristol Myers contract manufacturing facility in the United States'",2020-03-25 09:06:00-04:00,BMY,negative
175427.0,Infinity Receives Fast Track Designation For IPI-549 In Combination With The Checkpoint Inhibitor Opdivo For The Treatment Of Advanced Urothelial Cancer,2020-03-25 07:35:00-04:00,BMY,negative
175428.0,"The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down",2020-03-25 07:29:00-04:00,BMY,neutral
175429.0,"Shares of several healthcare companies are trading higher as equities gain amid hopes of a US stimulus agreement. Additionally, the coronavirus outbreak has increased demand for certain medical supplies.",2020-03-24 12:20:00-04:00,BMY,positive
175430.0,Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.,2020-03-23 11:31:00-04:00,BMY,negative
175431.0,"Bristol-Myers Reports Will Not Initiate New Clinical Trial Studies Until Apr. 13, 2020",2020-03-23 11:09:00-04:00,BMY,neutral
175432.0,"Societe Generale Downgrades Bristol-Myers Squibb to Hold, Announces $50 Price Target",2020-03-23 05:59:00-04:00,BMY,neutral
175433.0,"The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus",2020-03-22 14:25:00-04:00,BMY,positive
175434.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,BMY,negative
175435.0,"The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review",2020-03-15 09:55:00-04:00,BMY,neutral
175436.0,"Barron's Picks And Pans: Roundtable Picks, Airline And Oil Stocks, And More",2020-03-14 12:58:00-04:00,BMY,neutral
175437.0,Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.,2020-03-12 09:26:00-04:00,BMY,negative
175438.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,BMY,positive
175439.0,FDA Approves Opdivo + Yervoy For Patients With Hepatocellular Carcinoma Previously Treated With Sorafenib,2020-03-11 07:07:00-04:00,BMY,positive
175440.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,BMY,negative
175441.0,52 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-09 08:04:00-04:00,BMY,neutral
175442.0,Bristol Myers' Phase 3 Trial of Empliciti in Untreated Multiple Myeloma Did Not Meet its Primary Endpoint,2020-03-09 07:02:00-04:00,BMY,neutral
175443.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,BMY,negative
175444.0,Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,2020-03-04 07:48:00-05:00,BMY,positive
175445.0,"Voluntis, Bristol-Myers Report Will Co-Develop Digital Therapeutics For Oncology",2020-03-03 17:30:00-05:00,BMY,neutral
175446.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2020-03-02 16:46:00-05:00,BMY,neutral
175447.0,Heat Biologics Rallies On Provisional Coronavirus Patent Application,2020-03-02 11:11:00-05:00,BMY,neutral
175448.0,"EMA Says Bristol-Myer's Application For Use Of Opdivo, Yervoy To Treat Metastatic Non-Small Cell Lung Cancer Was Withdrawn",2020-02-28 06:38:00-05:00,BMY,negative
175449.0,"Benzinga's Top Upgrades, Downgrades For February 27, 2020",2020-02-27 09:37:00-05:00,BMY,positive
175450.0,"Barclays Initiates Coverage On Bristol-Myers Squibb with Equal-Weight Rating, Announces $69 Price Target",2020-02-27 08:01:00-05:00,BMY,neutral
175451.0,Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.,2020-02-24 08:37:00-05:00,BMY,negative
175452.0,Bristol-Myers Squibb Advances CytomX Therapeutics' Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion of Ongoing Clinical Trial,2020-02-24 08:07:00-05:00,BMY,neutral
175453.0,Bristol-Myers Squibb Option Alert: Mar 20 $70 Calls Sweep (37) near the Ask: 704 @ $0.31 vs 8146 OI; Ref=$65.53,2020-02-21 14:00:00-05:00,BMY,positive
175454.0,"Bristol-Myers Squibb Reports Japan's Ministry Of Health, Labor And Welfare Approves Opdivo For Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer",2020-02-21 07:00:00-05:00,BMY,negative
175455.0,Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma,2020-02-15 15:32:00-05:00,BMY,positive
175456.0,FDA Accepts For Priority Review Bristol-Myers Squibb's Biologics License Application For Lisocabtagene Maraleucel For Adult Patients With Relapsed Or Refractory Large B-Cell Lymphoma,2020-02-13 08:35:00-05:00,BMY,positive
175457.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,BMY,negative
175458.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,BMY,neutral
175459.0,Bristol-Myers Sees FY20 Adj. EPS $6-$6.20; FY21 Adj. EPS $7.15-$7.45,2020-02-06 07:50:00-05:00,BMY,neutral
175460.0,Bristol-Myers Q4 Sales $7.9B; Adds $5B To Buyback,2020-02-06 07:49:00-05:00,BMY,neutral
175461.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,BMY,negative
175462.0,44 Stocks Moving in Thursday's Pre-Market Session,2020-02-06 07:26:00-05:00,BMY,neutral
175463.0,Bristol-Myers Squibb shares are trading higher after the company reported better-than-expected Q4 EPS results.,2020-02-06 07:20:00-05:00,BMY,positive
175464.0,Bristol-Myers Squibb Q4 EPS $1.22 Beats $0.94 Estimate,2020-02-06 06:59:00-05:00,BMY,neutral
175465.0,"Earnings Scheduled For February 6, 2020",2020-02-06 04:30:00-05:00,BMY,neutral
175466.0,13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market,2020-02-05 16:11:00-05:00,BMY,neutral
175467.0,Catalent To Buy Cell Therapy CDMO MasTherCell For $315M,2020-02-03 10:32:00-05:00,BMY,neutral
175468.0,"Surprise, Surprise: Stocks Wearing Their Rally Hats Despite China Market Tanking",2020-02-03 09:44:00-05:00,BMY,positive
175469.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,BMY,neutral
175470.0,Bristol-Myers Squibb Withdraws European Application of Opdivo Plus Yervoy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer,2020-01-31 16:22:00-05:00,BMY,negative
175471.0,"Position Scrimmage: Coronavirus, End-Of-Month Profit Taking Influencing Markets",2020-01-31 09:46:00-05:00,BMY,positive
175472.0,"February Market Outlook: Coronavirus, D.C. Proceedings, Earnings Season Could Mean Volatility",2020-01-29 14:53:00-05:00,BMY,neutral
175473.0,Turnaround Tuesday? Stocks Look To Bounce Back As Apple Earnings Loom Later,2020-01-28 09:39:00-05:00,BMY,negative
175474.0,"Shares of several companies in the healthcare and pharmaceutical space are trading lower, not currently seeing sector-specific news. NOTE: The global spread of the Wuhan coronavirus has caused equities across to sell off.",2020-01-24 11:40:00-05:00,BMY,neutral
175475.0,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",2020-01-23 07:24:00-05:00,BMY,positive
175476.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-22 10:17:00-05:00,BMY,neutral
175477.0,"The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings",2020-01-22 08:25:00-05:00,BMY,neutral
175478.0,7 Blockbuster Drugs Expected To Be Launched In 2020,2020-01-20 14:18:00-05:00,BMY,positive
175479.0,9 Takeaways From The JPMorgan Healthcare Conference,2020-01-17 14:47:00-05:00,BMY,neutral
175480.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,BMY,neutral
175481.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,BMY,neutral
175482.0,FDA Accepts For Priority Review Bristol-Myers Squibb's Application For Opdivo Plus Yervoy In First-Line Non-Small Cell Lung Cancer,2020-01-15 06:59:00-05:00,BMY,negative
175483.0,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug",2020-01-14 07:55:00-05:00,BMY,positive
175484.0,"Barron's Picks And Pans: Apple, Bank of America, Lockheed Martin And More",2020-01-11 11:57:00-05:00,BMY,neutral
175485.0,Stocks That Hit 52-Week Highs On Friday,2020-01-10 12:18:00-05:00,BMY,neutral
175486.0,"A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations",2020-01-10 08:52:00-05:00,BMY,neutral
175487.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,BMY,positive
175488.0,"UPDATE: Nektar, Bristol Amendment Includes ' new joint development plan under which Nektar and Bristol-Myers Squibb will expand the active clinical development program for bempeg plus nivolumab from three ongoing registrational trials'",2020-01-10 07:00:00-05:00,BMY,positive
175489.0,"Nektar Therapeutics, Bristol-Myers Amend Strategic Collaboration For Bempegaldesleukin Plus Opdivo",2020-01-10 06:59:00-05:00,BMY,neutral
175490.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,BMY,neutral
175491.0,Bristol-Myers Squibb Company shares are trading higher after the company reported results for its pivotal Phase 3 Reblozyl MEDALIST trial in the New England Journal of Medicine.,2020-01-09 13:39:00-05:00,BMY,positive
175492.0,Bristol-Myers CMO Says Company Confident On Track To Receive US Approvals For Drugs Tied To Celgene CVR,2020-01-09 13:27:00-05:00,BMY,positive
175493.0,Bristol-Myers Squibb Highlights Publishing Of Results For Pivotal Phase 3 Reblozyl MEDALIST Trial In New England Journal Of Medicine,2020-01-09 06:59:00-05:00,BMY,neutral
175494.0,December's Investor Movement Index Ends 2019 On A HIgh Note,2020-01-07 12:42:00-05:00,BMY,neutral
175495.0,Investor Movement Index Summary: December 2019,2020-01-07 07:40:00-05:00,BMY,neutral
175496.0,"Citigroup Reinstates Buy on Bristol-Myers Squibb, Announces $73 Price Target",2020-01-06 09:13:00-05:00,BMY,neutral
175497.0,34 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-01-03 07:45:00-05:00,BMY,neutral
175498.0,Drugmakers Kick Off 2020 With Margin-Expanding Price Hikes,2020-01-02 10:41:00-05:00,BMY,neutral
175499.0,"Bristol-Myers Squibb, Gilead Sciences, Biogen Raised U.S. List Prices on 50+ Drugs on Wednesday an Average of 5%",2020-01-01 11:58:00-05:00,BMY,neutral
175500.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,BMY,neutral
175501.0,10 Biotech M&A Targets Under The Scanner For 2020,2019-12-24 07:30:00-05:00,BMY,neutral
175502.0,A Perspective On Biopharma's Record M&A Run In 2019,2019-12-23 14:57:00-05:00,BMY,neutral
175503.0,Bristol-Myers Squibb Reports EC Approved Revlimid In Combo With Rituximab For Treatment of Adult Patients with Previously Treated Follicular Lymphoma,2019-12-20 06:59:00-05:00,BMY,positive
175504.0,Bristol-Myers Squibb Reports Submission Of Biologics License Application For CAR T-Cell Therapy Liso-Cel,2019-12-18 16:19:00-05:00,BMY,neutral
175505.0,"iRhythm Announces Participation In GUARD-AF Study Focused On Undiagnosed Atrial Fibrillation, Sponsored By Bristol-Myers Squibb-Pfizer Alliance",2019-12-16 16:09:00-05:00,BMY,positive
175506.0,Bristol-Myers Squibb Wins Patent Royalty Fight Against Gilead; Co. Awarded $585M In Damages Plus Royalty,2019-12-13 14:31:00-05:00,BMY,positive
175507.0,Stocks That Hit 52-Week Highs On Friday,2019-12-13 11:19:00-05:00,BMY,neutral
175508.0,"The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer",2019-12-13 08:10:00-05:00,BMY,positive
175509.0,"Argus Research Upgrades Bristol-Myers Squibb to Buy, Announces $80 Price Target",2019-12-13 07:28:00-05:00,BMY,neutral
175510.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-12 10:21:00-05:00,BMY,neutral
175511.0,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win",2019-12-12 07:38:00-05:00,BMY,positive
175512.0,Stocks That Hit 52-Week Highs On Wednesday,2019-12-11 10:49:00-05:00,BMY,neutral
175513.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,BMY,negative
175514.0,Stocks That Hit 52-Week Highs On Tuesday,2019-12-10 14:27:00-05:00,BMY,neutral
175515.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,BMY,positive
175516.0,Bristol-Myers Squibb Presents Overall Survival And Safety Data From Pivotal CC-486 Study QUAZAR AML-001,2019-12-10 07:40:00-05:00,BMY,positive
175517.0,Bristol-Myers Reports Reblozyl Studies Evaluating Treatment Of Anemia In Rare Blood Diseases Presented At ASH,2019-12-09 16:37:00-05:00,BMY,neutral
175518.0,5 Stocks Moving On ASH Presentations,2019-12-09 14:46:00-05:00,BMY,neutral
175519.0,Bristol-Myers Squibb Company shares are trading higher after the company announced the Lisocabtagene Maraleucel (Liso-Cel) met its primary and secondary endpoints in the TRANSCEND NHL 001 study at the ASH 2019.,2019-12-09 08:13:00-05:00,BMY,positive
175520.0,"Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at ASH 2019",2019-12-08 18:34:00-05:00,BMY,positive
175521.0,Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study at ASH 2019,2019-12-07 14:22:00-05:00,BMY,neutral
175522.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,BMY,positive
175523.0,"Bristol-Myers, bluebird bio Report Top-Line Results From Phase 2 KarMMa Study Of Ide-cel: Met Primary, Key Secondary Endpoints",2019-12-06 16:18:00-05:00,BMY,neutral
175524.0,Bristol-Myers Squibb Option Alert: Dec 13 $60 Calls Sweep (7) near the Ask: 849 @ $0.686 vs 2653 OI; Earnings 1/23 Before Open [est] Ref=$59.99,2019-12-06 15:19:00-05:00,BMY,positive
175525.0,Bristol-Myers Squibb Option Alert: Mar 20 $70 Calls Sweep (29) near the Ask: 693 @ $0.391 vs 2058 OI; Earnings 1/23 Before Open [est] Ref=$60.11,2019-12-06 14:50:00-05:00,BMY,positive
175526.0,Bristol-Meyers Squibb And Acceleron Were Notified By FDA That Reblozyl Will Not Be Reviewed At Dec. 18 Oncologic Drugs Advisory Committee,2019-12-06 12:07:00-05:00,BMY,neutral
175527.0,Stocks That Hit 52-Week Highs On Friday,2019-12-06 10:33:00-05:00,BMY,neutral
175528.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,BMY,positive
175529.0,Bristol-Myers Raises Qtr. Dividend From $0.41 To $0.45/Share,2019-12-05 16:29:00-05:00,BMY,neutral
175530.0,Bristol-Myers Squibb Raises Quarterly Dividend From $0.41 To $0.45/Share,2019-12-05 16:18:00-05:00,BMY,neutral
175531.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-05 10:16:00-05:00,BMY,neutral
175532.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,BMY,negative
175533.0,Bristol-Myers Squibb Announces FDA Breakthrough Therapy Designation For ORENCIA To Help Prevent Acute Graft-Versus-Host Disease,2019-12-04 07:00:00-05:00,BMY,positive
175534.0,Bristol-Myers Squibb And Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl For Use In Patients With Myelodysplastic Syndromes,2019-12-03 07:40:00-05:00,BMY,neutral
175535.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,BMY,neutral
175536.0,Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates,2019-11-29 08:13:00-05:00,BMY,neutral
175537.0,"Benzinga's Top Upgrades, Downgrades For November 27, 2019",2019-11-27 09:47:00-05:00,BMY,positive
175538.0,Gabelli & Co. Initiates Coverage On Bristol-Myers Squibb with Buy Rating,2019-11-27 06:34:00-05:00,BMY,neutral
175539.0,"The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More",2019-11-24 16:19:00-05:00,BMY,positive
175540.0,AstraZeneca CEO: Closing In On A Cancer Cure,2019-11-22 15:39:00-05:00,BMY,negative
175541.0,"UPDATE: Morgan Stanley Reinstates Bristol-Meyers With Equal-Weight $60 Tgt Sees 'potential for earnings upside in the near-term, driven by bigger/faster cost synergy realization, balanced by patent erosion in mid-late 2020s and uncertainty about pipeline'",2019-11-22 11:44:00-05:00,BMY,negative
175542.0,"Morgan Stanley Reinstates Equal-Weight on Bristol-Myers Squibb, Announces $60 Price Target",2019-11-22 08:28:00-05:00,BMY,neutral
175543.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,BMY,positive
175544.0,Bristol-Myers Squibb Completes Acquisition Of Celgene,2019-11-20 16:17:00-05:00,BMY,neutral
175545.0,Bristol-Myers Squibb Announces CheckMate -915 Study Of Opdivo Did Not Show Statistically Significant Benefit In Co-Primary Endpoint Of Recurrence-Free Survival In,2019-11-20 07:00:00-05:00,BMY,positive
175546.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,BMY,neutral
175547.0,Bristol-Myers Squibb Receives FTC Clearance For Celgene Acquisition,2019-11-15 16:56:00-05:00,BMY,neutral
175548.0,"Bristol-Myers, Pfizer Report Randomized, Controlled Trial To Evaluate Effect Of Atrial Fibrillation Screening",2019-11-15 09:03:00-05:00,BMY,neutral
175549.0,"Bristol-Myers Reports Extension Of Expiration Date For Celgene Exchange Offer From Nov. 15, 2019 To Nov. 20, 2019",2019-11-15 07:00:00-05:00,BMY,neutral
175550.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,BMY,positive
175551.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,BMY,neutral
175552.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-12 10:11:00-05:00,BMY,neutral
175553.0,Bristol-Myers Squibb's Opdivo Plus Yervoy for Patients with Previously Treated Advanced Hepatocellular Carcinoma Accepted for Priority Review by the FDA,2019-11-11 07:00:00-05:00,BMY,positive
175554.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,BMY,neutral
175555.0,"'Fast Money Halftime Report' Traders Give Their View On Ford, Starbucks And More",2019-11-07 16:28:00-05:00,BMY,neutral
175556.0,Bristol-Myers Squibb Company Announces Extension Of The Expiration Date For Exchange Offers For Celgene Corporation Notes,2019-11-07 09:55:00-05:00,BMY,neutral
175557.0,AstraZeneca Named The Most Innovative Global Pharma Company,2019-11-06 11:20:00-05:00,BMY,positive
175558.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,BMY,neutral
175559.0,Stocks That Hit 52-Week Highs On Friday,2019-11-01 10:31:00-04:00,BMY,neutral
175560.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,BMY,neutral
175561.0,"Mid-Afternoon Market Update: US Markets Down, Dow Loses More Than 200 Points",2019-10-31 14:57:00-04:00,BMY,negative
175562.0,Mid-Day Market Update: Markets Dip After Morning Rise; Oil Plunges,2019-10-31 11:35:00-04:00,BMY,neutral
175563.0,Mid-Morning Market Update: Markets Inch Up; Bristol-Myers Squibb Reports Q3 Beat,2019-10-31 09:56:00-04:00,BMY,neutral
175564.0,"Bristol-Myers Squibb Posts Q3 Earnings Beat, Raises Full-Year Guidance",2019-10-31 09:37:00-04:00,BMY,neutral
175565.0,A Peek Into The Markets: US Stock Futures Trade Lower; European Markets Decline,2019-10-31 08:25:00-04:00,BMY,negative
175566.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,BMY,positive
175567.0,Bristol-Myers Raises FY19 Adj. EPS Guidance From $4.20-$4.30 To $4.25-$4.35 vs $4.28 Estimate,2019-10-31 07:01:00-04:00,BMY,neutral
175568.0,Bristol Myers Highlights CheckMate -9LA Met Primary Endpoint,2019-10-31 07:00:00-04:00,BMY,neutral
175569.0,"Bristol-Myers Squibb Q3 Adj. EPS $1.17 Beats $1.07 Estimate, Sales $6.007B Beat $5.9B Estimate",2019-10-31 07:00:00-04:00,BMY,neutral
175570.0,"9 Stocks To Watch For October 31, 2019",2019-10-31 06:43:00-04:00,BMY,neutral
175571.0,"Earnings Scheduled For October 31, 2019",2019-10-31 06:32:00-04:00,BMY,neutral
175572.0,13 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-30 07:32:00-04:00,BMY,neutral
175573.0,"The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings",2019-10-27 12:56:00-04:00,BMY,neutral
175574.0,"'Fast Money Halftime Report' Give Their View On Bristol-Myers, Adobe And More",2019-10-25 05:14:00-04:00,BMY,neutral
175575.0,European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) Four-Week Dosing Schedule For  Adjuvant Treatment Of Adult Patients With Melanoma With Involvement Of Lymph Nodes Or Metastatic Disease Who Have Undergone Complete Resection,2019-10-24 07:25:00-04:00,BMY,positive
175576.0,"UBS Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $53",2019-10-23 13:18:00-04:00,BMY,neutral
175577.0,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data",2019-10-23 07:54:00-04:00,BMY,negative
175578.0,8 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-22 07:30:00-04:00,BMY,neutral
175579.0,"Bristol-Myers Squibb shares are trading higher after the company announced that CheckMate -9LA, a pivotal Phase 3 trial evaluating Opdivo plus low-dose Yervoy combined with chemotherapy met its primary endpoint.",2019-10-22 07:27:00-04:00,BMY,positive
175580.0,Bristol-Myers Squibb Phase 3 Trial Of Opdivo Plus Low-Dose Yervoy Combined With Chemotherapy Meets Primary Endpoint,2019-10-22 07:00:00-04:00,BMY,neutral
175581.0,Bristol-Myers Squibb-Pfizer Alliance Announces They Are Collaborating With Fitbit To Develop Educational Content Around Atrial Fibrillation,2019-10-17 09:06:00-04:00,BMY,neutral
175582.0,"Bank of America Reinstates Buy on Bristol-Myers Squibb, Announces $60 Price Target",2019-10-17 07:27:00-04:00,BMY,neutral
175583.0,Biotech Stock On The Radar: Assessing Mirati's Oncology Franchise With An Eye On Multiple Readouts,2019-10-16 16:22:00-04:00,BMY,neutral
175584.0,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,2019-10-11 11:19:00-04:00,BMY,positive
175585.0,"Bank of America Reiterates Neutral on Bristol-Myers Squibb, Raises Price Target to $50",2019-10-10 09:32:00-04:00,BMY,neutral
175586.0,'Fast Money Halftime Report' Picks For October 8,2019-10-08 17:25:00-04:00,BMY,neutral
175587.0,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,2019-10-08 10:36:00-04:00,BMY,positive
175588.0,"Cramer Weighs In On Yeti, Square And More",2019-10-04 11:11:00-04:00,BMY,neutral
175589.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.,2019-10-02 10:33:00-04:00,BMY,negative
175590.0,"Apple, Biogen And More 'Fast Money' Picks For October 1",2019-10-01 11:05:00-04:00,BMY,neutral
175591.0,"Najarian Brothers See Unusual Options Activity In Bristol-Myers, AMD And More",2019-10-01 09:34:00-04:00,BMY,neutral
175592.0,8 Latest Short Seller Targets,2019-09-30 12:56:00-04:00,BMY,neutral
175593.0,Bristol-Myers Reports Opdivo Showed Statistically Significant Overall Survival Benefit Vs. Chemo In Patients With Advanced Esophageal Cancer,2019-09-30 10:33:00-04:00,BMY,positive
175594.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,BMY,positive
175595.0,Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo Plus Low-Dose Yervoy vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer at EMSO 2019,2019-09-28 18:29:00-04:00,BMY,neutral
175596.0,Bristol-Myers Squibb Says Adjuvant Treatment with Opdivo Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients,2019-09-28 17:31:00-04:00,BMY,neutral
175597.0,Bristol-Myers Squibb Announces Five-Year Outcomes for Opdivo in Combination with Yervoy Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma at ESMO 2019,2019-09-28 17:26:00-04:00,BMY,positive
175598.0,"The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J",2019-09-26 07:54:00-04:00,BMY,positive
175599.0,Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo,2019-09-24 07:00:00-04:00,BMY,positive
175600.0,Carter Worth And Mike Khouw's Bristol-Myers Squibb Options Trade,2019-09-23 11:12:00-04:00,BMY,positive
175601.0,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,2019-09-20 13:00:00-04:00,BMY,negative
175602.0,11 Most Aggressively Shorted Stocks,2019-09-19 11:15:00-04:00,BMY,negative
175603.0,"Bristol-Myers To Report Q3 Results Thurs., Oct. 31, Before Market Open",2019-09-12 07:02:00-04:00,BMY,neutral
175604.0,Bristol-Myers Squibb Earlier Announced Pooled Five-Year Results Showed Patients Treated With Opdivo (Nivolumab) Continued To Experience Long-Term Overall Survival (OS) Benefit Versus Docetaxel,2019-09-10 10:16:00-04:00,BMY,positive
175605.0,"The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug",2019-09-05 08:12:00-04:00,BMY,neutral
175606.0,UPDATE: Bristol-Myers Says Opdivo Trial Did Not Meet 1 Of Primary Endpoints; Data Monitoring Committee Recommended Trial Continue As Planned,2019-09-05 07:00:00-04:00,BMY,positive
175607.0,Bristol-Myers Squibb Offers Update On Phase 3 Opdivo CheckMate -548 Trial In Patients With Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme,2019-09-05 07:00:00-04:00,BMY,neutral
175608.0,Bristol-Myers Squibb And BioMotiv Announce PArtnership; Bristol-Myers Squibb To Become Limited Partner Of BioMotiv With Option To Invest Additional Funding In Selected Projects Of Mutual Interest,2019-09-04 07:09:00-04:00,BMY,positive
175609.0,"Bank of America Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $49",2019-09-03 08:54:00-04:00,BMY,neutral
175610.0,Celgene Strikes Cancer Immunotherapy Deal With Immatics For Up To $1.59B,2019-08-28 10:54:00-04:00,BMY,negative
175611.0,"The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved",2019-08-28 07:31:00-04:00,BMY,positive
175612.0,Bristol-Myers Squibb Announces European Commission Approval Of Empliciti Plus Pomalidomide And Low-Dose Dexamethasone (EPd) For Treatment Of Patients With Relapsed And Refractory Multiple Myeloma,2019-08-27 16:20:00-04:00,BMY,positive
175613.0,Alexion Trades Lower Amid Amgen-Celgene News,2019-08-26 12:55:00-04:00,BMY,negative
175614.0,Amgen's Proposed $13.4B Acquisition Of Celgene's Otezla: What You Need To Know,2019-08-26 10:17:00-04:00,BMY,neutral
175615.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday., August 26, 2019",2019-08-26 09:26:00-04:00,BMY,positive
175616.0,Amgen Earlier Announced It Will Acquire Global Rights To OTEZLA From Celgene For $13.4B,2019-08-26 08:57:00-04:00,BMY,neutral
175617.0,16 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-08-26 08:44:00-04:00,BMY,neutral
175618.0,26 Stocks Moving in Monday's Pre-Market Session,2019-08-26 08:00:00-04:00,BMY,neutral
175619.0,Bristol-Myers Squibb shares are trading higher after the company announced Celgene would sell OTEZLA to Amgen for $13.4B. The sale of OTEZLA is important for the pending merger between Bristol-Myers and Celgene.,2019-08-26 07:54:00-04:00,BMY,positive
175620.0,Bristol-Myers Squibb Says the Divestiture of OTEZLA is Important for its Pending Merger with Celgene,2019-08-26 06:32:00-04:00,BMY,positive
175621.0,Bristol-Myers Squibb Announces Agreement with Celgene to Divest OTEZLA to Amgen for $13.4B,2019-08-26 06:31:00-04:00,BMY,positive
175622.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,BMY,positive
175623.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,BMY,negative
175624.0,"Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",2019-08-15 13:40:00-04:00,BMY,neutral
175625.0,"Elliott Mgmt. 13F Shows New Stake In Marathon Petroleum, Liquidated Stakes In EQT, Bristol-Myers",2019-08-14 16:26:00-04:00,BMY,neutral
175626.0,"Benzinga's Top Upgrades, Downgrades For August 14, 2019",2019-08-14 10:00:00-04:00,BMY,positive
175627.0,A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street,2019-08-14 06:59:00-04:00,BMY,negative
175628.0,Atlantic Equities Upgrades Bristol-Myers Squibb to Overweight,2019-08-14 06:23:00-04:00,BMY,negative
175629.0,Large Option Trader Buying Nektar Calls Following Stock Crash,2019-08-09 14:03:00-04:00,BMY,negative
175630.0,"Nektar Therapeutics Tumbles To 2-Year Low On Q2 Revenue Miss, Manufacturing Issues With Cancer Drug",2019-08-09 10:08:00-04:00,BMY,negative
175631.0,"The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2",2019-08-09 07:19:00-04:00,BMY,negative
175632.0,Investor Movement Index Summary: July 2019,2019-08-05 14:22:00-04:00,BMY,neutral
175633.0,"Notable Insider Buys: AbbVie, Bristol-Myers And More",2019-08-04 08:01:00-04:00,BMY,neutral
175634.0,Nektar Therapeutics And Bristol-Myers Squibb Announce FDA Breakthrough Therapy Designation For NKTR-214 In Combination With Opdivo For The Treatment Of Patients With Untreated Advanced Melanoma,2019-08-01 07:46:00-04:00,BMY,positive
175635.0,Bristol-Myers Squibb Option Alert: Jan 17 $47 Calls at the Ask: 1000 @ $2.13 vs 9610 OI; Ref=$45.43,2019-07-29 14:25:00-04:00,BMY,positive
175636.0,"The Week In Cannabis: Tobacco And Retail Stray In The Weeds, Congress Holds SAFE Banking Hearings, New ETFs, And More",2019-07-28 15:51:00-04:00,BMY,positive
175637.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,BMY,negative
175638.0,"Bristol-Myers Reports Received Positive CHMP Opinion Recommending Approval Of Empliciti Plus Pomalidomide, Low-Dose Dexamethasone For Treatment Of Patients with Relapse, Refractory Multiple Myeloma",2019-07-26 07:00:00-04:00,BMY,positive
175639.0,"ECB Chimes In: Hints Of Rate Cut Could Support Ahead Of Amazon, Alphabet",2019-07-25 11:10:00-04:00,BMY,positive
175640.0,Bristol-Myers Squibb Company shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also issued FY19 EPS guidance ablove analyst estimates.,2019-07-25 10:13:00-04:00,BMY,positive
175641.0,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",2019-07-25 07:21:00-04:00,BMY,negative
175642.0,Bristol-Myers Squibb Raises FY2019 EPS Guidance from $4.1-4.2 to $4.2-4.3 vs $4.16 Est,2019-07-25 07:03:00-04:00,BMY,neutral
175643.0,"Bristol-Myers Squibb Q2 EPS $1.18 Beats $1.06 Estimate, Sales $6.273B Beat $6.11B Estimate",2019-07-25 07:00:00-04:00,BMY,neutral
175644.0,A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings,2019-07-25 06:07:00-04:00,BMY,neutral
175645.0,35 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-07-25 05:55:00-04:00,BMY,neutral
175646.0,"Earnings Scheduled For July 25, 2019",2019-07-25 04:36:00-04:00,BMY,neutral
175647.0,"12 Stocks To Watch For July 25, 2019",2019-07-25 04:36:00-04:00,BMY,neutral
175648.0,Bristol-Myers Squibb Company shares are trading lower after the company reported Part 2 of CheckMate - 227 did not meet the primary endpoint.,2019-07-24 16:27:00-04:00,BMY,neutral
175649.0,Bristol-Myers Reports Part 2 Of CheckMate -227 Did Not Meet Primary Endpoint,2019-07-24 16:20:00-04:00,BMY,neutral
175650.0,Bristol-Myers Reports CheckMat -227 Part 1a Meets Co-Primary Endpoint,2019-07-24 16:16:00-04:00,BMY,neutral
175651.0,What To Know About Jounce's Amended Licensing Deal With Celgene,2019-07-24 11:34:00-04:00,BMY,neutral
175652.0,Bristol-Myers Squibb Option Alert: Aug 30 $50 Calls Sweep (2) near the Ask: 2500 @ $0.111 vs 0 OI; Earnings 7/25 Before Open Ref=$42.76,2019-07-24 11:32:00-04:00,BMY,positive
175653.0,"Bristol-Myers Squibb Option Alert: Jan, 2021 $38 Puts at the Bid: 1800 @ $3.25 vs 6238 OI; Earnings 7/25 Before Open Ref=$43.105",2019-07-24 10:27:00-04:00,BMY,positive
175654.0,Hearing Unconfirmed Chatter Indicating Pfizer Has Made Takeover Offer For Bristol-Meyers,2019-07-24 09:52:00-04:00,BMY,negative
175655.0,List of Companies Reaching Yearly Lows Tuesday,2019-07-23 14:58:00-04:00,BMY,neutral
175656.0,"ICC International Cannabis, Biotii Technologie Sign Advisory Agreement With Dr. Alexandros Makriyannis",2019-07-23 10:55:00-04:00,BMY,positive
175657.0,"The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation",2019-07-23 07:26:00-04:00,BMY,negative
175658.0,The Week Ahead In Biotech: Pharma Earnings Pick Up Pace,2019-07-20 09:53:00-04:00,BMY,neutral
175659.0,"Bristol-Myers, Bayer, Ono Pharma Report Clinical Collaboration Deal To Evaluate Combo Of Bayer's Stivarga, Bristol/Ono's Opdivo In Patients With Micro-Satellite Stable Metastatic Colorectal Cancer",2019-07-18 06:33:00-04:00,BMY,negative
175660.0,"Jim Cramer Weighs In On Marvell, General Motors And More",2019-07-16 07:31:00-04:00,BMY,neutral
175661.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,BMY,negative
175662.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,BMY,positive
175663.0,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,2019-07-01 07:14:00-04:00,BMY,neutral
175664.0,"Bulls & Bears Of The Week: AT&T, Carnival, McDonald's, Microsoft And More",2019-06-29 10:51:00-04:00,BMY,neutral
175665.0,Meet The 3 Biggest Industries Investing In Cannabis,2019-06-28 15:51:00-04:00,BMY,neutral
175666.0,Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus,2019-06-27 09:00:00-04:00,BMY,positive
175667.0,60 Biggest Movers From Yesterday,2019-06-25 05:12:00-04:00,BMY,neutral
175668.0,40 Stocks Moving In Monday's Mid-Day Session,2019-06-24 12:35:00-04:00,BMY,neutral
175669.0,Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces Setback,2019-06-24 10:03:00-04:00,BMY,negative
175670.0,34 Stocks Moving In Monday's Pre-Market Session,2019-06-24 08:04:00-04:00,BMY,neutral
175671.0,Bristol-Myers Squibb shares are trading lower after the company announced its CheckMate -459 study evaluating Opdivo did not reach its primary endpoint and announced plans to sell OTEZLA to help ease FTC concerns regarding its acquisition of Celgene.,2019-06-24 07:59:00-04:00,BMY,positive
175672.0,Bristol-Myers Squibb to Sell OTEZLA to Help Ease Federal Trade Commission Concerns Regarding its Acquisition of Celgene,2019-06-24 07:00:00-04:00,BMY,positive
175673.0,Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Italy,2019-06-19 13:25:00-04:00,BMY,neutral
175674.0,"Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy, No Terms Disclosed",2019-06-19 06:59:00-04:00,BMY,negative
175675.0,Bristol-Myers Squibb Gives Updated Efficacy Data from its Phase 2 Trial Data of Emplicity,2019-06-14 07:00:00-04:00,BMY,neutral
175676.0,"UBS Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $51",2019-06-13 08:47:00-04:00,BMY,negative
175677.0,"FDA Greenlights Merck's Blockbuster Drug Keytruda For First-Line Treatment Of Head, Neck Cancer",2019-06-11 09:14:00-04:00,BMY,negative
175678.0,"Jim Cramer Shares His Thoughts On AMD, CME Group, Microsoft And More",2019-06-05 07:26:00-04:00,BMY,positive
175679.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,BMY,positive
175680.0,"'China to Audit Sanofi, Bristol-Myers in Drugmaker Accounts Probe' -Bloomberg",2019-06-04 07:45:00-04:00,BMY,neutral
175681.0,Bristol-Myers Squibb Announces Five-Year Survival Data In Phase 1 CA209-004 Study In Melanoma Patients Data Showed Evidence Of Long-Term Survival Following Discontinuation,2019-06-03 14:16:00-04:00,BMY,neutral
175682.0,Bristol-Myers Squibb Announces First Presentation of Results for Opdivo Plus Yervoy Combination in Advanced Hepatocellular Carcinoma at ASCO 2019,2019-06-03 07:41:00-04:00,BMY,positive
175683.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,BMY,neutral
175684.0,Goldman Downgrades Gilead Sciences: 'We Find It Difficult To See The Stock's Multiple Expanding',2019-05-28 11:08:00-04:00,BMY,negative
175685.0,"Benzinga's Top Upgrades, Downgrades For May 28, 2019",2019-05-28 09:15:00-04:00,BMY,positive
175686.0,"Goldman Sachs Initiates Coverage On Bristol-Myers Squibb with Buy Rating, Announces $54 Price Target",2019-05-28 07:36:00-04:00,BMY,neutral
175687.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2019-05-26 17:03:00-04:00,BMY,neutral
175688.0,"Trader Idea Feed: 'We took a look at the late-stage brain cancer pipeline, after $TOCA news and $ABBV and $BMY failures this month. And found only 5 active pivotal trials. Which includes $NWBO, so arguably only 4. Is $CELG the next big hope?' @ByAmyBrown",2019-05-22 14:14:00-04:00,BMY,negative
175689.0,Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond,2019-05-22 12:38:00-04:00,BMY,neutral
175690.0,"Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines",2019-05-20 14:28:00-04:00,BMY,neutral
175691.0,"Benzinga's Top Upgrades, Downgrades For May 20, 2019",2019-05-20 09:11:00-04:00,BMY,positive
175692.0,Argus Research Downgrades Bristol-Myers Squibb Company Common Stock to Hold,2019-05-20 07:42:00-04:00,BMY,neutral
175693.0,5 ASCO Abstracts That Moved Stocks,2019-05-16 14:50:00-04:00,BMY,neutral
175694.0,"The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi",2019-05-15 07:50:00-04:00,BMY,negative
175695.0,Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%,2019-05-10 13:09:00-04:00,BMY,positive
175696.0,Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study,2019-05-09 10:07:00-04:00,BMY,negative
175697.0,Bristol-Myers Squibb Reports Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint,2019-05-09 07:00:00-04:00,BMY,neutral
175698.0,JP Morgan Reinstates Overweight on Bristol-Myers Squibb Company Common Stock,2019-05-03 10:48:00-04:00,BMY,neutral
175699.0,10 Biggest Price Target Changes For Friday,2019-05-03 10:43:00-04:00,BMY,neutral
175700.0,"Benzinga's Top Upgrades, Downgrades For May 3, 2019",2019-05-03 08:53:00-04:00,BMY,positive
175701.0,A Peek Into The Markets: US Stock Futures Up; Jobs Data In Focus,2019-05-03 06:54:00-04:00,BMY,neutral
175702.0,"Barclays Upgrades Bristol-Myers Squibb Company Common Stock to Overweight, Raises Price Target to $55",2019-05-03 06:28:00-04:00,BMY,negative
175703.0,Exelixis Says Checkmate 9ER Recently Completed Enrollment,2019-04-25 14:58:00-04:00,BMY,neutral
175704.0,"Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation",2019-04-25 14:23:00-04:00,BMY,positive
175705.0,"From Bristol-Myers Q1 Earnings Conference Call: Co. To Focus On Smaller, Earlier Stage Deals In Near Term",2019-04-25 10:50:00-04:00,BMY,neutral
175706.0,"The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings",2019-04-25 07:58:00-04:00,BMY,neutral
175707.0,"A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Economic Data",2019-04-25 07:48:00-04:00,BMY,neutral
175708.0,Bristol-Myers Squibb  Reaffirms FY19 Adj. EPS Guidance Of $4.10-$4.20 vs $4.19 Est.,2019-04-25 07:00:00-04:00,BMY,neutral
175709.0,"Bristol-Myers Squibb Q1 EPS $1.1 Beats $1.07 Estimate, Sales $5.92B Beat $5.71B Estimate",2019-04-25 06:59:00-04:00,BMY,neutral
175710.0,"13 Stocks To Watch For April 25, 2019",2019-04-25 04:27:00-04:00,BMY,neutral
175711.0,"Earnings Scheduled For April 25, 2019",2019-04-25 04:26:00-04:00,BMY,neutral
175712.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-04-21 14:06:00-04:00,BMY,neutral
175713.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-18 10:51:00-04:00,BMY,negative
175714.0,"BMO Capital Maintains Outperform on Bristol-Myers Squibb, Raises Price Target to $63",2019-04-17 10:36:00-04:00,BMY,neutral
175715.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-17 10:31:00-04:00,BMY,negative
175716.0,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.,2019-04-16 15:34:00-04:00,BMY,negative
175717.0,Shares of some companies in the healthcare sector are trading higher in a potential rebound. Shares of several healthcare companies dipped last week on concerns of laws curbing drug prices.,2019-04-15 12:22:00-04:00,BMY,positive
175718.0,Celgene Shareholders Approve Deal With Bristol-Myers,2019-04-12 10:33:00-04:00,BMY,neutral
175719.0,Bristol-Myers Shareholders Approve Deal With Celgene,2019-04-12 10:23:00-04:00,BMY,neutral
175720.0,"FameWave Reports Signing Of Clinical Collaboration Deal With Bristol Myers Squibb For Evaluation Of CM-24, Opdivo Combo In Patients With Non-Small Cell Lung Cancer; BZ NOTE: FameWave Will Be Acquired By Kitov Pharma",2019-04-12 07:50:00-04:00,BMY,negative
175721.0,Egan-Jones Supports Bristol-Myers Deal With Celgene,2019-04-03 16:29:00-04:00,BMY,positive
175722.0,"UPDATE: Bristol-Myers, On Opdivo Pooled Results, Says 'in patients with PD-L1 ≥1% and <1%, four-year overall survival rates were 19% and 11%, respectively'",2019-04-02 13:01:00-04:00,BMY,positive
175723.0,Bristol-Myers Reports Long-Term Survival Results From Pooled Analyses Of Opdivo In Previously-Treated Non-Small Cell Lung Cancer Patients: '14% of all Opdivo-treated patients were alive at four years',2019-04-02 13:01:00-04:00,BMY,negative
175724.0,"The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial",2019-04-02 07:30:00-04:00,BMY,neutral
175725.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,BMY,neutral
175726.0,Bristol-Myers Offers Statement Following Celgene Settlement With Alvogen On Revlimid Patent Litigation,2019-03-29 13:34:00-04:00,BMY,negative
175727.0,ISS Has Issued Recommendation Bristol-Myers Shareholders Vote For Deal With Celgene,2019-03-29 09:12:00-04:00,BMY,neutral
175728.0,Yields In Focus Again As 10-Year Falls Below 2.4%; Homebuilder Earnings Digested,2019-03-27 09:57:00-04:00,BMY,neutral
175729.0,"Jim Cramer Gives His Opinion On Bristol-Myers Squibb, Moderna And More",2019-03-26 07:23:00-04:00,BMY,neutral
175730.0,"Bristol-Myers 8-K Shows Co., Celgene Received Request For Added Info, Documentary Materials From FTC Related To Merger",2019-03-26 07:16:00-04:00,BMY,neutral
175731.0,Bristol-Myers Squibb Sends Letter to Shareholders Encouraging Celgene Merger,2019-03-25 07:00:00-04:00,BMY,positive
175732.0,Activist Fund Starboard Value Issues Investor Presentation Opposing Bristol-Myers Squibb's Proposed Acquisition Of Celgene,2019-03-19 07:04:00-04:00,BMY,positive
175733.0,"Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'",2019-03-18 14:26:00-04:00,BMY,negative
175734.0,"Bristol-Myers CEO Speaking At Cowen Annual Health Care Conference, When Asked About Celgene Talks, Said Mgmt. Had Informal, High-Level Deal Talks With Others In The Past",2019-03-12 11:56:00-04:00,BMY,positive
175735.0,CNBC Reporting Third Point And D.E. Shaw Not Involved With Celgene/Bristol-Myers Deal,2019-03-12 09:52:00-04:00,BMY,neutral
175736.0,"Starboard Said to be Investigating Whether Third Point, D.E. Shaw Purchased Bristol-Myers Shares to Vote in Favor of Celgene Deal",2019-03-12 04:42:00-04:00,BMY,positive
175737.0,Third Point Holds Small Celgene Stake in Bet Bristol-Myers Deal will Close,2019-03-11 18:23:00-04:00,BMY,neutral
175738.0,Loncar Cancer Immunotherapy ETF Expresses opposition To Bristol-Myers/Celgene Deal,2019-03-06 09:44:00-05:00,BMY,negative
175739.0,Starboard Value Reiterates Belief That Proposed Merger With Celgene Is 'Ill-Advised And Not In Best Interests' Of Bristol-Myers Stockholders,2019-03-06 07:40:00-05:00,BMY,negative
175740.0,Bristol-Myers Squibb Files Investor Presentation And Board Of Directors Sends Letter To Shareholders Regarding Pending Transaction With Celgene,2019-03-06 07:00:00-05:00,BMY,neutral
175741.0,'Bristol-Myers' imperiled megamerger may depend on Wall Street's loudest whisperers' -STAT News,2019-03-01 14:06:00-05:00,BMY,neutral
175742.0,75 Biggest Movers From Yesterday,2019-03-01 04:55:00-05:00,BMY,neutral
175743.0,Major Shareholders Team To Scuttle Bristol-Myers Squibb's $74B Celgene Buyout: What's Next?,2019-02-28 12:42:00-05:00,BMY,neutral
175744.0,51 Stocks Moving In Thursday's Mid-Day Session,2019-02-28 12:28:00-05:00,BMY,neutral
175745.0,"Bristol-Myers Offers Response To Starboard Letter, Says Welcomes Opinions Of All Shareholders, Will Review Firm's Letter, Respond In Due Course",2019-02-28 12:01:00-05:00,BMY,positive
175746.0,"Starboard Value Issues Letter To Bristol-Myers Shareholders, Sees Co./Stock As 'Deeply Underavlued'",2019-02-28 09:38:00-05:00,BMY,positive
175747.0,34 Stocks Moving In Thursday's Pre-Market Session,2019-02-28 08:26:00-05:00,BMY,neutral
175748.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,BMY,positive
175749.0,"Bristol-Myers Squibb, In Letter To Employees On Feb 27, Says Very Disappointed By Position of Wellington Management with Regard to Celgene Acquisition",2019-02-28 06:20:00-05:00,BMY,negative
175750.0,"Bristol-Myers 13D From Wellington Shields Shows Sharply Raised Stake From ~33K Shares To ~125.7M Shares, Or 7.7% Stake",2019-02-27 17:34:00-05:00,BMY,positive
175751.0,10 Stocks Moving In Wednesday's After-Hours Session,2019-02-27 17:16:00-05:00,BMY,neutral
175752.0,Wellington Mgmt. Issues Press Release Highlighting It Does Not Support Bristol-Myers Purchase Of Celgene,2019-02-27 16:23:00-05:00,BMY,negative
175753.0,Starboard Gets Clearance For Its Bristol-Myers Investment,2019-02-26 10:00:00-05:00,BMY,neutral
175754.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,BMY,neutral
175755.0,Bristol-Myers Squibb Option Alert: Mar 1 $54 Calls Sweep (31) near the Ask: 753 @ $1.055 vs 521 OI; Ref=$52.51,2019-02-21 09:47:00-05:00,BMY,positive
175756.0,Bristol-Myers Shares Spike ~0.8% Higher As Traders Circulate Speculation From Dealreporter Sanofi Interested In Takeover Of Co.,2019-02-21 09:44:00-05:00,BMY,positive
175757.0,Merck To Buy Immune Design For $300M,2019-02-21 09:28:00-05:00,BMY,positive
175758.0,"Celgene Shares Fall 0.5% Over Last Min., Now Below $90.50 Level; Hearing Starboard Is Unhappy With Bristol-Myers Deal To Buy Co.",2019-02-20 14:22:00-05:00,BMY,negative
175759.0,"Bristol-Myers Reports Starboard Value Proposed John Leonard, Steven Shulman, Jeffrey Smith, James Tyree, Janet Vergis For Election To Co. Board",2019-02-20 09:37:00-05:00,BMY,positive
175760.0,"UPDATE: Bristol-Myers Sees Refiling Premerger Notification, Report Form Under HSR Act Wed., Feb. 20, 2019, Which Will Restart 30-Day Time Frame For FTC's Initial Review; Says Deal Closing Remains On Track For Q3'19",2019-02-20 09:03:00-05:00,BMY,neutral
175761.0,"UPDATE: Bristol-Myers Determined To Voluntarily Withdraw, Refile Its Premerger Notification, Report Form Under Hart-Scott-Rodino Antitrust Improvement Act",2019-02-20 09:03:00-05:00,BMY,positive
175762.0,Bristol-Myers Says Continuing Its Engagement With Regulatory Authorities Related To Deal With Celgene,2019-02-20 09:02:00-05:00,BMY,positive
175763.0,"Bristol-Myers Offers Update On Pending Deal With Celgene: Says Remains On Track To Hold Special Meeting For Shareholders Apr. 12, 2019",2019-02-20 09:01:00-05:00,BMY,positive
175764.0,"The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering",2019-02-20 07:34:00-05:00,BMY,negative
175765.0,Starboard Undecided Regarding Support for Celgene Acquisition by Bristol-Myers,2019-02-17 10:27:00-05:00,BMY,positive
175766.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings",2019-02-15 14:00:00-05:00,BMY,neutral
175767.0,"The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal",2019-02-15 07:39:00-05:00,BMY,positive
175768.0,Bristol-Myers Reports Opdivo Plus Yervoy Showed Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer,2019-02-14 16:00:00-05:00,BMY,negative
175769.0,"The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares",2019-02-12 08:04:00-05:00,BMY,negative
175770.0,Bristol-Myers Squibb Reports Opdivo Plus Low-Dose Yervoy Demonstrated Continued Survival Benefit At 30-Month Follow-up In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma,2019-02-11 17:01:00-05:00,BMY,positive
175771.0,Bristol-Myers' Sprycel Approved by the European Commission in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,2019-02-11 06:59:00-05:00,BMY,positive
175772.0,January's Market Bounce Resulted In Some Unexpected Retail Trading Trends,2019-02-05 16:45:00-05:00,BMY,neutral
175773.0,22 Stocks Moving In Monday's Pre-Market Session,2019-02-04 07:59:00-05:00,BMY,neutral
175774.0,Bristol-Myers shares are trading higher after a media report that hedge fund Starboard Value acquired a stake in the company.,2019-02-04 07:27:00-05:00,BMY,positive
175775.0,Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates,2019-02-01 13:30:00-05:00,BMY,neutral
175776.0,Pharma Catches Another Case Of M&A Fever,2019-02-01 10:15:00-05:00,BMY,neutral
175777.0,Premarket Prep Opening NYSE Imbalance Update: Bristol-Myers 102k Shares To Buy; Square 215k To Buy,2019-01-30 09:06:00-05:00,BMY,positive
175778.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2019-01-27 16:07:00-05:00,BMY,neutral
175779.0,"Barron's Picks And Pans: Caterpillar, Dell, Intel And More",2019-01-26 16:26:00-05:00,BMY,neutral
175780.0,Morning Earnings Recap: The Biggest Reports From Thursday's Session,2019-01-25 06:40:00-05:00,BMY,neutral
175781.0,"Market Seems Generally Pleased With Earnings Results, But Geopolitics Still Weigh",2019-01-24 10:58:00-05:00,BMY,positive
175782.0,Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug,2019-01-24 09:35:00-05:00,BMY,negative
175783.0,"Bristol Myers Says After Celgene Deal, Sees More Than $50B In 2025 Revenue, More Than $20 B In 2025 Earnings",2019-01-24 08:50:00-05:00,BMY,neutral
175784.0,"The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial",2019-01-24 07:45:00-05:00,BMY,negative
175785.0,Bristol-Myers Squibb Reaffirms FY19 Adj. EPS Guidance $4.10-$4.20 vs $4.14 Estimate,2019-01-24 07:00:00-05:00,BMY,neutral
175786.0,"Bristol-Myers Squibb Q4 EPS $0.94 Beats $0.85 Estimate, Sales $5.973B Miss $5.99B Estimate",2019-01-24 07:00:00-05:00,BMY,negative
175787.0,"12 Stocks To Watch For January 24, 2019",2019-01-24 04:45:00-05:00,BMY,neutral
175788.0,"Earnings Scheduled For January 24, 2019",2019-01-24 04:28:00-05:00,BMY,neutral
175789.0,Bristol-Myers Squibb Q4 Earnings Preview,2019-01-23 13:30:00-05:00,BMY,neutral
175790.0,Ligand Pharmaceuticals Hit By Bearish Citron Report,2019-01-16 15:35:00-05:00,BMY,neutral
175791.0,Bristol-Myers Squibb Reports European Commisison Approval Of Opdivo Plus Low-Dose Yervoy For Patients with Intermediate And Poor-Risk Advanced Renal Cell Carcinoma,2019-01-14 16:17:00-05:00,BMY,positive
175792.0,"Barron's Picks And Pans: Amazon, Apple, Bristol-Myers, Starbucks And More",2019-01-13 15:11:00-05:00,BMY,positive
175793.0,4 Biotech Pipeline Areas To Keep An Eye On In 2019,2019-01-11 14:53:00-05:00,BMY,neutral
175794.0,5 Top-Selling Drugs With Growth Potential In 2019,2019-01-07 15:04:00-05:00,BMY,positive
175795.0,Eli Lilly Agrees To Buy Loxo For $8B In Bid To Expand Oncology Franchise,2019-01-07 09:00:00-05:00,BMY,positive
175796.0,"The Week Ahead In Biotech: Conferences, Clinical Trials",2019-01-06 09:16:00-05:00,BMY,neutral
175797.0,'Celgene Boosted the Price of Its Top Cancer Drug on the Same Day of Mega-Deal' -Bloomberg,2019-01-04 11:31:00-05:00,BMY,negative
175798.0,Flex Pharma Finds A Lifeline In Merger With Oncology Biotech Salarius Pharma,2019-01-04 10:24:00-05:00,BMY,neutral
175799.0,Bristol-Myers Squibb Option Alert: Jun 21 $55 Calls Sweep (26) near the Ask: 678 @ $1.9 vs 26494 OI; Earnings 1/24 Before Open Ref=$46.3425,2019-01-04 10:01:00-05:00,BMY,positive
175800.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Jan. 4, 2019",2019-01-04 09:55:00-05:00,BMY,positive
175801.0,"The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO",2019-01-04 07:59:00-05:00,BMY,positive
175802.0,58 Biggest Movers From Yesterday,2019-01-04 05:35:00-05:00,BMY,neutral
175803.0,Moody's Is Reviewing Celgene Credit Rating For Upgrade Following Deal With Bristol-Myers,2019-01-03 17:48:00-05:00,BMY,positive
175804.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Thurs., Jan. 3, 2019",2019-01-03 17:45:00-05:00,BMY,positive
175805.0,Canaccord Downgrades Celgene From Buy To Hold,2019-01-03 15:38:00-05:00,BMY,neutral
175806.0,Moody's Reviewing Bristol-Myers For Credit Rating Downgrade Following Deal For Celgene,2019-01-03 15:14:00-05:00,BMY,positive
175807.0,Mid-Afternoon Market Update: Dow Down 575 Points; OHR Pharmaceutical Shares Spike Higher,2019-01-03 14:51:00-05:00,BMY,positive
175808.0,44 Stocks Moving In Thursday's Mid-Day Session,2019-01-03 12:27:00-05:00,BMY,neutral
175809.0,Mid-Day Market Update: Apple Falls On Lowered Sales Guidance; Kitov Pharma Shares Jum,2019-01-03 12:09:00-05:00,BMY,positive
175810.0,"Apple's Lowered Guidance Underscores Worries About Trade, Global Growth",2019-01-03 10:45:00-05:00,BMY,negative
175811.0,Mid-Morning Market Update: Markets Open Lower; Bristol-Myers Squibb To Buy Celgene,2019-01-03 10:19:00-05:00,BMY,negative
175812.0,Bristol-Myers shares are trading lower after the company announced a $74 billion acquisition of Celgene in cash and stock.,2019-01-03 08:49:00-05:00,BMY,neutral
175813.0,From Conference Call: Bristol-Meyers Squibb CEO Says Valuation Of Celgene's Revlimid Is 'Somewhat More Conservative Than What Is Reflected In Consensus',2019-01-03 08:46:00-05:00,BMY,neutral
175814.0,26 Stocks Moving In Thursday's Pre-Market Session,2019-01-03 08:23:00-05:00,BMY,neutral
175815.0,CORRECTION: Bristol-Myers Deal For Celgene At $50/Share In Cash Plus 1 Share Of Bristol-Myers Stock,2019-01-03 08:08:00-05:00,BMY,positive
175816.0,Bristol-Myers Squibb Bets Big On Celgene In $74B Cash And Stock Deal,2019-01-03 08:02:00-05:00,BMY,neutral
175817.0,"The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen",2019-01-03 07:36:00-05:00,BMY,negative
175818.0,"A Peek Into The Markets: US Stock Futures Drop, Apple Cuts Q1 Sales Guidance",2019-01-03 07:21:00-05:00,BMY,negative
175819.0,Gilead shares are trading up on news that Bristol-Myers will acquire Celgene in a $74 billion deal.,2019-01-03 07:13:00-05:00,BMY,positive
175820.0,Bristol-Myers To Purchase Celgene At $50/Share In Cash And 1 Share Of Bristol-Myers For ~$74B Deal,2019-01-03 06:59:00-05:00,BMY,positive
175821.0,Bristol-Myers Squibb Sees FY19 Adj. EPS $4.10-$4.20,2019-01-03 06:59:00-05:00,BMY,neutral
175822.0,Bristol-Myers Reports Sprycel Tablets Approved In Combo With Chemo In Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,2019-01-02 16:28:00-05:00,BMY,positive
175823.0,"Stocks That Will Be Trading Ex Dividend Thurs., Jan. 3, 2019",2019-01-02 10:51:00-05:00,BMY,neutral
175824.0,"The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede",2018-12-27 07:51:00-05:00,BMY,neutral
175825.0,6 Valuable Pipeline Drugs With Upcoming Catalysts,2018-12-26 14:22:00-05:00,BMY,positive
175826.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,BMY,neutral
175827.0,Bristol-Myers Squibb Announces Offer from Taisho Pharmaceutical  to Purchase UPSA for $1.6B,2018-12-19 04:11:00-05:00,BMY,neutral
175828.0,Eisai Announces Bristol-Myers Squibb and H3 Biomedicine Enter Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform,2018-12-18 03:47:00-05:00,BMY,positive
175829.0,"Bristol-Myers Reports Research Collaboration With Boston Medical Center For Investigation Of Markers Of Immuno-Oncology Response, Resistance",2018-12-17 16:30:00-05:00,BMY,neutral
175830.0,Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,2018-12-17 07:05:00-05:00,BMY,positive
175831.0,Bristol-Myers Announces a Multi-Year Collaboration Agreement with Eisai,2018-12-17 07:00:00-05:00,BMY,positive
175832.0,Taisho Said to be Near $1.6B Deal for Bristol-Myers's UPSA,2018-12-17 04:40:00-05:00,BMY,neutral
175833.0,"Bristol-Myers, Costco, JPMorgan And XLU: 'Fast Money' Picks For December 14",2018-12-14 07:38:00-05:00,BMY,neutral
175834.0,Bristol-Myers Squibb Option Alert: Dec 21 $55 Calls Sweep (2) near the Ask: 1000 @ $0.401 vs 9213 OI; Earnings 2/4 Before Open [est] Ref=$53.92,2018-12-13 12:21:00-05:00,BMY,positive
175835.0,"Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate",2018-12-11 12:42:00-05:00,BMY,positive
175836.0,"UPDATE: Gabelli On Clovis Says Continues 'to believe Bristol, Sanofi and Roche to be the most interested buyers'",2018-12-11 10:39:00-05:00,BMY,positive
175837.0,"Bristol-Myers Squibb, Vedanta Biosciences Announce New Clinical Collaboration to Evaluate OPDIVO and VE800 in Patients with Advanced or Metastatic Cancers; BMY to Make Equity Investment in Vedanta",2018-12-10 03:29:00-05:00,BMY,positive
175838.0,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",2018-12-07 08:04:00-05:00,BMY,neutral
175839.0,Bristol-Myers Raises Qtr. Dividend From $0.40 To $0.41/Share,2018-12-06 16:18:00-05:00,BMY,neutral
175840.0,"Benzinga's Top Upgrades, Downgrades For December 6, 2018",2018-12-06 09:15:00-05:00,BMY,positive
175841.0,"BMO Capital Upgrades Bristol-Myers Squibb to Outperform, Announces $60 Price Target",2018-12-06 06:16:00-05:00,BMY,neutral
175842.0,Bristol-Myers Squibb To Transfer $3.8B In U.S. Pension Liabilities Through Termination Of Its US Retirement Income Plan,2018-12-03 17:01:00-05:00,BMY,negative
175843.0,"TARGET PharmaSolutions Reports Strategic Partnership For TARGET-IBD With Bristol Myers Squibb, No Terms Disclosed",2018-12-03 08:42:00-05:00,BMY,negative
175844.0,Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates,2018-11-30 13:09:00-05:00,BMY,neutral
175845.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-11-27 12:25:00-05:00,BMY,neutral
175846.0,32 Stocks Moving In Tuesday's Pre-Market Session,2018-11-27 08:00:00-05:00,BMY,neutral
175847.0,"The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial",2018-11-27 07:32:00-05:00,BMY,negative
175848.0,Bristol-Myers shares down 2.2% as company reported its CheckMate -451 study did not meet its primary endpoint,2018-11-26 17:42:00-05:00,BMY,positive
175849.0,Bristol-Myers Reports CheckMate -451 Study Did Not Meet Its Primary Endpoint,2018-11-26 16:30:00-05:00,BMY,neutral
175850.0,Bristol-Myers Squibb Option Alert: Fri $57.5 Puts Sweep (74) near the Bid: 960 @ $2.793 vs 10442 OI; Ref=$54.57,2018-11-16 15:12:00-05:00,BMY,positive
175851.0,"BMO Capital Maintains Market Perform on Bristol-Myers Squibb, Raises Price Target to $58",2018-11-16 10:57:00-05:00,BMY,neutral
175852.0,"The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal",2018-11-16 08:08:00-05:00,BMY,positive
175853.0,"Bristol-Myers Reports CHMP Recommended Approval Of Opdivo Plus Low-Dose Yervoy As First-Line Treatment For Patients With Intermediate-, Poor-Risk Advance Renal Cell Carcinoma",2018-11-15 16:35:00-05:00,BMY,positive
175854.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,BMY,neutral
175855.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,BMY,negative
175856.0,FDA Approves Bristol-Myers Squibb Company's Empliciti Plus Pomalidomide And Dexamethasone For Relapsed Or Refractory Multiple Myeloma,2018-11-06 16:53:00-05:00,BMY,positive
175857.0,"Morgan Stanley Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $59",2018-11-06 12:35:00-05:00,BMY,negative
175858.0,Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo in Combination with IPI-549 in Urothelial Cancer,2018-11-05 07:22:00-05:00,BMY,negative
175859.0,"Bristol-Myers, Infinity Pharma Report New Clinical Collaboration To Evaluate Opdivo In Combo With IPI-549 For Urothelial Cancer",2018-11-05 06:59:00-05:00,BMY,negative
175860.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,BMY,neutral
175861.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,BMY,negative
175862.0,"Bristol-Meyers Sees Continued Growth From Opdivo In 2019, Says Eliquis Has 'Significant' Headroom For Further Growth",2018-10-25 10:44:00-04:00,BMY,positive
175863.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,BMY,negative
175864.0,UPDATE: Bristol-Myers Raises FY18 Adj. EPS From $3.55-$3.65 To $3.80-$3.90 vs $3.64 Estimate,2018-10-25 07:01:00-04:00,BMY,neutral
175865.0,Bristol-Myers Raises Guidance,2018-10-25 07:00:00-04:00,BMY,neutral
175866.0,"Bristol-Myers Squibb Company Q3 EPS $1.09 Beats $0.91 Estimate, Sales $5.691B Miss $5.72B Estimate",2018-10-25 06:59:00-04:00,BMY,negative
175867.0,"15 Stocks To Watch For October 25, 2018",2018-10-25 05:11:00-04:00,BMY,neutral
175868.0,"Earnings Scheduled For October 25, 2018",2018-10-25 04:48:00-04:00,BMY,neutral
175869.0,Bristol-Myers Squibb Q3 Earnings Outlook,2018-10-24 14:45:00-04:00,BMY,neutral
175870.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,BMY,negative
175871.0,"Benzinga's Top Upgrades, Downgrades For October 24, 2018",2018-10-24 09:19:00-04:00,BMY,positive
175872.0,"The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering",2018-10-24 07:48:00-04:00,BMY,positive
175873.0,"Wolfe Research Initiates Coverage On Bristol-Myers Squibb with Outperform Rating, Announces $66 Price Target",2018-10-24 06:16:00-04:00,BMY,neutral
175874.0,"'6 kids dead, 12 sick in viral outbreak at New Jersey rehabilitation center' -ABC 7 NY",2018-10-23 15:00:00-04:00,BMY,negative
175875.0,58 Biggest Movers From Yesterday,2018-10-23 05:09:00-04:00,BMY,neutral
175876.0,11 Stocks That Moved From ESMO 2018,2018-10-22 13:39:00-04:00,BMY,neutral
175877.0,45 Stocks Moving In Monday's Mid-Day Session,2018-10-22 12:39:00-04:00,BMY,neutral
175878.0,8 Biggest Price Target Changes For Monday,2018-10-22 10:01:00-04:00,BMY,neutral
175879.0,"Benzinga's Top Upgrades, Downgrades For October 22, 2018",2018-10-22 09:14:00-04:00,BMY,positive
175880.0,"Citigroup Downgrades Bristol-Myers Squibb to Neutral, Lowers Price Target to $57",2018-10-22 07:10:00-04:00,BMY,negative
175881.0,"Bristol-Myers Gives Results From an Analysis on its Phase 3 Checkmate Study, Says Opdivo in Combination with Yervoy Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",2018-10-22 06:46:00-04:00,BMY,positive
175882.0,Bristol-Myers Squibb Announces Opdivo Plus Low-Dose Yervoy Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer at ESMO 2018,2018-10-22 03:59:00-04:00,BMY,negative
175883.0,Bristol-Myers Squibb Announces Opdivo in Combination with Yervoy Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma at ESMO 2018,2018-10-22 03:48:00-04:00,BMY,positive
175884.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,BMY,neutral
175885.0,Bristol-Myers Squibb Announces Opdivo in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer at ESMO 2018,2018-10-20 16:56:00-04:00,BMY,negative
175886.0,UPDATE: Bristol Says Obtained Deal From CHMP For An Extension Of Clock-Stop For Type II Variation App To Address First Request For Supplementary Info,2018-10-19 16:18:00-04:00,BMY,neutral
175887.0,Bristol-Myers Offers Update On Ongoing Regulatory Review Of Opdivo Plus Low-Dose Yervoy In First-Line Lung Cancer Patients With Tumor Mutational Burden: CHMP Requested Added Info From CheckMate -227,2018-10-19 16:17:00-04:00,BMY,negative
175888.0,"Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $58",2018-10-12 08:14:00-04:00,BMY,neutral
175889.0,"A Peek Into The Markets: US Stock Futures Gain Ahead Of Citigroup, Wells Fargo Earnings",2018-10-12 07:49:00-04:00,BMY,positive
175890.0,Bristol-Myers Squibb Reports Phase 3 CheckMate -331 Study Did Not Meet Primary Endpoint,2018-10-12 07:00:00-04:00,BMY,neutral
175891.0,Compugen Shares are trading higher after the announcement of a $12M investment and collaboration with Bristol-Myers Squibb.,2018-10-11 07:37:00-04:00,BMY,positive
175892.0,"Bristol-Myers Squibb Reports Collaboration With Compugen To Evaluate Therapeutic Regimen In Advanced Solid Tumors, Will Make $12M Investment",2018-10-11 07:00:00-04:00,BMY,positive
175893.0,"Bristol-Myers, Disney, ETP, Paypal: 'Fast Money' Picks For October 9",2018-10-09 06:37:00-04:00,BMY,neutral
175894.0,"Stocks That Will Trade Ex Dividend Thurs., Oct. 4, 2018",2018-10-03 16:55:00-04:00,BMY,neutral
175895.0,European Medicines Agency Validates Bristol-Myers Squibb's Application For Empliciti Plus Pomalidomide And Low-Dose Dexamethasone In Patients With Multiple Myeloma,2018-09-18 06:59:00-04:00,BMY,positive
175896.0,Natera Signs Agreement with Bristol-Myers Squibb to Investigate Signatera ctDNA Assay as a Potential Biomarker for Opdivo In Phase 2 Clinical Trial,2018-09-13 13:03:00-04:00,BMY,positive
175897.0,Bristol-Myers Squibb Filing Shows Registration For Mixed Securities Shelf Offering,2018-09-12 16:37:00-04:00,BMY,positive
175898.0,"Bristol-Myers Squibb Announces Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial",2018-09-12 04:20:00-04:00,BMY,positive
175899.0,Health Care Has Been On Fire. Will The Uptrend Continue?,2018-09-07 14:40:00-04:00,BMY,positive
175900.0,"FDA Accepts Bristol-Myers Squibb's Application for Sprycel, Application Based On Results From Phase 2 CA180-372 Study",2018-08-30 06:59:00-04:00,BMY,positive
175901.0,"UPDATE: Bristol-Myers Says FDA Granted Application Priority Review With Action Date Of Dec. 27, 2018",2018-08-23 07:00:00-04:00,BMY,positive
175902.0,Bristol-Myers Reports FDA Accepted For Priority Review Co.'s Application For Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma,2018-08-23 06:59:00-04:00,BMY,positive
175903.0,Bristol-Myers Squibb Receives FDA Approval For Opdivo (nivolumab) For Certain Patients With Previously Treated Small Cell Lung Cancer,2018-08-17 07:01:00-04:00,BMY,negative
175904.0,"The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait",2018-08-16 09:37:00-04:00,BMY,negative
175905.0,REMINDER: Bristol-Myers Has FDA PDUFA Decision Date Today For CM-32 (Opdivo + Chemotherapy for Small Cell Lung Cancer),2018-08-16 05:54:00-04:00,BMY,neutral
175906.0,"Q2 13F Roundup: How Buffett, Einhorn, Loeb And Others Adjusted Their Portfolio",2018-08-15 10:23:00-04:00,BMY,neutral
175907.0,"The Week Ahead: Nvidia, Retailer Earnings In Focus",2018-08-13 13:26:00-04:00,BMY,neutral
175908.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-08-12 16:52:00-04:00,BMY,neutral
175909.0,"Benzinga's Top Upgrades, Downgrades For August 8, 2018",2018-08-08 09:12:00-04:00,BMY,positive
175910.0,Atlantic Equities Upgrades Bristol-Myers Squibb to Neutral,2018-08-08 08:42:00-04:00,BMY,neutral
175911.0,Trump Says Administration Will Be Making an Announcement Next Week Regarding Reducing Drug Prices,2018-08-07 20:07:00-04:00,BMY,neutral
175912.0,The Highs And Lows Of Earnings Season Dominate July's IMX Results,2018-08-07 16:10:00-04:00,BMY,negative
175913.0,Investor Movement Index July Summary,2018-08-07 09:12:00-04:00,BMY,neutral
175914.0,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,2018-08-01 07:38:00-04:00,BMY,neutral
175915.0,"BZ NOTE On Exelixis Spike Higher: Traders Likely Viewing Co.'s Renal Cancer Treatment Optimistically Following Comment on Bristol-Myers Q2 Earnings Conference Call It Will Receive Negative CHMP Opinion For OPDIVO, A Potential Renal Cancer Treatment",2018-07-26 10:47:00-04:00,BMY,negative
175916.0,"Bristol-Myers Says It Strongly Disagree's With CHMP Opinion, Says It Will Pursue A Reexamination",2018-07-26 10:43:00-04:00,BMY,positive
175917.0,"Exelixis Shares Spike 2.8% Higher, Could Be Related To Chatter Of Negative CHMP Opinion For Renal Cell Carcinoma Treatment Discussed On Bristol-Myers Q2 Earnings Conference Call",2018-07-26 10:42:00-04:00,BMY,negative
175918.0,Bristol-Myers Shares Fall 2.3% Over Last Min. As Traders Circulate Chatter Of Comment From Conference Call Suggesting Exec Said They Will Be Receiving Negative Opinion From CHMP for OPDIVO In Renal Cancer; Conference Call Just Recently Started At 10:30 a.m. EDT,2018-07-26 10:40:00-04:00,BMY,negative
175919.0,UPDATE: Bristol-Myers Raises FY18 Adj. EPS Outlook From $3.35-$3.45 To $3.55-$3.65 vs $3.42 Estimate,2018-07-26 07:14:00-04:00,BMY,neutral
175920.0,Bristol-Myers Raises FY18 Outlook,2018-07-26 06:59:00-04:00,BMY,neutral
175921.0,"Bristol-Myers Squibb Q2 EPS $1.01 Beats $0.88 Estimate, Sales $5.704B Beat $5.44B Estimate",2018-07-26 06:59:00-04:00,BMY,neutral
175922.0,"Earnings Scheduled For July 26, 2018",2018-07-26 04:20:00-04:00,BMY,neutral
175923.0,Q2 Earnings Preview For Bristol-Myers Squibb,2018-07-25 14:50:00-04:00,BMY,neutral
175924.0,Morgan Stanley: Newly Public Neon Therapeutics Has Outperformance Potential,2018-07-23 14:42:00-04:00,BMY,neutral
175925.0,Bristol-Myers Squibb Announces Departure of Chief Commercial Officer Murdo Gordon,2018-07-23 08:34:00-04:00,BMY,neutral
175926.0,"BMO Capital Maintains Market Perform on Bristol-Myers Squibb, Raises Price Target to $51",2018-07-23 08:05:00-04:00,BMY,neutral
175927.0,Bristol-Myers Squibb Reports Clinical Research Collaboration With Gritstone Oncology To Evaluate Novel Immunotherapy Approach In Advanced Solid Tumors,2018-07-19 07:05:00-04:00,BMY,positive
175928.0,Bristol-Meyers Squibb Announces Opdivo With Low-Dose Yervoy Received FDA Approval For Treatment Of  MSI-H And dMMR,2018-07-11 07:03:00-04:00,BMY,positive
175929.0,Bristol-Myers Squibb Says Immuno-Oncology Combination Therapy Approved By Health Canada,2018-07-09 13:29:00-04:00,BMY,positive
175930.0,"The Week Ahead: Trump Goes To London, Big Banks Herald Earnings Season's Return",2018-07-09 13:16:00-04:00,BMY,neutral
175931.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-07-08 19:16:00-04:00,BMY,neutral
175932.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,BMY,neutral
175933.0,UPDATE: Bristol-Myers Squibb Is Looking To Sell It's French Over-The-Counter Business Which Is Valued At More Than E$1B,2018-07-05 10:42:00-04:00,BMY,positive
175934.0,Bristol-Myers Squibb Announces European Commission Has Approved Expanded Indication For Sprycel To Include Treatment Of Children With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia In Chronic Phase,2018-07-05 07:01:00-04:00,BMY,positive
175935.0,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,2018-06-30 18:05:00-04:00,BMY,neutral
175936.0,Dapagliflozin as Adjunct Therapy to Insulin for People with Type 1 Diabetes May Improve Glycemic Control,2018-06-24 21:23:00-04:00,BMY,positive
175937.0,"Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap",2018-06-22 08:51:00-04:00,BMY,neutral
175938.0,Bristol-Myers Announces FDA Accepts Application For Opdivo Plus Low-Dose Yervoy For Treatment of First-Line Non-Small Cell Lung Cancer In Patients With Tumor Mutational Burden ≥10 mut/Mb,2018-06-21 16:16:00-04:00,BMY,negative
175939.0,Bristol-Myers Squibb On Sunday Announced Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone Reduces Risk Of Disease Progression By 46% Versus Pomalidomide/Dexamethasone Alone In Patients With Relapsed Or Refractory Multiple Myeloma,2018-06-18 08:44:00-04:00,BMY,negative
175940.0,"Bristol-Myers Squibb Announces That The China National Drug Administration Has Approved Opdivo For NSCLC, Says It's The First And Only PD-1 Inhibitor Approved In China",2018-06-15 08:33:00-04:00,BMY,positive
175941.0,"Apexigen, Yale Cancer Center Report Clinical Collaboration To Evaluate APX005M, Cabiralizumab, Opdivo In Patients Whose Disease Has Progressed On Anti-PD-1/PD-L1 Therapy",2018-06-14 07:06:00-04:00,BMY,negative
175942.0,Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early RA at EULAR 2018,2018-06-13 06:09:00-04:00,BMY,neutral
175943.0,Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate,2018-06-12 11:47:00-04:00,BMY,positive
175944.0,"Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More",2018-06-08 16:33:00-04:00,BMY,neutral
175945.0,Intercept Pharma Shares Up 3.2%; Traders Circulating Word Bristol-Myers Could Be Interested In NASH Space,2018-06-08 09:39:00-04:00,BMY,positive
175946.0,"Nektar Therapeutics Shares Down ~43.5% Ahead Of Close Following Prelim. Data From Co., Bristol-Myers Related To NKTR-214 In Combo With Opdivo",2018-06-04 15:49:00-04:00,BMY,positive
175947.0,Mid-Afternoon Market Update: Dow Up 180 Points; Nektar Therapeutics Shares Plummet,2018-06-04 14:32:00-04:00,BMY,positive
175948.0,5 Biotech Stocks Moving On ASCO Presentations,2018-06-04 13:18:00-04:00,BMY,neutral
175949.0,Bristol-Myers Announces Opdivo Phase 3 CheckMate Trial Results From ASCO Meeting Presentation; Continues To Demonstrate Statistically Longer Survival In Follow Up Of 24 Months,2018-06-04 09:02:00-04:00,BMY,neutral
175950.0,"Bristol-Myers Squibb Gives Data it Plans to Present at ASCO; In Other News, Late Friday FDA Removed Partial Hold On CheckMate-602",2018-06-04 07:00:00-04:00,BMY,neutral
175951.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,BMY,negative
175952.0,"Nektar, ristol-Myers Squibb Announce Preliminary Data for NKTR-214 in Combination with Opdivo for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at #ASCO2018",2018-06-02 20:37:00-04:00,BMY,neutral
175953.0,Bristol-Myers Says Opdivo Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate -214 Study,2018-06-01 07:00:00-04:00,BMY,positive
175954.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2018-05-26 11:07:00-04:00,BMY,neutral
175955.0,"UBS Global Healthcare Conference 2018 Continues Today, Presenters Include: Civitas Solutions, Revance, Akebia Therapeutics, Bristol-Myers, Senseonics, Lantheus, Acceleron Pharma, and HCA Healthcare",2018-05-22 07:05:00-04:00,BMY,positive
175956.0,"Benzinga's Top Upgrades, Downgrades For May 21, 2018",2018-05-21 09:19:00-04:00,BMY,positive
175957.0,UBS Downgrades Bristol-Myers Squibb to Neutral,2018-05-21 08:21:00-04:00,BMY,neutral
175958.0,Uniqure Notches Bullish Initiation On Gene Therapy Prospects,2018-05-20 16:38:00-04:00,BMY,positive
175959.0,"Merck, Bristol Myers Shares Move On Alleged FDA Alert On Keytruda",2018-05-18 11:33:00-04:00,BMY,positive
175960.0,"Merck Shares Dip Lower, Bristol-Myers Squibb Shares Spike Higher Following FDA Alert On Issue Found In Trials Of Keytruda, Tecentriq",2018-05-18 10:43:00-04:00,BMY,positive
175961.0,"Q1 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolio",2018-05-16 11:38:00-04:00,BMY,neutral
175962.0,"Jim Cramer Advises His Viewers On Consolidated Edison, L Brands And More",2018-05-16 07:09:00-04:00,BMY,neutral
175963.0,13F From Cooperman's Omega Shows New 468K Share Stake In Bristol-Myers Squibb,2018-05-15 10:13:00-04:00,BMY,positive
175964.0,Portola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote,2018-05-04 14:14:00-04:00,BMY,positive
175965.0,"BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position",2018-04-27 15:12:00-04:00,BMY,neutral
175966.0,"Benzinga's Top Upgrades, Downgrades For April 27, 2018",2018-04-27 09:27:00-04:00,BMY,positive
175967.0,BMO Capital Upgrades Bristol-Myers Squibb to Market Perform,2018-04-27 07:07:00-04:00,BMY,neutral
175968.0,"Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings",2018-04-26 08:07:00-04:00,BMY,neutral
175969.0,A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings,2018-04-26 07:50:00-04:00,BMY,neutral
175970.0,"Bristol-Myers Squibb Q1 Adj. EPS $0.94 Beats $0.85 Est., Sales $5.193B Misses $5.24B Est.",2018-04-26 07:00:00-04:00,BMY,negative
175971.0,"16 Stocks To Watch For April 26, 2018",2018-04-26 04:53:00-04:00,BMY,neutral
175972.0,"Earnings Scheduled For April 26, 2018",2018-04-26 04:46:00-04:00,BMY,neutral
175973.0,Bristol-Myers Reports European Commission Approves Opdivo 4-Week Dosing Schedule,2018-04-25 16:21:00-04:00,BMY,positive
175974.0,19 Companies Google Could Buy With Its $102 Billion In Cash,2018-04-24 15:56:00-04:00,BMY,neutral
175975.0,Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure,2018-04-24 10:49:00-04:00,BMY,positive
175976.0,"Best Buy, ExxonMobil, And 3 Other Stocks In Strong Trends This Week",2018-04-24 09:52:00-04:00,BMY,positive
175977.0,"Stocks That Made New 52-Week Lows Today Include: Kimberly-Clark, Philip-Morris, CenterPoint Energy, Fortune Brands Home, Mallinckrodt, Clorox, Bristol-Myers, Simon Property Group, Pepsi, Kimco Realty, Hasbro, and Procter & Gamble",2018-04-23 11:27:00-04:00,BMY,positive
175978.0,"Benzinga's Bulls & Bears Of The Week: Dropbox, GE, Microsoft, Twitter And More",2018-04-22 16:14:00-04:00,BMY,neutral
175979.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-20 14:00:00-04:00,BMY,neutral
175980.0,"Stocks That Made New 52-Week Lows Today Include: L Brands, Campbell Soup, Ventas, Kimco Realty, Bristol-Myers, Molson Coors, Kraft Heinz, Mattel, Kimberly-Clark, PepsiCo",2018-04-20 10:20:00-04:00,BMY,negative
175981.0,Bristol-Myers Stock Makes New 52-Week Low of $51.55,2018-04-19 13:04:00-04:00,BMY,negative
175982.0,"Bristol-Myers Reports FDA Acceptance of sBLA For Opdivo in Previously Treated Patients with Small Cell Lung Cancer, Grants Priority Review",2018-04-18 16:19:00-04:00,BMY,negative
175983.0,"Benzinga's Top Analyst Calls From April 18, 2018",2018-04-18 13:09:00-04:00,BMY,positive
175984.0,"Bank of America Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $61.00",2018-04-18 10:58:00-04:00,BMY,negative
175985.0,"One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings",2018-04-17 14:16:00-04:00,BMY,neutral
175986.0,Stock Market Gets Lift From Earnings As Geopolitical Fears Wane,2018-04-17 10:21:00-04:00,BMY,negative
175987.0,7 Biggest Price Target Changes For Tuesday,2018-04-17 09:42:00-04:00,BMY,neutral
175988.0,"Benzinga's Top Upgrades, Downgrades For April 17, 2018",2018-04-17 09:24:00-04:00,BMY,positive
175989.0,"The Market In 5 Minutes: Netflix Surges, Tesla Pauses, Cohen-Hannity And More",2018-04-17 09:00:00-04:00,BMY,neutral
175990.0,Morgan Stanley Downgrades Bristol-Myers Squibb to Equal-Weight,2018-04-17 06:22:00-04:00,BMY,neutral
175991.0,Morgan Stanley Downgrades Bristo-Myers Squibb to Equal Weight from Overweight; Lowers PT to $58 from $78,2018-04-17 04:28:00-04:00,BMY,negative
175992.0,Bristol-Myers Announces Collaboration With Johnson & Johnson's Janssen to Develop and Commercialize Next-Gen Cardiovascular Therapy,2018-04-16 16:32:00-04:00,BMY,neutral
175993.0,Bristol-Myers Announces Data From CM-141 Presented At AACR Meeting,2018-04-16 16:07:00-04:00,BMY,neutral
175994.0,U.S. Food and Drug Administration Approves Opdivo  + Yervoy Combo As First-Line Treatment For Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma,2018-04-16 12:52:00-04:00,BMY,positive
175995.0,"The Week Ahead: Netflix Earnings, Big Bank Results, FDA Actions Abound",2018-04-16 12:10:00-04:00,BMY,neutral
175996.0,UPDATE: Bristol Highlights 'Near doubling of overall response rate with the combination (45.3%) versus chemotherapy (26.9%); 68% of responders had ongoing responses at one year (25% with chemotherapy)',2018-04-16 09:09:00-04:00,BMY,neutral
175997.0,"Bristol-Myers Squibb Reports Opdivo Plus Low-Dose Yervoy Combo Reduced Risk Of Progression, Death By 42% vs Chemo In First-Line Lunch Cancer Patients With High Tumor Mutational Burden",2018-04-16 09:08:00-04:00,BMY,negative
175998.0,"REMINDER: Bristol-Myers Has PDUFA Date Today For Checkmate-214, Opdivo+Yervoy in First-line Renal Cell Carcinoma",2018-04-16 09:05:00-04:00,BMY,neutral
175999.0,"UPDATE: Bristol-Myers Says Efficacy, Safety Of Opdivo In Predominantly Chinese Patient Population With Advanced NSCLC Were Consistent With Results Of CheckMate -017, -057 Studies",2018-04-13 16:42:00-04:00,BMY,positive
176000.0,"UPDATE: Bristol-Myers Says Opdivo Response Rates 17% vs 4% For Docetaxel, Median Duration Of Response Was Note Reached With Opdivo vs 5.3 Mos. With Docetaxel",2018-04-13 16:41:00-04:00,BMY,positive
176001.0,Bristol-Myers Squibb Reports Opdivo Phase 3 CheckMate -078 Trial Reduced Risk Of Death By 32% vs. Chemo,2018-04-13 16:41:00-04:00,BMY,negative
176002.0,"Bristol-Myers Squibb, Illumina Report Strategic Collaboration To Develop, Commercialize Companion Diagnostics For Bristol's Oncology Immunotherapies",2018-04-13 16:15:00-04:00,BMY,neutral
176003.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-13 11:38:00-04:00,BMY,neutral
176004.0,"Nektar Therapeutics Announces Bristol-Myers' Collaboration Effective Today, Resulting In Nektar's Receipt Of $1B Upfront Cash Payment",2018-04-03 17:38:00-04:00,BMY,positive
176005.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2018-04-03 08:14:00-04:00,BMY,neutral
176006.0,What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy,2018-04-02 12:18:00-04:00,BMY,negative
176007.0,"Biotech Stock Roundup: Protagonist Therapeutics, Verona, Amgen And More",2018-03-29 11:28:00-04:00,BMY,neutral
176008.0,Bristol-Myers Squibb's Supplemental Biologics License Application for Opdivo is Accepted by the FDA,2018-03-27 07:00:00-04:00,BMY,positive
176009.0,Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma,2018-03-26 07:16:00-04:00,BMY,positive
176010.0,Biohaven Restructures License Agreement With Bristol-Myers Squibb to Reduce Royalties Payable on its Migraine Product Candidates,2018-03-12 03:51:00-04:00,BMY,positive
176011.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-11 16:58:00-04:00,BMY,neutral
176012.0,An Eventful February Took Its Toll On TD Ameritrade's Investor Index,2018-03-06 16:17:00-05:00,BMY,neutral
176013.0,Investor Movement Index February Summary,2018-03-06 11:55:00-05:00,BMY,neutral
176014.0,Bristol-Myers Squibb's Opdivo Label Update for Flexible Flat-Dosing Every Two and Four Weeks Approved by the FDA,2018-03-06 07:01:00-05:00,BMY,positive
176015.0,The Week Ahead: Discount Retailers Close Out Earnings Season,2018-03-05 14:17:00-05:00,BMY,neutral
176016.0,REMINDER: Bristol-Myers Has FDA PDUFA Date for Opdivo Dosing sBLAs Today,2018-03-05 11:45:00-05:00,BMY,neutral
176017.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-02 14:12:00-05:00,BMY,neutral
176018.0,"Jim Cramer Weighs In On Albemarle, Square And More",2018-03-02 07:13:00-05:00,BMY,neutral
176019.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2018-02-28 10:08:00-05:00,BMY,neutral
176020.0,DZ Bank Downgrades Bristol-Myers Squibb to Hold,2018-02-28 09:17:00-05:00,BMY,neutral
176021.0,"Benzinga's Bulls & Bears Of The Week: Bristol-Myers, GE, Target, Under Armour And More",2018-02-18 14:16:00-05:00,BMY,neutral
176022.0,"Stocks That Made New 52-Wk Highs Earlier Include: Accenture, M&T Bank, PNC, Ansys, Lockheed Martin, Deere, Raytheon, Intuit, Comerica, Interpuclic, Northrop Grumman, VeriSign, Estee Lauder, Bristol-Myers, Red Hat, Nike, NVIDIA and Global Payments",2018-02-16 13:03:00-05:00,BMY,neutral
176023.0,"Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight",2018-02-15 09:38:00-05:00,BMY,negative
176024.0,Morgan Stanley Upgrades Bristol-Myers Squibb Company to Overweight,2018-02-15 07:12:00-05:00,BMY,negative
176025.0,"Leerink Partners Global Healthcare Conf. Concludes Today, Presenters Include: Synlogic, Quanterix, Acorda Therapeutics, Bristol-Myers, Alnylam, and HCA Healthcare",2018-02-15 07:08:00-05:00,BMY,neutral
176026.0,"Adam Feuerstein Tweet:For $BMY — Paying a ton for NKTR-214 doesn't exactly inspire confidence in Opdivo business, as is. What is lurking under the hood of the -227 study we haven't seen?",2018-02-14 07:08:00-05:00,BMY,negative
176027.0,"Bristol-Myers Squibb, Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar's CD122-biased Agonist, NKTR-214; Nektar To Pay $1.85B Upfront Comprised Of $1B In Cash & Purchase Of 8.28M Shares At $102.60/Share",2018-02-14 07:00:00-05:00,BMY,positive
176028.0,Bristol Myers Squibb To Make and Upfront Payment and Potential Future Payments to Sirenas,2018-02-12 08:13:00-05:00,BMY,neutral
176029.0,"Leerink Swann Maintains Outperform on Bristol-Myers Squibb, Raises Price Target to $76.00",2018-02-06 09:04:00-05:00,BMY,neutral
176030.0,Mid-Afternoon Market Update: Dow Tumbles Over 400 Points; Crude Oil Down 2%,2018-02-05 14:30:00-05:00,BMY,negative
176031.0,The Week Ahead: IPOs Ramp Up Just As Earnings Season Fades,2018-02-05 13:22:00-05:00,BMY,neutral
176032.0,Mid-Day Market Update: Dow Falls Over 250 Points; Enphase Energy Shares Spike Higher,2018-02-05 12:21:00-05:00,BMY,positive
176033.0,Mid-Morning Market Update: Markets Open Lower; Bristol-Myers Profit Tops Expectations,2018-02-05 10:13:00-05:00,BMY,positive
176034.0,Benzinga Pro's 5 Stocks To Watch Today,2018-02-05 09:33:00-05:00,BMY,neutral
176035.0,Bristol-Meyers Squibb Company Shares Up  3.94% Premarket After Q4 Earnings Beat,2018-02-05 08:47:00-05:00,BMY,positive
176036.0,28 Stocks Moving In Monday's Pre-Market Session,2018-02-05 08:07:00-05:00,BMY,neutral
176037.0,"Adam Feuerstein Tweets: I guess it's okay to change up your biomarkers in a ph3 clinical trial, as long as you're Big Pharma and not a micro-cap biotech? $BMY",2018-02-05 07:43:00-05:00,BMY,positive
176038.0,Bristol-Myers Squibb Company Announces Phase 3 CHeckMate -227 Met Its Co-Primary Endpoint Of Progression-Free SUrvival With Opdivo And Yervoy,2018-02-05 07:06:00-05:00,BMY,neutral
176039.0,Bristol-Myers Squibb Sees FY18 Adj. EPS $3.15 to $3.30 vs $3.23 Est.,2018-02-05 07:00:00-05:00,BMY,neutral
176040.0,"Bristol-Myers Squibb Reports Q4 Adj. EPS $0.68 vs $0.67 Est., Sales $5.45B vs $5.35B Est.",2018-02-05 06:59:00-05:00,BMY,neutral
176041.0,"Earnings Scheduled For February 5, 2018",2018-02-05 04:28:00-05:00,BMY,neutral
176042.0,"7 Stocks To Watch For February 5, 2018",2018-02-05 04:05:00-05:00,BMY,neutral
176043.0,PreMarket Opening NYSE Imbalance Update: Abbott 28k Shares To Sell; Bristol-Myers 10k To Sell; Alibaba 39k To Buy; Twitter 57k To Buy; BofA 81k To Buy; Goldman 54k To Sell;,2018-01-31 08:35:00-05:00,BMY,positive
176044.0,Five Prime Therapeutics Receives $25M Milestone Payment From Bristol-Myers,2018-01-25 16:09:00-05:00,BMY,neutral
176045.0,Bristol-Myers Squibb's Yervoy Approved by the European Commission for the Treatment of Pediatric Patients,2018-01-22 06:59:00-05:00,BMY,positive
176046.0,Bristol-Myers Squibb Announces Opdivo in Combination with Yervoy Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer,2018-01-21 10:19:00-05:00,BMY,negative
176047.0,The Top 10 Value Stocks In The S&P 500,2018-01-19 13:12:00-05:00,BMY,positive
176048.0,Key Takeaways From The J.P. Morgan Healthcare Conference,2018-01-11 12:06:00-05:00,BMY,neutral
176049.0,"UPDATE: Five Prime Says Is Eligible To Receive Up To $300M In Future Development, Regulatory, Sales-Based Milestone Payments",2018-01-08 08:41:00-05:00,BMY,neutral
176050.0,UPDATE: Five Prime Says Bristol Extended Research Term Of Collaboration Deal With Co. For Second Time,2018-01-08 08:40:00-05:00,BMY,neutral
176051.0,Five Prime Therapeutics Reports Earned IND Milestone Payment Of $5M Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb,2018-01-08 08:40:00-05:00,BMY,positive
176052.0,4 Reasons To Consider Adding Celldex To Your Portfolio,2018-01-02 12:09:00-05:00,BMY,neutral
176053.0,HTG Molecular's Deal With Merck KGaA 'Provides Further Validation' For EdgeSeq Technology,2017-12-27 13:18:00-05:00,BMY,neutral
176054.0,"After Hitting Support, Vetr Issues Buy Rating On Bristol Myers",2017-12-20 17:26:00-05:00,BMY,positive
176055.0,Bristol-Myers Reports FDA Approval For Opdivo As Adjuvant Therapy In Patients With Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease,2017-12-20 15:29:00-05:00,BMY,positive
176056.0,"TARIS Biomedical, Bristol-Myers Squibb Reports Clinical Trial Collaboration For TAR-200 With Opdivo For Treatment Of Muscle Invasive Bladder Cancer",2017-12-20 07:00:00-05:00,BMY,negative
176057.0,Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Yervoyfor the Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma,2017-12-18 06:59:00-05:00,BMY,positive
176058.0,"Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More",2017-12-15 07:33:00-05:00,BMY,positive
176059.0,"STAT News' Adam Feuerstein Responds To Tweet Highlighting '$PFE $AGN rumor - no source': 'The other day I heard $PFE for $BMY,' 'Also $ABBV for $BMY'",2017-12-14 10:05:00-05:00,BMY,negative
176060.0,Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment,2017-12-14 03:55:00-05:00,BMY,neutral
176061.0,"Bristol-Myers Reports FDA Accepted Application For Opdivo Plus Yervoy Combo For Intermediate, Poor-Risk Patients With ARCC; Grants Priority Review",2017-12-13 17:31:00-05:00,BMY,positive
176062.0,PsiOxus Therapeutics Receives $15M Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves,2017-12-12 04:37:00-05:00,BMY,neutral
176063.0,PreMarket Opening NYSE Imbalance Update: ExxonMobil 128k Shares To Sell; Deere 69k Shares To Sell; Bristol-Myers Squibb 45k Shares To Sell; Visa 51k Shares To Sell;,2017-12-11 09:12:00-05:00,BMY,positive
176064.0,Bristol-Myers Squibb Announces Sprycel Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive ALL at #ASH2017,2017-12-09 14:54:00-05:00,BMY,positive
176065.0,Bristol-Myers Raises Qtr. Dividend From $0.39/Share To $0.40/Share,2017-12-07 16:28:00-05:00,BMY,neutral
176066.0,FDA Decisions In November: The Month In Review,2017-12-01 14:05:00-05:00,BMY,neutral
176067.0,Bristol-Myers Shares Indicated Up ~0.6% Premarket Following Late Thurs. Release Highlighting Its CheckMate -078 Opdivo Lung Cancer Trial Was Stopped Early For Showing Superior Overall Survival,2017-12-01 06:52:00-05:00,BMY,negative
176068.0,A Lazarus Act For This Pharma ETF,2017-11-29 17:03:00-05:00,BMY,neutral
176069.0,Bristol-Myers Shares Volatile At Session Highs Following Large Block Trade: 2.8M Shares At $62.56/Share; Order Was Worth ~$175M,2017-11-28 12:21:00-05:00,BMY,positive
176070.0,UPDATE: CytomX FDA Acceptance Of INDA Triggers $10M Milestone Payment From Bristol-Myers Squibb,2017-11-28 08:31:00-05:00,BMY,positive
176071.0,Bristol-Myers Says the European Medicines Agency Validates its Type II Variation Application for Opdivo Plus Yervoy in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma,2017-11-28 06:42:00-05:00,BMY,positive
176072.0,How Digital Pills Could Change The Health Insurance Game,2017-11-27 09:12:00-05:00,BMY,neutral
176073.0,PreMarket NYSE Imbalance Update: GE 294k Shares To Buy; BABA 105k Shares To Buy; SQ 125k Shares To Buy; VZ 49k Shares To Sell; SNAP 59k Shares To Buy; PFE 88k Shares To Sell; BMY 39k Shares To Sell,2017-11-16 08:57:00-05:00,BMY,positive
176074.0,"Jefferies 2107 London Healthcare Conference Begins Today, Presenters Include: Alkermes, Bristol-Myers, Immunogen, and Eagle Pharmaceuticals",2017-11-15 09:00:00-05:00,BMY,neutral
176075.0,LabCorp Reports New Expanded Use For PD-L1 Test With Bristol's OPDIVO,2017-11-15 08:48:00-05:00,BMY,neutral
176076.0,Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate,2017-11-15 07:36:00-05:00,BMY,positive
176077.0,Analyst: Nektar Has A Handful Of Milestones Ahead In 2018,2017-11-13 11:49:00-05:00,BMY,neutral
176078.0,"Nektar Therapeutics, Bristol-Myers Squibb Announce First Presentation of Data from PIVOT-02 Phase 1/2 Study Showing Potential Benefits Presented at SITC 2017",2017-11-12 07:30:00-05:00,BMY,positive
176079.0,"Bristol Myers Announces 'Encouraging' Response with Opdivo Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003",2017-11-10 07:04:00-05:00,BMY,positive
176080.0,FDA Expands Approval of Bristol-Myers Squibb's Sprycel to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase,2017-11-10 06:31:00-05:00,BMY,positive
176081.0,Pharma ETFs Down Post Q3 Earnings,2017-11-09 12:34:00-05:00,BMY,neutral
176082.0,REMINDER: Bristol-Myers Has FDA PDUFA Date For Sprycel sNDA Today,2017-11-09 10:21:00-05:00,BMY,neutral
176083.0,"Bristol-Myers Squibb, Five Prime Report Phase 1a/1b Data Evaluating Cabiralizumab With Opdivo In Patients With Advanced Solid Tumors",2017-11-09 08:06:00-05:00,BMY,positive
176084.0,Pre-Market Imbalance Update: General Electric 258k Shares To Buy; Alibaba 121k Shares To Buy; Square 168k Shares To Buy; Pfizer 41k Shares To Sell; Bristol-Myers 51k Shares To Sell; Disney 70k Shares To Buy,2017-11-07 08:58:00-05:00,BMY,positive
176085.0,"Pharma Stock Roundup: Pfizer, Teva, Novartis, And More",2017-11-06 12:19:00-05:00,BMY,neutral
176086.0,"The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket",2017-11-06 10:48:00-05:00,BMY,neutral
176087.0,UPDATE: Bristol-Myers Says Opdivo Reduced 'the risk of death by 26% versus everolimus in the phase 3 CheckMate -025 study',2017-11-06 07:28:00-05:00,BMY,negative
176088.0,Bristol-Myers Reports Opdivo Showed Superior 3-Year Survival Benefit For Patients Previously Treated With RCC,2017-11-06 07:27:00-05:00,BMY,positive
176089.0,Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon,2017-10-31 07:52:00-04:00,BMY,neutral
176090.0,The Bull Thesis For Merck Is Evaporating,2017-10-30 11:14:00-04:00,BMY,neutral
176091.0,Analyst Grows Cautious On Merck's Keytruda After Company Withdraws European Application,2017-10-30 10:08:00-04:00,BMY,negative
176092.0,8 Technical Levels Highlighted On Monday's PreMarket Prep,2017-10-30 09:59:00-04:00,BMY,neutral
176093.0,"Benzinga's Top Upgrades, Downgrades For October 30, 2017",2017-10-30 09:22:00-04:00,BMY,positive
176094.0,11 Technical Levels Discussed On Thursday's PreMarket Prep,2017-10-26 09:35:00-04:00,BMY,neutral
176095.0,"Pre-Market Imbalance Update: GE 365K Shares To Sell, AT&T 329K To Buy, Twitter 164K To Buy, Cat 78K To Sell, Square 63K To Buy, Bristol-Myers 49K To Sell, GM 38K To Sell, Alibaba 26K To Buy",2017-10-26 09:13:00-04:00,BMY,positive
176096.0,"A Peek Into The Markets: U.S. Stock Futures Edge Higher; Alphabet, Amazon Earnings In Focus",2017-10-26 07:35:00-04:00,BMY,positive
176097.0,Bristol-Myers Squibb Increases FY17 Adj. EPS From $2.90-$3.00 to $2.95-$3.05,2017-10-26 07:00:00-04:00,BMY,neutral
176098.0,Bristol-Myers Squibb Increases FY17 Adj. EPS,2017-10-26 06:59:00-04:00,BMY,neutral
176099.0,"Bristol-Myers Squibb Reports Q3 Adj. EPS $0.75 vs $0.77 Est., Sales $5.3B vs $5.2B Est.",2017-10-26 06:59:00-04:00,BMY,neutral
176100.0,"15 Stocks To Watch For October 26, 2017",2017-10-26 04:44:00-04:00,BMY,neutral
176101.0,"Earnings Scheduled For October 26, 2017",2017-10-26 04:20:00-04:00,BMY,neutral
176102.0,Healthcare ETFs Set To Soar As Q3 Earnings Unfold,2017-10-24 12:35:00-04:00,BMY,neutral
176103.0,Benzinga's Option Alert Recap From October 23,2017-10-23 16:56:00-04:00,BMY,positive
176104.0,Is A Beat In Store For Bristol-Myers In Q3 Earnings?,2017-10-23 12:36:00-04:00,BMY,neutral
176105.0,A Preview Of Next Week's Blue-Chip Earnings,2017-10-22 19:44:00-04:00,BMY,neutral
176106.0,"Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever",2017-10-18 09:07:00-04:00,BMY,positive
176107.0,Bristol-Myers Says FDA Accepted Opdivo for Priority Review and Breakthrough Therapy Designation,2017-10-16 16:16:00-04:00,BMY,positive
176108.0,Bristol-Myers Stock May Have Exhausted Its Upside For Now,2017-10-16 10:08:00-04:00,BMY,negative
176109.0,"Benzinga's Top Upgrades, Downgrades For October 16, 2017",2017-10-16 09:13:00-04:00,BMY,positive
176110.0,"The Market In 5 Minutes: Health Insurers, Tesla Firings And Big Analyst Rating Changes",2017-10-16 08:47:00-04:00,BMY,neutral
176111.0,Jefferies Downgrades Bristol-Myers Squibb to Hold,2017-10-16 06:19:00-04:00,BMY,neutral
176112.0,"Bristol-Myers Squibb Announces Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032",2017-10-16 04:07:00-04:00,BMY,negative
176113.0,Bank Of America Sees NewLink Genetics As 'Undervalued',2017-10-13 09:58:00-04:00,BMY,neutral
176114.0,"Lightning Round: Jim Cramer Weighs In On Bristol-Myers Squibb, Mazor Robotics And More",2017-10-13 07:47:00-04:00,BMY,neutral
176115.0,Bristol-Myers Reports Extension Of Strategic Partnership With TARGET PharmaSoltuions For TARGET-NASH,2017-10-12 09:01:00-04:00,BMY,neutral
176116.0,5 Biggest Price Target Changes For Wednesday,2017-10-11 09:37:00-04:00,BMY,neutral
176117.0,These Were The Most Bought And Sold Stocks In September,2017-10-10 16:12:00-04:00,BMY,neutral
176118.0,Najarian Brothers See Unusual Options Activity In BlackBerry And Bristol-Myers Squibb,2017-09-29 18:41:00-04:00,BMY,neutral
176119.0,"Attention Biotech Investors, Here's Your PDUFA Primer For October",2017-09-28 10:51:00-04:00,BMY,neutral
176120.0,Infinity Pharma and Bristol-Myers Expand Clinical Collaboration Evaluating IPI-549 in Combination with Opdivo,2017-09-25 08:03:00-04:00,BMY,positive
176121.0,The Street Has Finally Recognized The Exelixis Clinical Program Potential,2017-09-22 13:13:00-04:00,BMY,neutral
176122.0,"Bristol-Myers' Opdivo Approved by the Japanese Ministry of Health, Labor and Welfare for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy",2017-09-22 07:17:00-04:00,BMY,negative
176123.0,AbbVie and Bristol-Myers Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors,2017-09-22 07:00:00-04:00,BMY,positive
176124.0,Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers,2017-09-20 11:49:00-04:00,BMY,neutral
176125.0,"Mirati Therapeutics Sitravatinib Data, Explained",2017-09-15 10:42:00-04:00,BMY,neutral
176126.0,The Market In 5 Minutes,2017-09-14 10:07:00-04:00,BMY,neutral
176127.0,"Bristol-Myers and Halozyme Enter Collaboration and License Agreement Using Halozyme's ENHANZE, Halozyme to Receive $105M Upfront",2017-09-14 07:00:00-04:00,BMY,positive
176128.0,This Analyst Predicts Bullish Growth Outlook For Incyte,2017-09-12 09:28:00-04:00,BMY,positive
176129.0,Array BioPharma And Others Shine At The ESMO 2017 Congress,2017-09-11 13:30:00-04:00,BMY,neutral
176130.0,Bristol-Myers In Collaboration With Transgene Receives FDA Approval To Launch Phase 2 Trial Of TG4010 and NIVOLUMAB,2017-09-11 11:49:00-04:00,BMY,positive
176131.0,"Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers",2017-09-11 09:15:00-04:00,BMY,neutral
176132.0,"Pre-Market Imbalance Update: Bristol-Myers Squibb 152K Shares To Sell, GE 145K To Sell, Pfizer 108K to Sell, Home Depot 102K Shares To Buy, Alibaba 101K Shares To Buy, USG 94K To Buy, Lowe's 48K To Buy, Heritage Insurance 43K To Buy, Rockwell Collins 38K",2017-09-11 08:57:00-04:00,BMY,positive
176133.0,Bristol-Myers Squibb Announces Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMate-214 Trial at ESMO 2017,2017-09-10 17:36:00-04:00,BMY,positive
176134.0,What Pharmaceuticals Spend On Lobbying To Influence Trump,2017-09-09 16:28:00-04:00,BMY,negative
176135.0,"European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5",2017-09-08 09:15:00-04:00,BMY,neutral
176136.0,Watch These 5 Huge Put Purchases In Friday Trade,2017-09-08 04:09:00-04:00,BMY,positive
176137.0,Benzinga's Option Alert Recap From September 7,2017-09-07 16:37:00-04:00,BMY,positive
176138.0,Bristol Myers Squibb Option Alert: Dec 15 $50 Puts at the Ask: 3750 @ $0.331 vs 2253 OI; Ref=$62.86,2017-09-07 13:45:00-04:00,BMY,positive
176139.0,Bristol Myers Squibb Option Alert: Fri $62 Calls Sweep (10) at the Bid: 621 @ $1.045 vs 96 OI; Ref=$62.94,2017-09-07 12:58:00-04:00,BMY,positive
176140.0,"Bristol-Myers Reports CheckMate -214 Study Evaluating Opdivo In Combo With Yervoy Stopped Early For Showing Overall Survival Benefit In Patients With Previously Untreated Advanced, Metastatic Renal Cell Carcinoma",2017-09-07 07:00:00-04:00,BMY,positive
176141.0,Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts,2017-09-01 14:03:00-04:00,BMY,neutral
176142.0,"Jim Cramer Shares His Thoughts On Genworth Financial, AeroVironment And Bristol-Myers Squibb",2017-08-31 07:23:00-04:00,BMY,positive
176143.0,Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo and DS-8201,2017-08-28 16:01:00-04:00,BMY,neutral
176144.0,"Bristol-Myers Squibb, Pfizer Present Observational Real-World Data Analysis on Effectiveness and Safety of Eliquis vs to Warfarin in Select High-Risk Patients with NVAF",2017-08-28 04:22:00-04:00,BMY,positive
176145.0,"Bristol-Myers Squibb, Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation and Treating Deep Vein Thrombosis/Pulmonary Embolism  at ESC Congress 2017",2017-08-18 07:00:00-04:00,BMY,positive
176146.0,Bristol-Myers Squibb Receives FDA  Orphan Drug Designation for Nivolumab and Ipilimumab for Treatment of Mesothelioma,2017-08-18 06:22:00-04:00,BMY,neutral
176147.0,Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive',2017-08-16 11:59:00-04:00,BMY,neutral
176148.0,"Bristol-Myers Announces Top-line Results From Phase 3 Opdivo Study, Met 1 Co-Primary Endpoint, Missed Another; Study Will Continue To Evaluate 3rd Co-Primary Endpoint",2017-08-15 16:31:00-04:00,BMY,negative
176149.0,13F From Rosenstein's JANA Shows Liquidated ~716K Share Stake In Bristol-Myers Squibb,2017-08-14 10:23:00-04:00,BMY,positive
176150.0,Bristol-Myers Squibb to Acquire IFM Therapeutics For $300M Upfront WIth Potential Of Up To $1.01B In Milestones,2017-08-03 16:00:00-04:00,BMY,neutral
176151.0,Seattle Genetics Buys Bothell Manufacturing Facility From Bristol-Myers Squibb,2017-08-01 16:01:00-04:00,BMY,neutral
176152.0,Key FDA Events To Watch Out For In August 2017,2017-08-01 12:39:00-04:00,BMY,neutral
176153.0,"Bristol-Myers Shares Plunge ~$1 Over Last Min., Stock Now Down 1.9% For Session",2017-08-01 10:33:00-04:00,BMY,positive
176154.0,August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty,2017-08-01 09:20:00-04:00,BMY,neutral
176155.0,Bristol-Myers Squibb Receives FDA Approval for Opdivo,2017-08-01 07:29:00-04:00,BMY,positive
176156.0,Bristol-Myers and Clovis Oncology to Collaborate on Opdivo and Rubraca In Phase 2 and Phase 3 Trials,2017-07-31 07:00:00-04:00,BMY,neutral
176157.0,5 Biggest Price Target Changes For Friday,2017-07-28 09:48:00-04:00,BMY,neutral
176158.0,20 Biggest Mid-Day Losers For Thursday,2017-07-27 12:51:00-04:00,BMY,negative
176159.0,Why Is AstraZeneca Sinking Today?,2017-07-27 09:18:00-04:00,BMY,neutral
176160.0,20 Stocks Moving In Thursday's Pre-Market Session,2017-07-27 08:30:00-04:00,BMY,neutral
176161.0,"Bristol-Myers Squibb Reports Q2 Adj. EPS $0.74, Inline, Sales $5.1B vs $5.09B Est.",2017-07-27 07:00:00-04:00,BMY,neutral
176162.0,"15 Stocks To Watch For July 17, 2017",2017-07-27 05:12:00-04:00,BMY,neutral
176163.0,"Earnings Scheduled For July 27, 2017",2017-07-27 05:07:00-04:00,BMY,neutral
176164.0,"Bristol-Myers Reports FDA Acceptance Of sBLAs For Opdivo 4-Week Dosing Schedule, Action Date March 5, 2018",2017-07-24 16:16:00-04:00,BMY,positive
176165.0,Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers,2017-07-24 15:29:00-04:00,BMY,neutral
176166.0,Bristol-Meyers' Yervoy FDA Approval Expanded to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma,2017-07-24 06:59:00-04:00,BMY,positive
176167.0,These Were The Most Popular Buys And Sells Among Retail Investors In June,2017-07-17 11:17:00-04:00,BMY,positive
176168.0,"Novartis Shares Spike to $84 High Following Panel Approval, Now Relatively Unaffected; Shares Of Bristol Myers Fell 1.8%",2017-07-12 15:34:00-04:00,BMY,positive
176169.0,TD Ameritrade's Investor Movement Index (IMX) For June 2017,2017-07-10 16:19:00-04:00,BMY,neutral
176170.0,Bristol-Myers sNDA Accepted by the FDA to Include an Indication for Sprycel,2017-07-10 06:59:00-04:00,BMY,positive
176171.0,Bristol-Myers Squibb's ORENCIA Receives FDA Approval,2017-07-06 07:34:00-04:00,BMY,positive
176172.0,Opdivo News Doesn't Give Bristol-Myers Much Of A Boost,2017-07-05 11:37:00-04:00,BMY,positive
176173.0,"Pre-Market Imbalance Update: Ford 279K Shares To Sell, NIKE 223K To Sell, JP Morgan 82K Shares To Buy, Disney 65K To Buy, Wells Fargo 58K To Buy, Bristol-Myers 51K To Buy, ExxonMobil 50K To Sell, Visa 47K To Buy",2017-07-05 09:16:00-04:00,BMY,positive
176174.0,A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Fed Minutes,2017-07-05 07:31:00-04:00,BMY,neutral
176176.0,"Barron's Picks And Pans: Bristol-Myers, Texas Instruments, Altaba And More",2017-07-02 17:01:00-04:00,BMY,neutral
176177.0,Stocks Going Ex Dividend The First Week of July,2017-06-30 13:12:00-04:00,BMY,neutral
176178.0,"A Surprisingly Clean, Straightforward Approval Gives Portola Pharma Shares A Shot Of Upside",2017-06-26 14:03:00-04:00,BMY,positive
176179.0,Bristol-Myers Squibb Company  Announces Four-Year Follow-up with Empliciti Plus Lenalidomide/Dexamethasone  in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial #EHA2017,2017-06-24 16:57:00-04:00,BMY,positive
176181.0,"Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma",2017-06-22 07:06:00-04:00,BMY,neutral
176187.0,Bristol-Myers Squibb Reports ORR of 65% or Greater For Opdivo In Adult Patients With Relapsed or Progressed Classical Hodgkin Lymphoma Regardless Of Prior brentuximab vedotin Therapies,2017-06-16 07:00:00-04:00,BMY,positive
176188.0,"Bristol-Myers Squibb to Sell Manufacturing Facility in Swords, Ireland to SK Biotek; Terms Not Disclosed",2017-06-16 04:38:00-04:00,BMY,neutral
176189.0,A Deep Dive On The May IMX's Most Bought And Sold Stocks,2017-06-15 16:53:00-04:00,BMY,neutral
176190.0,"UPDATE: Seattle Genetics, Bristol-Myers Reports Combo Data Show 85% Objective Response Rate, 63% Complete Response Rate with an Acceptable Safety Profile",2017-06-15 07:02:00-04:00,BMY,positive
176191.0,"Seattle Genetics, Bristol-Myers Reports Interim Phase 1/2 Data Evaluating Combo Of ADCETRIS, Opdivo In Relapsed Hodgkin Lymphoma",2017-06-15 07:01:00-04:00,BMY,neutral
176192.0,Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS and OPDIVO,2017-06-15 06:58:00-04:00,BMY,positive
176194.0,Bristol-Myers Squibb Announces Availability of New ORENCIA Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis,2017-06-08 07:31:00-04:00,BMY,negative
176195.0,Bristol-Myers Squibb REports Availability of New ORENCIA Subcutaneous Administration Option for Patients 2 Years of Age and Older With JIA,2017-06-08 07:31:00-04:00,BMY,neutral
176196.0,"Bristol-Myers Squibb Reports New Collaboration to Evaluate Combo Therapy in Colorectal Cancer: Phase 1/2 study to evaluate the combination of Opdivo, Opdivo + Yervoy regimen with Mekinist",2017-06-05 16:06:00-04:00,BMY,negative
176197.0,Investor Movement Index (IMX) For May 2017: Tech Buying Continues,2017-06-05 13:26:00-04:00,BMY,neutral
176198.0,Incyte and Bristol-Myers Give Update on Phase 1/2 ECHO Trial,2017-06-05 07:31:00-04:00,BMY,neutral
176199.0,Bristol-Myers Squibb Announces New Data Evaluating Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients #ASCO17,2017-06-04 09:07:00-04:00,BMY,positive
176200.0,"Bristol-Myers Squibb, QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies",2017-06-03 15:36:00-04:00,BMY,positive
176201.0,Bristol-Myers Squibb Announces Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy #ASCO17,2017-06-03 08:45:00-04:00,BMY,neutral
176202.0,Bristol-Myers Squibb Reports EC Approved Co.'s Opdivo for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy,2017-06-02 17:00:00-04:00,BMY,positive
176203.0,Bristol-Myers Gives Update on CHeckMate -358,2017-06-02 07:00:00-04:00,BMY,neutral
176204.0,Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo and ADCETRIS in Phase 3 Trial,2017-06-02 06:06:00-04:00,BMY,positive
176205.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-05-30 08:06:00-04:00,BMY,neutral
176206.0,A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Economic Data,2017-05-30 07:31:00-04:00,BMY,neutral
176207.0,Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo,2017-05-30 07:01:00-04:00,BMY,neutral
176208.0,Array BioPharma and Bristol Myeres to Collaborate on Array's MEK Inhibitor,2017-05-30 07:00:00-04:00,BMY,negative
176209.0,"FDA Accepts Priority Review For Bristol-Myers Squibb's Application For Opdivo In Previously Treated Hepatocellular Carcinoma, Action Date Is Sept. 24th 2017",2017-05-24 11:18:00-04:00,BMY,positive
176210.0,"UBS Global Health Care Conference Begins Today; Presenters Include: AbbVie, Aetna, Universal Health, Mylan, Community Health, Tenet Healthcare, & Bristol-Myers Squibb",2017-05-22 08:57:00-04:00,BMY,positive
176211.0,The Most Notable Abstracts Released Ahead Of ASCO 2017,2017-05-19 08:21:00-04:00,BMY,neutral
176212.0,EMA Validates Application for Bristol-Myers Squibb's Sprycel in Children with Chronic Myelogenous Leukemia,2017-05-19 08:14:00-04:00,BMY,positive
176213.0,Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns,2017-05-16 11:15:00-04:00,BMY,neutral
176214.0,"Appaloosa Dissolves Stake In Bristol Myers Squibb, JC Penny",2017-05-12 16:06:00-04:00,BMY,neutral
176215.0,"Sympathy Moves, Explained: Unsympathetic Earnings Season Continues As Nvidia, Advanced Micro Devices Diverge",2017-05-12 11:55:00-04:00,BMY,positive
176216.0,"Here's What The FDA Approval Of Keytruda Means For Merck, And For Bristol-Myers",2017-05-11 11:52:00-04:00,BMY,positive
176217.0,"Bristol-Myers Squibb, Calithera Biosciences Expand Collaboration Evaluating Opdivo in Combination with CB-839 into NSCLC, Melanoma",2017-05-10 07:12:00-04:00,BMY,positive
176218.0,Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers,2017-05-06 09:03:00-04:00,BMY,negative
176219.0,Watch These 5 Huge Put Purchases In Friday Trade,2017-05-05 04:25:00-04:00,BMY,positive
176220.0,Benzinga's Option Alert Recap From May 4,2017-05-04 16:14:00-04:00,BMY,positive
176221.0,Option Alert: Bristol Myers Sq; Jun $50 Put; 3850 @Bid @$0.17; Ref=$55.52,2017-05-04 11:43:00-04:00,BMY,positive
176222.0,"Deutsche Bank Health Care Conference Concludes Today, Presenters Include: Eagle Pharma, Foamix, Universal Health Services, NovoCure, & Bristol-Myers",2017-05-04 08:28:00-04:00,BMY,positive
176223.0,"Benzinga's Top Upgrades, Downgrades For May 3, 2017",2017-05-03 09:27:00-04:00,BMY,positive
176224.0,The Market In 5 Minutes,2017-05-03 08:46:00-04:00,BMY,neutral
176225.0,A Peek Into The Markets: U.S. Stock Futures Down; All Eyes On Fed Decision,2017-05-03 07:17:00-04:00,BMY,neutral
176226.0,BMO Capital Downgrades Bristol-Myers Squibb to Underperform,2017-05-03 07:01:00-04:00,BMY,neutral
176227.0,"Companies Holding Shareholder Meetings Today Include Valeant Pharmaceuticals, Ally Financial, Bristol-Myers, Ally Financial, Eli Lilly, DryShips, Insys, Kona Grill And Sprouts Farmers Market",2017-05-02 08:20:00-04:00,BMY,neutral
176228.0,Watch These 8 Huge Call Purchases In Tuesday Trade,2017-05-02 04:01:00-04:00,BMY,positive
176229.0,Benzinga's Option Alert Recap From May 1,2017-05-01 18:14:00-04:00,BMY,positive
176230.0,Option Alert: Bristol Myers Squibb Sep 62.5 Calls Sweep: 999 @  ASK  $1.05: 1081 traded vs 3097 OI:  Earnings 7/27 Before Open [est]  $56.71 Ref,2017-05-01 13:53:00-04:00,BMY,positive
176231.0,Bristol-Myers Gets Chinese Approval for an Antiviral Regimen of Daklinza and Sunvepra,2017-04-28 07:24:00-04:00,BMY,positive
176232.0,Adam Feuerstein Tweets: New $BMY CSO Tom Lynch is VERY good on conference calls.,2017-04-27 11:19:00-04:00,BMY,positive
176233.0,"D.C. Issues, Including Tax Plan, Steal Some Thunder From Big Earnings Day",2017-04-27 10:36:00-04:00,BMY,negative
176234.0,Bristol Myers Squibb Raises FY 2017 Guidance from $2.70 - $2.90 to $2.85 - $3.00 vs $2.80 Est,2017-04-27 07:05:00-04:00,BMY,neutral
176235.0,"Bristol-Myers Squibb Q1 EPS $0.84 vs $0.74 Est, Sales $4.93B vs $4.72B Est",2017-04-27 07:04:00-04:00,BMY,neutral
176236.0,"12 Stocks To Watch For April 27, 2017",2017-04-27 06:43:00-04:00,BMY,neutral
176237.0,"Earnings Scheduled For April 27, 2017",2017-04-27 06:30:00-04:00,BMY,neutral
176238.0,"With More Than 100% Upside Seen In Idera Pharma Shares, Baird Initiates At Outperform",2017-04-25 16:08:00-04:00,BMY,positive
176239.0,"Transgene, Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line NSCLC",2017-04-25 03:47:00-04:00,BMY,neutral
176240.0,"Spell Out Relief: French Vote As Expected, So Attention Turns To Earnings, Tax Reform",2017-04-24 10:02:00-04:00,BMY,positive
176241.0,"Bristol-Myers Squibb Announces BMS-986036 Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with NASH in Phase 2 Trial at EASL",2017-04-22 09:29:00-04:00,BMY,positive
176242.0,Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo For Treatment Of Type Of Bladder Cancer,2017-04-21 14:07:00-04:00,BMY,positive
176243.0,Exclusive: Idera CEO Discusses The Potential For His Company's Lead Drug Candidate,2017-04-20 14:15:00-04:00,BMY,positive
176244.0,"Bristol-Myers Squibb, Nordic Bioscience Report Collaboration for Fibrosis Biomarker Technology",2017-04-17 07:00:00-04:00,BMY,neutral
176245.0,A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Initial Jobless Claims Report,2017-04-13 07:30:00-04:00,BMY,negative
176246.0,UPDATE: Bristol-Myers Says Will Receive Combined $470M Upfront,2017-04-13 07:00:00-04:00,BMY,neutral
176247.0,"Bristol-Myers Squibb Reports Separate Deals with Biogen, Roche to License Anti-eTau, Anti-Myostatin Compounds, Respectively",2017-04-13 06:59:00-04:00,BMY,positive
176248.0,"Bristol-Myers Squibb, Apexigen, Inc. Report Clinical Collaboration to Evaluate Opdivo In Combination With APX005M IN Advanced Solid Tumors",2017-04-11 07:07:00-04:00,BMY,positive
176249.0,Bristol-Myers Squibb Announces FDA Accepts Priority Review For Opdivo In Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer,2017-04-04 16:16:00-04:00,BMY,negative
176250.0,Bristol-Myers Squibb Reports CheckMate -143 Did Not Meet Primary Endpoint,2017-04-03 10:48:00-04:00,BMY,positive
176251.0,"Bristol-Myers Reports Opdivo in Combo with Yervoy, Opdivo Monotherapy Significantly Improved Overall Survival vs Yervoy Alone in Patients with Previously Untreated Advanced Melanoma",2017-04-03 08:33:00-04:00,BMY,positive
176252.0,Bristol-Myers Reports First Report of 5-Year Overall Survival Data from Phase 1 Dose-Ranging Study CA209-003 Evaluating Opdivo in Patients,2017-04-03 08:31:00-04:00,BMY,neutral
176253.0,"Bristol-Myers Squibb, Incyte Announce Agreement to Advance the Combination of Opdivo and Epacadostat into First-line Registrational Trials",2017-04-02 09:31:00-04:00,BMY,positive
176254.0,Bristol-Myers Reports Collaboration Deal to Leverage Foundation Medicine's Molecular Info Platform,2017-03-30 07:00:00-04:00,BMY,neutral
176255.0,Watch These 8 Huge Call Purchases In Wednesday Trade,2017-03-29 04:12:00-04:00,BMY,positive
176256.0,Benzinga's Option Alert Recap From March 28,2017-03-28 16:26:00-04:00,BMY,positive
176257.0,Option Alert: Bristol Myers Apr 65.0 Calls: 7000 @  ASK  $0.10: 21k traded vs 3041 OI:  Earnings 4/27 Before Open  $56.24 Ref,2017-03-28 14:54:00-04:00,BMY,positive
176258.0,Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck,2017-03-24 08:33:00-04:00,BMY,negative
176259.0,FDA.gov Drug Safety Communication Page On Diabetes Drug Metformin Updated Today; Features Revised Warnings On Use In Patients With Reduced Kidney Function; Potential Negative For Bristol-Myers,2017-03-22 09:59:00-04:00,BMY,negative
176260.0,Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide,2017-03-20 14:34:00-04:00,BMY,positive
176261.0,12 Biggest Mid-Day Gainers For Monday,2017-03-20 12:38:00-04:00,BMY,neutral
176262.0,Mid-Day Market Update: Nektar Surges After Positive Results From NKTR-181 Study; Cerulean Pharma Shares Drop,2017-03-20 12:13:00-04:00,BMY,positive
176263.0,22 Stocks Moving In Monday's Pre-Market Session,2017-03-20 08:16:00-04:00,BMY,neutral
176264.0,"Bristol-Myers Squibb, CytomX Therapeutics Extend Worldwide Partnership to Discover Probody Therapeutics for the Treatment of Cancer and Other Diseases; CytomX To Receive $200M Upfront Payment",2017-03-20 06:59:00-04:00,BMY,negative
176265.0,"Barclays Global Healthcare Conference Continues Today; Presenters Include HCA Holdings, Valeant, Incyte, Celgene, Cotiviti, Aetna, Anthem, Seattle Genetics, Teva Pharma, Pfizer, & Bristol-Myers",2017-03-15 08:25:00-04:00,BMY,neutral
176266.0,Watch These 8 Huge Call Purchases In Wednesday Trade,2017-03-15 05:02:00-04:00,BMY,positive
176267.0,Benzinga's Option Alert Recap From March 14,2017-03-14 17:00:00-04:00,BMY,positive
176268.0,Option Alert: Bristol Myers Mar 60.0 Calls: 3000 @  ASK  $0.06: 6189 traded vs 52k OI:  Earnings 4/27 Before Open  $56.95 Ref,2017-03-14 14:23:00-04:00,BMY,positive
176269.0,Transgene Announces First Patient in Phase 2 Trial Evaluating Co.'s TG4010 in Combo with Bristol-Myers' Opdivo for Second Line Treatment of Metastatic NSCLC,2017-03-13 13:07:00-04:00,BMY,neutral
176270.0,Bristol-Myers Names Dr. Thomas Lynch Chief Scientific Officer,2017-03-08 12:25:00-05:00,BMY,neutral
176271.0,"Cowen Annual Healthcare Conference Begins Today; Presenters Include Insulet, PARAXEL, Zoetis, Alexion, Bristol-Myers, Acadia, Alnylam, Axovant, Ardelyx, Aurinia Pharma, And Puma Biotech",2017-03-06 08:39:00-05:00,BMY,neutral
176272.0,Icahn's (Potential) Move Into Biotech,2017-03-04 19:25:00-05:00,BMY,neutral
176273.0,The Unlikely Story Of How Amicus Therapeutics Came To Be,2017-03-02 13:31:00-05:00,BMY,neutral
176274.0,Bristol-Myers Squibb Announced Equity Investment And Research Collaboration With GRAIL For Early Cancer Detection,2017-03-01 08:13:00-05:00,BMY,negative
176275.0,Short Sellers Pile On Pfizer After Buyout Rumors,2017-03-01 06:54:00-05:00,BMY,neutral
176276.0,Is Carl Icahn Losing His Midas Touch?,2017-02-27 12:22:00-05:00,BMY,negative
176277.0,Carl Icahn's Track Record In Big Pharma,2017-02-24 09:40:00-05:00,BMY,neutral
176278.0,"AutoNation, Bristol-Myers, General Electric, Oracle: Fast Money Picks For February 24",2017-02-24 06:50:00-05:00,BMY,neutral
176279.0,Activist Investors Are Back And More Active Than Ever,2017-02-22 15:13:00-05:00,BMY,positive
176280.0,Jim Cramer: Maybe Investors Aren't Paying As Much For Corporate Earnings,2017-02-22 13:11:00-05:00,BMY,neutral
176281.0,Bristol-Myers Oncology Growth Potential Remains High,2017-02-22 10:06:00-05:00,BMY,positive
176282.0,The Market In 5 Minutes,2017-02-22 09:29:00-05:00,BMY,neutral
176283.0,Wall Street's M&A Chatter From February 21,2017-02-22 07:07:00-05:00,BMY,neutral
176284.0,Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?,2017-02-21 16:48:00-05:00,BMY,neutral
176285.0,"BZ NOTE: Earlier This Morning, Bristol-Myers Reported A $2B Accelerated Buyback",2017-02-21 15:43:00-05:00,BMY,positive
176286.0,Icahn Sees Bristol-Myers as Possible Takeover Target,2017-02-21 15:39:00-05:00,BMY,neutral
176287.0,Icahn Takes Stake in Bristol Myers; See Value in Pipeline -DJ,2017-02-21 15:39:00-05:00,BMY,positive
176288.0,"Dow Jones Reporting Carl Icahn Takes Stake In Bristol Myers, Sees Co. As Possible Takeover Target",2017-02-21 15:38:00-05:00,BMY,neutral
176289.0,Bristol Myers Spikes to High of $57.21 on Report of Possible Icahn Stke,2017-02-21 15:37:00-05:00,BMY,neutral
176290.0,Bristol-Myers Squibb Says It Expects To Incur $1.5-$2.0B Through 2020 In Connection With Oct. 2016 Restructuring Announcement,2017-02-21 12:18:00-05:00,BMY,neutral
176291.0,Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers,2017-02-15 14:26:00-05:00,BMY,negative
176292.0,"Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma",2017-02-15 10:29:00-05:00,BMY,neutral
176293.0,Deutsche Bank on Bristol-Myers Unconfirmed Takeover Chatter Tuesday: 'we would be surprised to see PFE make a move on BMY at this stage',2017-02-15 09:18:00-05:00,BMY,positive
176294.0,Valeant's Stock Having One Of Its Best Days Of 2017,2017-02-14 13:49:00-05:00,BMY,positive
176295.0,Bristol-Myers Shares Up $0.40 Over Last Min as Hearing Unconfirmed Chatter of Interest in Co.,2017-02-14 12:02:00-05:00,BMY,positive
176296.0,Key Presenters At Leerink's Healthcare Conference,2017-02-13 15:52:00-05:00,BMY,neutral
176297.0,How China Lifting Its One-Child Policy Played Into Reckitt Benckiser's $90/Share Offer For Mead Johnson,2017-02-05 17:41:00-05:00,BMY,positive
176298.0,"Bristol-Myers Reports Received FDA Approval for Opdvio in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer",2017-02-02 16:15:00-05:00,BMY,negative
176299.0,"FDA Has Granted Accelerated Approval for Bristol-Myers' Nivolumab for Treatment of Locally Advanced, Metastatic Urothelial Carcinoma",2017-02-02 14:27:00-05:00,BMY,positive
176300.0,FDA Grants Accelerated Approval To Bristol-Myers Squibb's nivolumab For Treatment Of Urothelial Carcinoma,2017-02-02 14:20:00-05:00,BMY,positive
176301.0,UPDATE: Bristol-Myers Says EPO Upheld Decision Related to Patent '038,2017-02-01 12:21:00-05:00,BMY,neutral
176302.0,Bristol-Myers Reports European Patent Office Decision on Sprycel,2017-02-01 12:20:00-05:00,BMY,neutral
176303.0,"Pre-Market Prep Host Dennis Dick Tweets: Notable opening imbalances: $BABA -105K, $C -115K, $BAC -139K, $MS -92K, $BA -109K, $GE -170K, $PFE +111K, $BMY +69K",2017-01-30 09:19:00-05:00,BMY,negative
176304.0,Martin Shkreli In Facebook Post Says 'I think I like $BMY long - anyone following closely?',2017-01-30 08:27:00-05:00,BMY,positive
176305.0,"Bristol-Myers CFO Lowers FY17 Outlook Due To Foreign Exchange Rates, Potential For Earlier-Than-Expected Entry Of Merck's Keytruda/Chemo Combo In May",2017-01-26 10:48:00-05:00,BMY,negative
176306.0,Bristol-Myers Squibb Hits Lowest Level In 2 Years After Mixed Q4 Report,2017-01-26 10:43:00-05:00,BMY,negative
176307.0,"In Lockstep: Dow 20,000 Significance Magnified By Record Highs For SPX",2017-01-26 10:38:00-05:00,BMY,positive
176308.0,Merck's Keytruda Gains Momentum At The Expense Of Bristol-Myers,2017-01-26 10:33:00-05:00,BMY,positive
176309.0,"The Market In 5 Minutes: Earnings, Trump And Dow20k",2017-01-26 09:02:00-05:00,BMY,neutral
176310.0,Bristol-Myers Affirms FY17 Adj. EPS Outlook $2.70-$2.90 vs $2.86 Est.,2017-01-26 06:59:00-05:00,BMY,neutral
176311.0,"Bristol-Myers Reports Q4 Adj. EPS $0.63 vs $0.67 Est., Sales $5.2B vs $5.13B Est.",2017-01-26 06:59:00-05:00,BMY,neutral
176312.0,"15 Stocks To Watch For January 26, 2017",2017-01-26 06:35:00-05:00,BMY,neutral
176313.0,"Earnings Scheduled For January 26, 2017",2017-01-26 06:03:00-05:00,BMY,neutral
176314.0,Which Pharma Players Dominate The Lung Cancer Space?,2017-01-25 14:40:00-05:00,BMY,negative
176315.0,Trump Helps Send Markets To New Highs With Keystone Pipeline Order,2017-01-25 10:59:00-05:00,BMY,positive
176316.0,"UPDATE: Merck's Payment To Bristol-Myers Will Be Recorded In Its Q4 And FY16 Results, Excluded From Non-GAAP Results",2017-01-20 16:05:00-05:00,BMY,negative
176317.0,"Merck Announces Setlement With Bristol-Myers Resolving KEYTRUDA Patent Litigation, Will Pay $625M And Provide Royalties On KEYTRUDA In Any Market In Which It's Approved",2017-01-20 16:02:00-05:00,BMY,positive
176318.0,Mid-Afternoon Market Update: Skyworks Surges After Strong Earnings Report; Affimed Shares Drop,2017-01-20 14:38:00-05:00,BMY,positive
176319.0,15 Biggest Mid-Day Losers For Friday,2017-01-20 13:01:00-05:00,BMY,negative
176320.0,Mid-Day Market Update: Crude Oil Up 2.8%; Bristol-Myers Squibb Shares Slide After Opdivo Decision,2017-01-20 12:04:00-05:00,BMY,negative
176321.0,Bristol-Myers Squibb Falls 10% After Opdivo Decision,2017-01-20 10:35:00-05:00,BMY,neutral
176322.0,Mid-Morning Market Update: Markets Open Higher; General Electric Revenue Misses Views,2017-01-20 09:55:00-05:00,BMY,negative
176323.0,18 Stocks Moving In Friday's Pre-Market Session,2017-01-20 08:18:00-05:00,BMY,neutral
176324.0,Bristol-Myers Squibb -4.7% Premarket @ $52.86; Co Said Will Not Seek Faster Opdivo/Yervoy Lung Cancer Approval,2017-01-20 07:15:00-05:00,BMY,negative
176325.0,Bristol-Myers Offers Regulatory Update Related to First-line Lung Cancer: Says Decided Not to Pursue Accelerated Regulatory Pathway for Combo of Opdivo Plus Yervoy in First-Line Lung Cancer,2017-01-19 18:31:00-05:00,BMY,negative
176326.0,"Bristol-Myers Squibb Reports Opdivo Demonstrated 37% Reduction Of Death Risk vs. Placebo, 12 Month Overall Survival Rates of 26.6% vs. 10.9% In Placebo Patients",2017-01-19 09:01:00-05:00,BMY,negative
176327.0,The Best BioPharma Plays Amid Uncertainty From Trump Comments,2017-01-12 13:58:00-05:00,BMY,positive
176328.0,Here's What Merck's Keytruda News Means For Bristol-Myers,2017-01-11 14:26:00-05:00,BMY,neutral
176329.0,Technical Alert:  Bristol Meyers Squibb Lower Following Good News For Merck's Keytruda,2017-01-11 09:05:00-05:00,BMY,positive
176330.0,Bristol-Myers Shares Down 2.2% After Hours as Merck Shares Trade Up ~2.5% Following News KEYTRUDA Accepted for Supplemental BLA,2017-01-10 17:12:00-05:00,BMY,positive
176331.0,"JP Morgan Healthcare Conf. Continues Today; Presenters Include Cooper Companies, Mckesson, Dexcom, CVS, Bristol-Myers, & NanoString",2017-01-10 08:07:00-05:00,BMY,positive
176332.0,Bristol-Myers Opdivo Study Halt Due To Having Reached Pre-Registration Limit As No Safety Issues/Adverse Events Reported,2017-01-06 10:14:00-05:00,BMY,positive
176333.0,Bristol-Myers Shares at Session Lows as Traders Passing Around Word of 3 Opdivo-Related Trial Suspensions; BZ NOTE: There was Similar Discussion on Thurs.,2017-01-06 10:01:00-05:00,BMY,positive
176334.0,Brisol Myers Announces Exploratory Biomarker Research Collaboration with GeneCentric,2017-01-06 07:00:00-05:00,BMY,neutral
176335.0,"Alphabet, Bristol-Myers And More: Fast Money Picks For January 6",2017-01-06 06:48:00-05:00,BMY,neutral
176336.0,"Seattle Genetics, Bristol-Myers Study of Opdivo and Adcetris Combo Halted Pending Protocol Amendment To Allow Additional Patients TO Be Enrolled and Treated To Further Characterize Safety And Efficacy",2017-01-05 11:27:00-05:00,BMY,positive
176337.0,Hearing JANA Partners Takes New Stake in Bristol-Myers,2017-01-05 09:46:00-05:00,BMY,neutral
176338.0,Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo in Combination with Darzalex,2017-01-05 06:59:00-05:00,BMY,neutral
176339.0,"Five Prime Therapeutics, Bristol-Myers Squibb Extend Research Term in Partner to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways",2017-01-04 16:15:00-05:00,BMY,positive
176340.0,Watch These 7 Huge Call Purchases In Wednesday Trade,2017-01-04 04:13:00-05:00,BMY,positive
176342.0,6 Worst Biotech Stocks Of 2016,2016-12-23 11:50:00-05:00,BMY,negative
176343.0,Momenta Pharma Shares Sell Off Below $15.20 Level as Hearing Co. Has Lost Patent Challenge Against Bristol-Myers Related to '239 Orencia Patent,2016-12-22 14:08:00-05:00,BMY,positive
176344.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher,2016-12-21 14:42:00-05:00,BMY,negative
176345.0,12 Biggest Mid-Day Gainers For Wednesday,2016-12-21 12:42:00-05:00,BMY,neutral
176346.0,Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations,2016-12-21 09:57:00-05:00,BMY,negative
176347.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-12-21 08:25:00-05:00,BMY,neutral
176348.0,Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo in Combination with CB-839 in Clear Cell Renal Cell Carcinoma,2016-12-21 06:59:00-05:00,BMY,positive
176349.0,"Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, Bristol to Make $50M Upfront Payment",2016-12-20 06:59:00-05:00,BMY,positive
176350.0,Jefferies' 2017 Global Pharma Outlook,2016-12-19 10:56:00-05:00,BMY,neutral
176351.0,"Jefferies' Huge Pharma Pair Trade: Bristol-Myers Upgraded To Buy, Merck Downgraded To Sell",2016-12-19 09:09:00-05:00,BMY,positive
176352.0,"Benzinga's Top Upgrades, Downgrades For December 19, 2016",2016-12-19 09:08:00-05:00,BMY,positive
176353.0,"The Market In 5 Minutes: 'Rogue One', Bullish Commentary Pumps Disney Up",2016-12-19 09:03:00-05:00,BMY,neutral
176354.0,Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa,2016-12-19 08:00:00-05:00,BMY,positive
176355.0,A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Yellen Speech,2016-12-19 07:39:00-05:00,BMY,neutral
176356.0,"Jefferies Upgrades Bristol-Myers Squibb to Buy, Raises Target to $69.00",2016-12-19 06:40:00-05:00,BMY,neutral
176357.0,Japan to Review Drug Prices Each Year vs Every Two Years Previously -Reuters,2016-12-19 04:17:00-05:00,BMY,neutral
176358.0,Bristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S. Geographic Footprint,2016-12-13 09:37:00-05:00,BMY,positive
176359.0,"CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration, Will Receive $2M Milestone Payment",2016-12-13 08:02:00-05:00,BMY,neutral
176360.0,Bristol-Myers Raises Qtr. Dividend from $0.38 to $0.39/Share,2016-12-08 16:15:00-05:00,BMY,neutral
176361.0,Bristol-Myers Squibb To Pay $19.5M In Multi-State Settlement Over Alleged Off-Label Promotion of Anti-Psychotic Drug,2016-12-08 12:02:00-05:00,BMY,negative
176362.0,"Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open",2016-12-07 09:34:00-05:00,BMY,negative
176363.0,"Citi Global Healthcare Conf. Takes Place Today; Presenters Include Pfizer, Aerie Pharmaceuticals, Bristol-Myers, Alexion, Illumina, & Envision Healthcare",2016-12-07 08:38:00-05:00,BMY,neutral
176364.0,Bristol Myers Announces Updated Opdivo Phase 1/2 Results; No New Safety Signals Observed,2016-12-06 08:47:00-05:00,BMY,positive
176365.0,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell,2016-12-05 15:55:00-05:00,BMY,negative
176366.0,"Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron",2016-12-01 08:21:00-05:00,BMY,neutral
176367.0,Heat Biologics Shares Continue Higher (Up 22%) on Heavy Volume Fri. Following 27% Run-Up on Wed. as $1.50 Resistance Level Breached; BZ NOTE: Co. Announced Last Thursday It will Be Reporting Phase Ib Results for HS-110 In Combo with Bristol's Opdivo Dec. ,2016-11-25 11:39:00-05:00,BMY,positive
176368.0,"Bristol-Myers Squibb, Cerner, General Motors, Monsanto: Fast Money Picks For November 25",2016-11-25 07:11:00-05:00,BMY,neutral
176369.0,European Commission Approves Bristol-Myers Squibb's Opdivo for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin,2016-11-22 15:00:00-05:00,BMY,positive
176370.0,"QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to Generate Real World Insights On Usage of Anti-Cancer Therapies Across Europe",2016-11-22 08:04:00-05:00,BMY,neutral
176371.0,Stifel Healthcare Conference Continues Today,2016-11-16 10:26:00-05:00,BMY,neutral
176372.0,"Bristol-Myers Squibb, Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules",2016-11-16 04:07:00-05:00,BMY,positive
176373.0,UPDATE: Chardan On Bristol-Myers: 'the safety signal presented by HBV reactivation relative to competing HCV DAAs creates the potential for accelerated declines in Daklinza revenues versus consensus',2016-11-11 09:46:00-05:00,BMY,positive
176374.0,"UPDATE: Chardan Sees Safety Risks To Bristol-Myers Saying 'Safety risks from HBV reactivation has the potential to slow Daklinza revenues faster than consensus',",2016-11-11 09:45:00-05:00,BMY,positive
176375.0,Hearing Chardan Issuing Negative Comments of Bristol-Myers,2016-11-11 09:43:00-05:00,BMY,negative
176376.0,"Bristol-Myers Reports Opdivo Received FDA Approval for Immuno-Oncology Treatment, Based on Overall Survival in Head and Neck Cancer",2016-11-10 17:01:00-05:00,BMY,negative
176377.0,Bristol-Myers Reports Opdivo Showed Overall Survival Benefit in Patients With Unresectable Advanced or Recurrent Gastric Cancer in Phase 3 Study,2016-11-10 06:55:00-05:00,BMY,negative
176378.0,Can Trump Make Your Portfolio Great Again?,2016-11-09 11:27:00-05:00,BMY,positive
176379.0,"Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%",2016-11-09 09:41:00-05:00,BMY,neutral
176380.0,Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo in Combination with IPI-549 in Advanced Solid Tumors,2016-11-09 07:13:00-05:00,BMY,positive
176381.0,Lexicon Pharmaceuticals Acquires Exclusive Rights To Development Candidate For Neuropathic Pain From Its Alliance With Bristol-Myers Squibb,2016-11-07 07:07:00-05:00,BMY,negative
176382.0,BZ NOTE Related to Traders Passing Around CNBC Story on New Cancer Drugs Possibly Damaging the Heart: NBC News via AP Published the Same Story ~7 p.m. EDT Wed. Evening,2016-11-03 11:19:00-04:00,BMY,negative
176383.0,Traders Passing Around Recent CNBC Article on Cancer Treatments: 'New cancer drugs may damage the heart',2016-11-03 11:16:00-04:00,BMY,negative
176384.0,The Election Can't Come Soon Enough For Biotechs,2016-11-01 10:39:00-04:00,BMY,neutral
176385.0,Bristol-Myers Squibb  Gets Approval From Health Canada For Opdivo & Yervoy Regimen For  Unresectable Or Metastatic Melanoma,2016-10-31 13:47:00-04:00,BMY,positive
176386.0,Hilliard Lyons Upgrades Bristol-Myers Squibb Company Common Stock to Long-Term Buy,2016-10-28 09:32:00-04:00,BMY,neutral
176387.0,Technical Alert: Bristol-Myers Squibb Higher After Q3 Beat,2016-10-27 12:55:00-04:00,BMY,positive
176388.0,20 Biggest Mid-Day Gainers For Thursday,2016-10-27 12:26:00-04:00,BMY,neutral
176389.0,Bristol-Myers  Says Expects Opdivo to Face Pressure from New Roche Treatment for Second-line Lung Cancer -Reuters,2016-10-27 10:59:00-04:00,BMY,negative
176390.0,"It's Big Tech Day, With Amazon, Alphabet, Twitter Stepping To The Plate",2016-10-27 10:38:00-04:00,BMY,positive
176391.0,"The Market In 5 Minutes: Twitter, Tesla Earnings And Jobless Claims Fall",2016-10-27 08:59:00-04:00,BMY,neutral
176392.0,20 Stocks Moving In Thursday's Pre-Market Session,2016-10-27 08:24:00-04:00,BMY,neutral
176393.0,A Peek Into The Markets: U.S. Stock Futures Up; Twitter Shares Gain Following Earnings Beat,2016-10-27 07:50:00-04:00,BMY,positive
176394.0,"Investors Cheer Bristol-Myers' Q3 Results, Outlook",2016-10-27 07:35:00-04:00,BMY,positive
176395.0,Bristol-Myers Increases FY16 Guidance From EPS $2.55-$2.65 To $2.80-$2.90; FY17 $2.85-$3.05 vs. Est. $2.91,2016-10-27 07:00:00-04:00,BMY,neutral
176396.0,"Bristol-Myers Squibb Reports Q3 EPS $0.77 vs. Est. $0.65, Rev. $4.922B vs. Est. $4.79B",2016-10-27 06:59:00-04:00,BMY,neutral
176397.0,"15 Must Watch Stocks for October 27, 2016",2016-10-27 05:20:00-04:00,BMY,neutral
176398.0,"Earnings Scheduled For October 27, 2016",2016-10-27 04:19:00-04:00,BMY,neutral
176399.0,6 Big Pharma Companies Left To Report September Quarterly Figures,2016-10-25 13:45:00-04:00,BMY,neutral
176400.0,Citi Launches Positive Coverage On Five Prime Therapeutics,2016-10-25 11:07:00-04:00,BMY,positive
176401.0,Bristol-Myers Squibb Reports Data In Expanded Population Of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients,2016-10-25 08:00:00-04:00,BMY,neutral
176402.0,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments,2016-10-21 11:36:00-04:00,BMY,negative
176403.0,"Roche Group, Competitor To Bristol-Myers And Merck, Has PDUFA DateFor Tecentriq Drug",2016-10-19 08:31:00-04:00,BMY,neutral
176404.0,"European Medicine Agency's CHMP Committee Released Its Monthly Drug Opinions Earlier Today; Called For Extensions Of Indications For Lucentis, Opdivo, And Trisenox",2016-10-14 08:47:00-04:00,BMY,neutral
176405.0,Bristol-Myers Reports Received Positive CHMP Opinion for Opdivo for Treatment of Adults with Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin,2016-10-14 07:00:00-04:00,BMY,positive
176406.0,These Were The Most And Least Popular Stocks In September,2016-10-10 17:18:00-04:00,BMY,negative
176407.0,Investor Movement Index for September 2016,2016-10-10 16:30:00-04:00,BMY,neutral
176408.0,The ESMO Conference Proves Its Ability To Move Stocks,2016-10-10 14:44:00-04:00,BMY,positive
176409.0,Technical Alert: Bristol-Myers Squibb Under $50 For The First Time Since October 2014,2016-10-10 13:28:00-04:00,BMY,positive
176410.0,8 Biggest Mid-Day Losers For Monday,2016-10-10 13:01:00-04:00,BMY,negative
176411.0,"This Wasn't A Great ESMO For Bristol-Myers Squibb, But 2017 Could Be A Much Better Year",2016-10-10 10:56:00-04:00,BMY,positive
176412.0,Stocks Hitting 52-Week Lows,2016-10-10 10:26:00-04:00,BMY,negative
176413.0,Bristol-Myers' Opdivo Vs. Merck's Keytruda In Front-Line Lung Treatment,2016-10-10 10:25:00-04:00,BMY,neutral
176414.0,SunTrust Cuts Target On Bristol-Myers As Opdivo Estimates Revised Lower,2016-10-10 10:08:00-04:00,BMY,negative
176415.0,Mid-Morning Market Update: Markets Open Higher; Dover Lowers Full-Year Forecast,2016-10-10 10:05:00-04:00,BMY,negative
176416.0,16 Stocks Moving In Monday's Pre-Market Session,2016-10-10 08:42:00-04:00,BMY,neutral
176417.0,"Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer at ESMO 2016",2016-10-09 08:33:00-04:00,BMY,positive
176418.0,Bristol-Myers Squibb to Present Opdivo Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in Pivotal Phase 3 CheckMate -141 Study at ESMO 2016,2016-10-09 08:32:00-04:00,BMY,neutral
176419.0,Bristol-Myers Squibb Announces Yervoy Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study,2016-10-09 08:04:00-04:00,BMY,positive
176420.0,Jim Cramer Shares His Thoughts On Bristol-Myers Squibb Co And Sirius XM Holdings Inc.,2016-10-08 18:25:00-04:00,BMY,positive
176421.0,Brean Likes Nektar Therapeutics' Upcoming Launches; Assumes Coverage At Buy,2016-09-30 08:34:00-04:00,BMY,positive
176422.0,Technical Alert: Bristol-Myers Squibb Makes New Low For The Move,2016-09-29 15:08:00-04:00,BMY,neutral
176423.0,Fast Money Halftime Report Final Trades For September 28,2016-09-28 16:35:00-04:00,BMY,neutral
176424.0,The Drug Price Increase Debate: Separating The Winners From The Losers,2016-09-27 11:23:00-04:00,BMY,positive
176425.0,"Bristol-Myers, Nektar Therapeutics Report Oncology Clinical Collaboration to Evaluate Combo of Opdivo, NKTR-214",2016-09-27 06:59:00-04:00,BMY,neutral
176426.0,The Market In 5 Minutes: No Interest Rate Hike...Yet,2016-09-22 09:04:00-04:00,BMY,positive
176427.0,Can You Guess This Chart?,2016-09-22 07:31:00-04:00,BMY,neutral
176428.0,7 Biggest  Price Target Changes For Tuesday,2016-09-20 10:28:00-04:00,BMY,neutral
176429.0,"Citi Research Reevaluates Bristol-Myers, Lowers Price Target",2016-09-20 09:13:00-04:00,BMY,negative
176430.0,Bristol Myers Announces European Medicines Agency Validated Type II Variation Application,2016-09-20 07:00:00-04:00,BMY,positive
176431.0,Seattle Genetics No Longer On Goldman Sachs' Sell List,2016-09-15 09:48:00-04:00,BMY,negative
176432.0,Technical Alert: Bristol-Myers SQUIBB Finds Support At The $55 Area Again,2016-09-14 14:30:00-04:00,BMY,positive
176433.0,"2100: Goldman Sachs Is A Short-Term Bear, But A Long-Term Bull",2016-09-12 10:13:00-04:00,BMY,neutral
176434.0,"Barclays Raises Target On Merck, Lowers Target On Bristol-Myers",2016-09-09 09:56:00-04:00,BMY,negative
176435.0,Retail Investors Loved Beat Up Stocks In August,2016-09-06 16:05:00-04:00,BMY,positive
176436.0,Investor Movement Index (IMX) for August 2016,2016-09-06 15:33:00-04:00,BMY,neutral
176437.0,European Commission Approves Bristol-Myers Squibb's ORENCIA for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate,2016-09-06 07:01:00-04:00,BMY,positive
176438.0,Technical Alert: Bristol-Myers Continues Lower,2016-09-02 10:54:00-04:00,BMY,neutral
176439.0,Technical Alert: Bristol-Myers Squibb Makes New For Move,2016-08-17 15:31:00-04:00,BMY,positive
176440.0,Brean Downgrades The Healthcare Sector On Technical Indicators,2016-08-17 12:02:00-04:00,BMY,neutral
176441.0,Bristol-Myers Squibb Sells Off to Low  of $58.82 After Open on Volume,2016-08-17 09:33:00-04:00,BMY,negative
176442.0,Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain,2016-08-16 10:11:00-04:00,BMY,positive
176443.0,7 Biggest Price Target Changes For Thursday,2016-08-11 09:51:00-04:00,BMY,neutral
176444.0,Benzinga's Top Downgrades,2016-08-11 09:10:00-04:00,BMY,positive
176445.0,"The Market In 5 Minutes: Valeant's Fraud, Macy's Beat, And Arianna's Departure",2016-08-11 08:59:00-04:00,BMY,negative
176446.0,"Berenberg Downgrades Bristol-Myers Squibb, Says Competitors Better Exposed For Near-Term Upside",2016-08-11 08:16:00-04:00,BMY,positive
176447.0,A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Jobless Claims Report,2016-08-11 07:37:00-04:00,BMY,neutral
176448.0,"Berenberg Downgrades Bristol-Myers Squibb to Hold, Lowers PT to $70.00",2016-08-11 06:19:00-04:00,BMY,negative
176449.0,"Argus: Bristol-Myers Selloff Is Overdone, Reiterating $90 Target",2016-08-10 11:42:00-04:00,BMY,neutral
176450.0,"Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict",2016-08-09 11:49:00-04:00,BMY,neutral
176451.0,Bristol-Myers Hit With A Trio Of Analyst Price Target Cuts,2016-08-09 08:33:00-04:00,BMY,negative
176452.0,Deutsche Analysts React To Bristol-Myers Clinical Trial Disappointment,2016-08-08 16:27:00-04:00,BMY,negative
176453.0,Technical Alert - Bristol Meyers Squibb Continues To Tumble,2016-08-08 11:03:00-04:00,BMY,positive
176454.0,"After Roaring To New Highs on Jobs Data, Market Faces Retail Sales, Job Openings",2016-08-08 10:42:00-04:00,BMY,neutral
176455.0,"CheckMate Miss Is A Game Changer; Credit Suisse Downgrades Bristol, Upgrades Merck",2016-08-08 10:12:00-04:00,BMY,positive
176456.0,8 Biggest Price Target Changes For Monday,2016-08-08 09:58:00-04:00,BMY,neutral
176457.0,Benzinga's Top Downgrades,2016-08-08 09:15:00-04:00,BMY,positive
176458.0,Citi Doesn't See Merck's Lung Cancer Success Lasting Long,2016-08-08 07:36:00-04:00,BMY,negative
176459.0,"Credit Suisse Downgrades Bristol-Myers Squibb to Neutral, Lowers PT to $63.00",2016-08-08 03:49:00-04:00,BMY,positive
176460.0,Watch These 7 Huge Call Purchases In Monday Trade,2016-08-08 02:26:00-04:00,BMY,positive
176461.0,Friday Market Wrap: Stock Market Jumps On Employment Numbers,2016-08-06 11:48:00-04:00,BMY,neutral
176462.0,Deutsche Downgrades Ligand As Risk/Reward Becomes Challenging,2016-08-05 14:25:00-04:00,BMY,positive
176463.0,Moody's Says Bristol's Lung Cancer Trial Result is Major Setback,2016-08-05 14:02:00-04:00,BMY,negative
176464.0,Technical Alert - Bristol Meyers Squibb Revisits March 24 Low After Opdivo Trial Misses Endpoint,2016-08-05 13:41:00-04:00,BMY,negative
176465.0,18 Biggest Mid-Day Losers For Friday,2016-08-05 13:14:00-04:00,BMY,negative
176466.0,25 Biggest Mid-Day Gainers For Friday,2016-08-05 12:43:00-04:00,BMY,neutral
176467.0,Benzinga's Volume Movers,2016-08-05 10:31:00-04:00,BMY,neutral
176468.0,Option Alert: BMY Jan 2018 70.0 Calls: 4094 @  Above Ask!  $4.65: 5290 traded vs 678 OI: $62.48 Ref,2016-08-05 10:27:00-04:00,BMY,positive
176469.0,Stocks Hitting 52-Week Highs,2016-08-05 10:14:00-04:00,BMY,neutral
176470.0,Bristol's Opdivo Misses Endpoint In Late-Stage Trial; Merck Rallies Sharply Amid Keytruda Potential,2016-08-05 09:03:00-04:00,BMY,negative
176471.0,The Market In 5 Minutes: Blowout Jobs Report Pushes Markets Higher,2016-08-05 08:55:00-04:00,BMY,neutral
176472.0,Bristol-Myers Shares Down ~$13 Upon Resumption,2016-08-05 08:33:00-04:00,BMY,positive
176473.0,Bristol-Myers Squibb Sells off to Low of $58.10 Following Resumption,2016-08-05 08:33:00-04:00,BMY,negative
176474.0,UPDATE: Merck's KEYTRUDA is Viewed as Strongest Competitor to Bristol's Opdivo,2016-08-05 08:26:00-04:00,BMY,positive
176475.0,Merck Spike in Price Likely Attributed to Negative Results on Bristol-Myers' Opdivo,2016-08-05 08:23:00-04:00,BMY,negative
176476.0,"Bristol-Myers Squibb Reports Results from CheckMate -026 Study, Opdivo Did Not Meet Primary Endpoint",2016-08-05 08:20:00-04:00,BMY,neutral
176477.0,"Gilead Shares Indicated Higher, Up ~0.4%; BZ NOTE: Co. Was Discussed as a Possible Takeover Candidate for Bristol-Myers, as Recently as Aug. 1",2016-08-05 08:05:00-04:00,BMY,positive
176478.0,Bristol-Myers Squibb Co. Halted; Pending News,2016-08-05 07:57:00-04:00,BMY,neutral
176479.0,"Biogen, JC Penney And More: Fast Money Picks For August 2",2016-08-02 06:30:00-04:00,BMY,neutral
176480.0,"Merck's Q2 Good, But Not Good Enough, Says BMO",2016-08-01 14:12:00-04:00,BMY,positive
176481.0,Option Alert: BMY Aug16 77.5 Calls Sweep: 503 @  ASK  $0.84: 5612 traded vs 6710 OI: $75.91 Ref,2016-08-01 13:53:00-04:00,BMY,positive
176482.0,Option Alert: BMY Aug16 77.5 Calls Sweep: 3535 @  ASK  $0.73: 5074 traded vs 6710 OI: $75.60 Ref,2016-08-01 12:56:00-04:00,BMY,positive
176483.0,UPDATE: Free Cash-Flow For Bristol-Myers Squibb Has Been Negative For 2 Straight Quarters,2016-08-01 11:30:00-04:00,BMY,positive
176484.0,Gilead Spikes to High; Hearing Unconfirmed Market Chatter Co Talking With BMY Regarding Merger,2016-08-01 11:22:00-04:00,BMY,negative
176485.0,Technical Alert: Finding Support In Bristol-Myers After Q2 Report,2016-07-28 13:00:00-04:00,BMY,positive
176486.0,UPDATE: Bristol-Myers Raises FY16 Adj. EPS $2.55-$2.65,2016-07-28 07:00:00-04:00,BMY,neutral
176487.0,"Bristol-Myers Reports Q2 Adj. EPS $0.69, Sales $4.9B; Raises FY16 Outlook",2016-07-28 06:59:00-04:00,BMY,neutral
176488.0,"15 Stocks To Watch For July 28, 2016",2016-07-28 05:18:00-04:00,BMY,neutral
176489.0,"Earnings Scheduled For July 28, 2016",2016-07-28 04:03:00-04:00,BMY,neutral
176490.0,Can Keytruda Deliver Earnings Growth For Merck?,2016-07-27 11:22:00-04:00,BMY,positive
176491.0,Watch These 10 Huge Call Purchases In Wednesday Trade,2016-07-27 01:22:00-04:00,BMY,positive
176492.0,Option Alert: BMY Fri 9/2 77.5 Calls (Wkly) Sweep: 500 @  ASK  $0.94: 500 traded vs 1 OI:  Earnings 7/28 Before Open  $75.06 Ref,2016-07-26 13:32:00-04:00,BMY,positive
176493.0,Bristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung Cancer,2016-07-26 06:59:00-04:00,BMY,negative
176494.0,AbbVie And Bristol-Myers Squibb Strike Oncology Clinical Alliance To Assess Rova-T plus Opdivo And Opdivo + Yervoy Regimen,2016-07-25 13:42:00-04:00,BMY,negative
176495.0,Bristol-Myers Squibb Gets CHMP's Positive Opinion For ORENCIA,2016-07-25 12:38:00-04:00,BMY,positive
176496.0,"AbbVie, Bristol-Myers Report Clinical Trial Collaboration to Evaluate Safety, Tolerability, EFficacy of AbbVie's Rova-T In Combo with Bristol's Opdivo",2016-07-25 07:02:00-04:00,BMY,positive
176497.0,"Bristol-Myers Reports CHMP Opinion for ORENCIA for Treatment of Highly Active, Progressive Disease in Adult Patients with RA",2016-07-25 06:59:00-04:00,BMY,positive
176498.0,"Barron's Picks And Pans: Pharmacy-Benefit Managers, Mortgage Insurers And More",2016-07-24 15:34:00-04:00,BMY,neutral
176499.0,Bristol-Myers Squibb Says FDA-Approved ORENCIA Is Available For Adults With Moderate To Severe Rheumatoid Arthritis,2016-07-20 08:14:00-04:00,BMY,negative
176500.0,Jim Cramer Shares His Thoughts On Bristol-Myers Squibb And The RNC,2016-07-20 07:22:00-04:00,BMY,positive
176501.0,Bristol-Myers Reports Availability of FDA-Approved ORENCIA ClickJect,2016-07-20 07:04:00-04:00,BMY,neutral
176502.0,BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations,2016-07-18 12:02:00-04:00,BMY,neutral
176503.0,Bristol-Myers Squibb Reveals Regulatory Approvals For Opdivo Marketing Application,2016-07-18 07:58:00-04:00,BMY,neutral
176504.0,"Bristol-Myers Squibb Announces Regulatory Updates for Opdivo in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, FDA And EMA Accept Marketing Applications In This Patient Population",2016-07-18 07:00:00-04:00,BMY,positive
176505.0,U.S. Companies On Hiring Sprees Across The Country,2016-07-11 11:07:00-04:00,BMY,neutral
176506.0,A Peek Into The Markets: U.S. Stock Futures Drop Ahead Of Factory-Orders Report,2016-07-05 07:49:00-04:00,BMY,negative
176507.0,Bristol-Myers Squibb Buys Privately Held Cormorant Pharmaceuticals,2016-07-05 07:34:00-04:00,BMY,neutral
176508.0,"Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals  For $95M, With Additional Consideration Of Up To $425M Upon Development & Regulatory Milestones",2016-07-05 06:59:00-04:00,BMY,neutral
176509.0,"Bristol-Myers Squibb, PsiOxus Therapeutics Announce Immuno-Oncology Clinical Partnership to Evaluate the Combination of Opdivo and Enadenotucirev; Bristol-Myers To Make One-Time Payment Of $10M To PsiOxus",2016-06-30 06:59:00-04:00,BMY,neutral
176510.0,Bristol-Myers Squibb's Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer,2016-06-27 06:59:00-04:00,BMY,negative
176511.0,Bristol-Myers Announces Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer,2016-06-20 16:15:00-04:00,BMY,neutral
176512.0,5 Pharmaceutical Price Target Raises From Jefferies,2016-06-14 15:13:00-04:00,BMY,neutral
176513.0,"SunTrust Highlights Upcoming Pharma Calendar, Favorite Names",2016-06-13 15:20:00-04:00,BMY,positive
176514.0,"Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators",2016-06-13 09:37:00-04:00,BMY,negative
176515.0,"Bristol-Myers Squibb Announces New Data on Opdivo Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial at EHA",2016-06-10 04:17:00-04:00,BMY,positive
176516.0,Bristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion and Immuno-Oncology Advancements Across Multiple Blood Cancers,2016-06-09 07:04:00-04:00,BMY,neutral
176517.0,Bristol-Myers Squibb Reveals Fresh Rheumatoid Arthritis Research And Real-World Data At European Congress Of Rheumatology,2016-06-08 10:09:00-04:00,BMY,positive
176518.0,Option Alert: BMY Jun16 73.5 Puts Sweep: 2137 @  ASK  $0.89: 2157 traded vs 155 OI:  Earnings 7/28  $73.78 Ref,2016-06-08 10:06:00-04:00,BMY,positive
176519.0,"Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology, Held June 8-11 In London",2016-06-08 07:50:00-04:00,BMY,neutral
176520.0,Bristol-Myers And MD Anderson Cancer Center Makes Fresh Research Alliance In Immuno-Oncology Focused On Lung-Cancer,2016-06-07 07:47:00-04:00,BMY,negative
176521.0,"Bristol-Myers, MD Anderson Report New Research Collab in Immuno-Oncology Focused on Lung Cancer",2016-06-07 07:00:00-04:00,BMY,negative
176522.0,4 Key Takeaways From ASCO,2016-06-06 17:32:00-04:00,BMY,neutral
176523.0,Mid-Afternoon Market Update: Helios and Matheson Analytics Jumps Amid News Of Merger With Zone Technologies; ProNAi Therapeutics Shares Drop,2016-06-06 14:31:00-04:00,BMY,neutral
176524.0,Vascular Biogenics Surges 80% Off Double Catalyst,2016-06-06 12:06:00-04:00,BMY,neutral
176525.0,Unconfirmed Chatter That Vascular Biogenics May Be Takeover Candidate For Bristol Myers Squibb,2016-06-06 10:03:00-04:00,BMY,negative
176526.0,"Bristol-Myers Squibb Announces Opdivo, Yervoy Combination Regimen Shows Clinically Meaningful Responses in First-Line Advanced NSCLC, In Updated Phase 1b Study CheckMate -012; Data to be Presented at #ASCO16",2016-06-04 14:43:00-04:00,BMY,positive
176527.0,"Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions",2016-06-03 13:49:00-04:00,BMY,negative
176528.0,"Seeing Late Day Options Activity In BMY Jun $65 Calls, 23,973 contracts trade",2016-05-26 15:58:00-04:00,BMY,neutral
176529.0,Bristol-Myers Squibb Reports Health Canada Approval of Daklinza in Combo with Sofosbuvir,2016-05-24 07:11:00-04:00,BMY,positive
176530.0,Option Alert: BMY Fri 5/27 70.0 Calls (Wkly) Sweep: 4519 @  Above Ask!  $0.62: 4623 traded vs 54 OI: $69.78 Ref,2016-05-23 12:50:00-04:00,BMY,positive
176531.0,Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness,2016-05-23 11:46:00-04:00,BMY,neutral
176532.0,Inovalon And Bristol-Myers Squibb Strike Deal To Focus On Real World Outcomes & Value-Based Contracting Initiatives,2016-05-19 12:03:00-04:00,BMY,negative
176533.0,JPMorgan's Take On Big Pharma's New ASCO Abstracts,2016-05-19 11:07:00-04:00,BMY,neutral
176534.0,Bristol-Myers Squibb Announces Opdivo Granted First Approval of PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1,2016-05-18 04:36:00-04:00,BMY,positive
176535.0,Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma,2016-05-17 17:26:00-04:00,BMY,neutral
176536.0,Option Alert:  SWEEP (SELL) - BMY June $75 Call - 23999 @ 0.99 in 3 orders. 26122 traded. OI: 6008,2016-05-16 15:51:00-04:00,BMY,positive
176537.0,Mid-Day Market Update: NVIDIA Gains On Earnings Beat; ConforMIS Shares Drop,2016-05-13 12:09:00-04:00,BMY,positive
176538.0,Mid-Morning Market Update: Markets Mixed; J C Penney Sales Miss Estimates,2016-05-13 10:08:00-04:00,BMY,negative
176539.0,HTG Molecular Diagnostics Reports Immuno-Oncology Research Collaboration Deal with Bristol-Myers,2016-05-12 16:15:00-04:00,BMY,neutral
176540.0,"Bristol-Myers, AbbVie Report EC Approval of Empliciti for Treatment of Multiple Mylemona in Adults",2016-05-11 14:26:00-04:00,BMY,positive
176541.0,"Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead",2016-05-11 13:05:00-04:00,BMY,positive
176542.0,The Market In 5 Minutes: Don't Stop Me Now,2016-05-11 09:34:00-04:00,BMY,positive
176543.0,"TheStreet's Adam Feuerstein Tweets '$MRK $BMY are not working with $NWBO on cancer immunotherapy combination clinical trials, per their respective spokespersons.'",2016-05-03 10:33:00-04:00,BMY,negative
176544.0,"Bristol-Myers Squibb Target, Estimates Under Review At Goldman Sachs",2016-04-28 13:05:00-04:00,BMY,neutral
176545.0,UPDATE: Bristol-Myers Raises Adj. EPS $2.50-$2.60 vs $2.40 Est.,2016-04-28 07:00:00-04:00,BMY,neutral
176546.0,Bristol-Myers Raises FY16 Outlook,2016-04-28 06:59:00-04:00,BMY,neutral
176547.0,"Bristol-Myers Reports Q1 Adj. EPS $0.74 vs $0.65, Sales $4.39B vs $4.25B Est.",2016-04-28 06:59:00-04:00,BMY,neutral
176548.0,"Earnings Scheduled For April 28, 2016",2016-04-28 05:00:00-04:00,BMY,neutral
176549.0,Check-up on Energy: XOM and CVX Earnings Preview,2016-04-27 11:43:00-04:00,BMY,positive
176550.0,Bristol-Myers Squibb Canada Says Health Canada Approves Opdivo,2016-04-25 15:26:00-04:00,BMY,positive
176551.0,"The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers",2016-04-25 13:57:00-04:00,BMY,neutral
176552.0,"The Market In 5 Minutes: Monday, April 25, 2016",2016-04-25 09:55:00-04:00,BMY,neutral
176553.0,Bristol Myers Receives Breakthrough Therapy Designation for Opdivo,2016-04-25 06:59:00-04:00,BMY,neutral
176554.0,Bristol-Myers Squibb Chooses Medidata Clinical Cloud to Drive Drug Development and Business Transformation,2016-04-20 17:31:00-04:00,BMY,neutral
176555.0,Eiger BioPharmaceuticals Reports It Has Licensed Pegylated Interferon Lambda-1a Worldwide Rights From Bristol-Myers Squibb For HDV Franchise,2016-04-20 16:32:00-04:00,BMY,neutral
176556.0,Bristol-Myers Squibb Announces First Presentation of Two-Year Overall Survival Data for Opdivo in Combination with Yervoy Showed Superior Efficacy vs Yervoy Alone in Advanced Melanoma,2016-04-17 18:59:00-04:00,BMY,positive
176557.0,Bristol-Myers Announces FDA Accepts Priority Review for sBLA for Opdivo for Treatment of Classical Hodgkin Lymphoma Patients,2016-04-14 06:59:00-04:00,BMY,positive
176558.0,"Benzinga's M&A Chatter for Tuesday April 12, 2016",2016-04-12 20:10:00-04:00,BMY,neutral
176559.0,Option Alert: BMY Jun16 70.0 Calls Sweep: 500 @  ASK  $1.38: 562 traded vs 20k OI:  Earnings 4/28 Before Open  $67.06 Ref,2016-04-12 11:15:00-04:00,BMY,positive
176560.0,Celgene Shares Move to High of $105.10; Unconfirmed Market Chatter of Potential Merger with Bristol Myers Squibb,2016-04-12 11:06:00-04:00,BMY,positive
176561.0,SocGen Picks New Favorites In Big Pharma,2016-04-06 13:44:00-04:00,BMY,positive
176562.0,Societe Generale Initiates Coverage on Bristol-Myers Squibb at Sell,2016-04-06 11:47:00-04:00,BMY,neutral
176563.0,European Commission Approves Expanded Use of Opdivo to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer,2016-04-06 11:14:00-04:00,BMY,negative
176564.0,Bristol-Myers Squibb Reports Received Positive CHMP Opinion for Opdivo in Combo with Yervoy for Advanced Melanoma,2016-04-01 11:53:00-04:00,BMY,positive
176565.0,EMA Validates Bristol-Myers Squibb's Application for Opdivo for the Treatment of Classical Hodgkin Lymphoma Patients,2016-03-30 16:15:00-04:00,BMY,positive
176566.0,Citi Downgrades Novartis Following SAG Investigation,2016-03-29 10:10:00-04:00,BMY,neutral
176567.0,The Market In 5 Minutes: Can I Kick It?,2016-03-23 11:30:00-04:00,BMY,neutral
176568.0,"Bristol-Myers Squibb Reports Will Buy Padlock Therapeutics, $225M in Milestone Payments, Added $375M in Contingent Consideration",2016-03-23 06:59:00-04:00,BMY,neutral
176569.0,Organovo Is A Company 3D Printing Human Tissue And Its CEO Is Excited About Creating Livers,2016-03-17 15:57:00-04:00,BMY,positive
176570.0,Bristol-Myers Squibb to Present New Overall Survival Data for Opdivo as Monotherapy and in Combination with Yervoy at the AACR 2016 Annual Meeting,2016-03-16 16:30:00-04:00,BMY,neutral
176571.0,Allied-Bristol Life Sciences Launches iβeCa Therapeutics to Develop Novel Cancer Therapeutics Targeting the Wnt Signalling Pathway,2016-03-16 04:36:00-04:00,BMY,negative
176572.0,"Morgan Stanley Calls AMGN, BMY, BIIB, MCK, STJ It's Favorite Health Care Names",2016-03-11 05:52:00-05:00,BMY,positive
176573.0,Jimmy Carter Boosts Social Media Buzz For Merck's Blockbuster Drug,2016-03-08 13:30:00-05:00,BMY,positive
176574.0,"Bristol-Myers Squibb Spokesperson Says Company has Voluntarily Stopped Certain Initiatives in China; Says Continues to Review Activities, Build Upon Business Model In China -Reuters",2016-03-08 08:47:00-05:00,BMY,positive
176575.0,Bristol-Myers Squibb Names Peter J. Arduini to Board of Directors,2016-03-03 13:15:00-05:00,BMY,neutral
176576.0,Stocks To Watch During Cowen's 36th Annual Healthcare Conference,2016-03-01 13:21:00-05:00,BMY,neutral
176577.0,3 Mega Biotechs Leerink Loves,2016-02-29 13:25:00-05:00,BMY,positive
176578.0,Bristol Myers Squibb Selects Veeva Vault Registrations And Submissions Archive To Manage Registration Tracking,2016-02-29 07:10:00-05:00,BMY,neutral
176579.0,Bristol-Myers Squibb Receives Two Positive CHMP Opinions for Opdivo for Patients with Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer and Renal Cell Carcinoma,2016-02-26 07:14:00-05:00,BMY,positive
176580.0,Data Presented at APASL from First Completed Phase 3 Trial of All-oral Chronic Hepatitis C Regimen in Chinese Patient Population Shows Daclatasvir and Asunaprevir DUAL Therapy Demonstrated High Cure Rates Among HCV Genotype 1b Patients,2016-02-22 06:59:00-05:00,BMY,neutral
176581.0,Bristol-Myers Looks To A Promising Future,2016-02-17 08:17:00-05:00,BMY,positive
176582.0,"Morgan Stanley Adam Parker Overweight On Healthcare, First Time Since 2014, Adds BMY & AMGN To Portfolio",2016-02-16 09:08:00-05:00,BMY,negative
176583.0,Barron's: Are Trump And Sanders Killing The Market?,2016-02-14 14:15:00-05:00,BMY,negative
176584.0,"Barron's Picks And Pans: Bristol-Myers Squibb, KeyCorp, Core-Mark And More",2016-02-14 14:09:00-05:00,BMY,neutral
176585.0,Schroer: Biotech Will Turn Around,2016-02-13 22:12:00-05:00,BMY,neutral
176586.0,Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place,2016-02-08 15:56:00-05:00,BMY,positive
176587.0,BristolMyersSquibb Declines Comment on Rumored Takeover Talks With Celgene,2016-02-04 12:45:00-05:00,BMY,neutral
176588.0,Hearing Unconfirmed Market Chatter of Potential Bristol Myers Bid for Celgene,2016-02-04 10:24:00-05:00,BMY,negative
176589.0,Is Big Pharma Hinting At A SMID-Cap Biotech Rally?,2016-02-03 13:16:00-05:00,BMY,neutral
176590.0,"Hearing Intercept Pharma hires JPM to Handle Interest from Pfizer, Gilead, BristolMyers -Daily Mail",2016-02-02 09:43:00-05:00,BMY,positive
176591.0,UPDATE: Portola Pharma Licensing Deals for Andexanet Alfa in Japan Valued at Up to $120M,2016-02-01 07:04:00-05:00,BMY,positive
176592.0,Bristol-Myers and Pfizer Announce Collaboration with Portoloa Pharma,2016-02-01 06:56:00-05:00,BMY,neutral
176593.0,Hearing EMA Issues Jan. Recommendations: Approval of Bristol's Elotuzumab Under Accelerated Assessment,2016-01-29 07:14:00-05:00,BMY,positive
176594.0,Earnings Recap For January 28,2016-01-28 16:34:00-05:00,BMY,neutral
176595.0,"European Commission Approves Daklinza for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV",2016-01-28 12:45:00-05:00,BMY,positive
176596.0,"Vetr Top Raters Upgrade Bristol-Myers Squibb, Over 80% Bullish",2016-01-28 12:20:00-05:00,BMY,positive
176597.0,"Bristol Myers Ticks Higher Following Q4 Beat, Encouraging Guidance",2016-01-28 07:54:00-05:00,BMY,positive
176598.0,Bristol Myers Sees FY EPS $2.30 to $2.40 vs $2.30 est,2016-01-28 07:00:00-05:00,BMY,neutral
176599.0,Bristol-Myers Squibb Phase 3 Opdivo Head & Neck Trial Stopped Early,2016-01-28 07:00:00-05:00,BMY,negative
176600.0,"Bristol Myers Q4 EPS $0.38 vs $0.28 est, Revenue $4.3B vs $4.15B est",2016-01-28 06:59:00-05:00,BMY,neutral
176601.0,"12 Stocks To Watch For January 28, 2016",2016-01-28 04:32:00-05:00,BMY,neutral
176602.0,"Earnings Scheduled For January 28, 2016",2016-01-28 04:04:00-05:00,BMY,neutral
176603.0,"JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?",2016-01-25 11:43:00-05:00,BMY,positive
176604.0,US Big Pharma: What To Watch For In Q4 Results,2016-01-25 11:16:00-05:00,BMY,neutral
176605.0,"Stock Marquee Crowded With Oil, Apple, And The Fed",2016-01-25 10:25:00-05:00,BMY,neutral
176606.0,Benzinga's Top Downgrades,2016-01-25 09:30:00-05:00,BMY,positive
176607.0,BMO Downgrades Whole Foods And Bristol-Myers Squibb To Start Week: Why?,2016-01-25 09:17:00-05:00,BMY,neutral
176608.0,BMO Capital Downgrades Bristol-Myers Squibb to Market Perform,2016-01-25 06:35:00-05:00,BMY,neutral
176609.0,Bristol-Myers Squibb's Opdivo + Yervoy Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1,2016-01-24 06:55:00-05:00,BMY,positive
176610.0,"Berenberg Upgrades Bristol-Myers Squibb To Buy, Sees $77 Price Target",2016-01-22 08:59:00-05:00,BMY,neutral
176611.0,Benzinga's Top Upgrades,2016-01-22 08:50:00-05:00,BMY,positive
176612.0,Berenberg Upgrades Bristol-Myers Squibb to Buy,2016-01-22 06:19:00-05:00,BMY,neutral
176613.0,Fast Money Traders Share Their Biotech Picks,2016-01-12 07:14:00-05:00,BMY,positive
176614.0,Fast Money Final Trades Of 2015,2016-01-04 06:14:00-05:00,BMY,neutral
176615.0,Option Alert: BMY Jun16 75.0 Calls Sweep: 2217 @  ASK  $2.16: 2228 traded vs 1015 OI:  Earnings 1/28 Before Open  $68.58 Ref,2015-12-24 10:32:00-05:00,BMY,positive
176616.0,Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS in Combination with Opdivo in Relapsed or Refractory Non-Hodgkin Lymphoma,2015-12-23 08:01:00-05:00,BMY,neutral
176617.0,Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook,2015-12-19 17:08:00-05:00,BMY,positive
176618.0,3 Biotechs Atlantic Equities Loves And 1 It's Avoiding,2015-12-18 14:10:00-05:00,BMY,positive
176619.0,"Atlantic Equities Initiates Coverage on Bristol-Myers Squibb at Underweight, Announces $57.00 T",2015-12-18 08:41:00-05:00,BMY,neutral
176620.0,Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare for $350M Upfront Plus Milestone Payments,2015-12-18 04:17:00-05:00,BMY,neutral
176621.0,Shares of Eli Lilly Up ~0.6% After Credit Suisse Adds to 'Focus List'; Shares of Bristol-Myers Down ~0.7% as Stock Removed from Same List,2015-12-17 09:51:00-05:00,BMY,positive
176622.0,"Bristol Myers Squibb Dropped From Credit Suisse Focus List, Outperform Rating Maintained & PT $81",2015-12-17 04:10:00-05:00,BMY,positive
176623.0,Fast Money Picks For December 15,2015-12-15 07:18:00-05:00,BMY,neutral
176624.0,Bristol-Myers Reports Collaboration Deal with UCLA for Immuno-Oncology Rare Population Malignancy Research Program,2015-12-14 07:00:00-05:00,BMY,neutral
176625.0,Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds,2015-12-12 14:05:00-05:00,BMY,neutral
176626.0,9 Healthcare Picks For 2016,2015-12-10 14:26:00-05:00,BMY,neutral
176627.0,"Bristol-Myers Squibb, Princeton University Establish Center For Molecular Synthesis; Financial Terms Not Disclosed",2015-12-08 16:12:00-05:00,BMY,neutral
176628.0,Bristol-Myers Squibb Increases Qtr. Dividend From $0.37 To $0.38/Share,2015-12-08 16:06:00-05:00,BMY,neutral
176629.0,Bristol-Myers Squibb CompanyNew Longer-Term Data for Empliciti Showed Continued Progression-Free Survival Benefit in Patients with Relapsed or Refractory Multiple Myeloma #ASH2015,2015-12-05 10:27:00-05:00,BMY,positive
176630.0,Bristol-Myers Reports Receive Multiple Myeloma Research Foundation's '15 Collaborator Award,2015-12-04 08:00:00-05:00,BMY,positive
176631.0,Barclays' Biopharmaceuticals Blueprint For 2016,2015-12-01 11:54:00-05:00,BMY,neutral
176632.0,"Bristol-Myers, AbbVie Release Confirms Earlier FDA Approval of Empliciti",2015-11-30 15:15:00-05:00,BMY,positive
176633.0,FDA Reports Approval of Bristol-Myers' Empliciti to Treat Multiple Myeloma,2015-11-30 10:20:00-05:00,BMY,positive
176634.0,European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo European Marketing Authorization Application,2015-11-24 06:59:00-05:00,BMY,positive
176635.0,Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma,2015-11-24 06:55:00-05:00,BMY,positive
176636.0,FDA Approves Opdivo to Treat Advanced Form of Kidney Cancer -Reuters,2015-11-23 14:57:00-05:00,BMY,positive
176637.0,Bristol Myers Squibb Spikes To $69,2015-11-20 15:39:00-05:00,BMY,neutral
176638.0,Bristol-Myers Squibb Spokesperson Declines Comment on Earlier Chatter of Gilead Interest in Co.,2015-11-17 15:02:00-05:00,BMY,positive
176639.0,Hearing Unconfirmed Market Chatter of Gilead Deal to Acquire BMY,2015-11-17 10:36:00-05:00,BMY,negative
176640.0,"Shares of Bristol-Myers Break Above $65.50 Level Over Last Min, Now Up to $66",2015-11-17 10:36:00-05:00,BMY,positive
176641.0,Pamela Anderson And Hepatitis C: Which Drug Makers Are Working On A Cure?,2015-11-09 09:03:00-05:00,BMY,neutral
176642.0,"Bristol-Myers Squibb Acquires Cardioxyl Pharma. For $300M Near-Term Payments, With Potential Consideration Of $1.775B",2015-11-02 07:00:00-05:00,BMY,neutral
176643.0,UPDATE:  FDA Broadens Use of Bristol-Myer's Yervoy to Lower Risk That Melanoma Will Return Following Surgery,2015-10-28 16:58:00-04:00,BMY,negative
176644.0,FDA Approves Yervoy for Adjuvant Therapy in Stage III Melanoma -Adam F,2015-10-28 16:54:00-04:00,BMY,positive
176645.0,‏@adamfeuerstein  tweets: $BMY - FDA approves Yervoy for adjuvant therapy in stage III melanoma.,2015-10-28 16:54:00-04:00,BMY,positive
176646.0,13 Stocks To Watch In The Healthcare Space,2015-10-27 14:38:00-04:00,BMY,neutral
176647.0,These Three Pharma Giants Just Crushed Earnings,2015-10-27 10:09:00-04:00,BMY,negative
176648.0,Bristol-Myers Sees FY15 Adj. EPS $1.85-$1.90 vs $1.84 Est.,2015-10-27 06:59:00-04:00,BMY,neutral
176649.0,"Bristol-Myers Reports Q3 Adj. EPS $0.39 vs $0.35 Est., Sales $4.1B vs $3.86B Est.",2015-10-27 06:59:00-04:00,BMY,neutral
176650.0,"Earnings Scheduled For October 27, 2015",2015-10-27 04:14:00-04:00,BMY,neutral
176651.0,"Earnings Boom This Week: Big Pharma, E-Commerce Giant BABA And More",2015-10-26 15:57:00-04:00,BMY,neutral
176652.0,Fed Meeting A Mid-Week Bump In Flurry Of Earnings News,2015-10-26 14:02:00-04:00,BMY,neutral
176653.0,Bristol-Myers Squibb to Present Data from Multiple Studies of Difficult-to-Treat Chronic Hepatitis C Patients at AASLD,2015-10-21 07:09:00-04:00,BMY,neutral
176654.0,How Five Prime's Bristol-Myers Partnership Helps Investors,2015-10-19 15:35:00-04:00,BMY,positive
176655.0,Hearing Unconfirmed Market Chatter of Pfizer Bid for BMY; $75+/Share,2015-10-16 10:59:00-04:00,BMY,negative
176656.0,"Bristol-Myers Squibb Says NICE Recommends Daklinza for Treatment of Certain Patients with Chronic Hep C Genotypes 1, 3 and 4",2015-10-15 19:37:00-04:00,BMY,positive
176657.0,Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results,2015-10-15 15:28:00-04:00,BMY,negative
176658.0,Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics Shares Spike Higher,2015-10-15 12:25:00-04:00,BMY,negative
176659.0,Benzinga's Volume Movers,2015-10-15 10:46:00-04:00,BMY,neutral
176660.0,Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops Estimates,2015-10-15 10:18:00-04:00,BMY,positive
176661.0,Morning Market Gainers,2015-10-15 09:48:00-04:00,BMY,neutral
176662.0,Benzinga's Top #PreMarket Gainers,2015-10-15 08:30:00-04:00,BMY,positive
176663.0,"Five Prime Therapeutics +68% Premarket Following Announcement of Worldwide License, Collaboration Agreement on CSF1R Antibody Program With Bristol-Myers Squibb",2015-10-15 07:41:00-04:00,BMY,positive
176664.0,"Bristol-Myers Squibb,  Five Prime Therapeutics Announce Worldwide License, Collaboration Agreement on CSF1R Antibody Program",2015-10-15 04:20:00-04:00,BMY,positive
176665.0,Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program,2015-10-15 04:16:00-04:00,BMY,positive
176666.0,Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy Fund,2015-10-14 14:09:00-04:00,BMY,negative
176667.0,"Bristol-Myers Squibb's Opdivo Receives Expanded FDA Approval in Previously-Treated Metastatic Non-Small Cell Lung Cancer , Offering Improved Survival to More Patients",2015-10-09 15:06:00-04:00,BMY,positive
176668.0,FDA Expands Approved Usage For Opdivo In Advanced Lung Cancer Scenarios,2015-10-09 13:57:00-04:00,BMY,negative
176669.0,Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-line Hodgkin Lymphoma,2015-10-07 08:00:00-04:00,BMY,neutral
176670.0,Bristol Myers Announces FDA Granted Daklinza Priority Review,2015-10-06 07:03:00-04:00,BMY,positive
176671.0,Full SEC Comments Regarding Bristol-Myers Squibb FCPA Violations,2015-10-05 11:13:00-04:00,BMY,negative
176672.0,"Hearing SEC Has Charged Bristol-Myers with FCPA Violations, Co. to Pay $14M+ to Settle",2015-10-05 11:11:00-04:00,BMY,negative
176673.0,Bristol-Myers Spikes to High Following FDA Approval of Merck's Keytruda,2015-10-02 13:58:00-04:00,BMY,positive
176674.0,"Hearing Unconfirmed Market Chatter of Potential Bids from Bristol Myers, Pfizer for Celgene",2015-10-02 10:42:00-04:00,BMY,negative
176675.0,Fast Money Picks For October 2,2015-10-02 06:13:00-04:00,BMY,neutral
176676.0,Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma,2015-10-01 06:59:00-04:00,BMY,positive
176677.0,UBS On Bristol-Myers Squibb: 'We Like This Opportunity Right Here Right Now',2015-09-29 10:32:00-04:00,BMY,positive
176678.0,Benzinga's Top Upgrades,2015-09-29 09:16:00-04:00,BMY,positive
176679.0,"US Stock Futures Rise Ahead Of Housing, Consumer Confidence Data",2015-09-29 07:10:00-04:00,BMY,positive
176680.0,"UBS Upgrades Bristol-Myers Squibb to Buy, Raises PT to $75.00",2015-09-29 06:43:00-04:00,BMY,neutral
176681.0,Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -057,2015-09-27 18:10:00-04:00,BMY,negative
176682.0,Bristol-Myers Squibb Reports FDA Regulatory Filing Update for Opdivo_Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma,2015-09-25 16:17:00-04:00,BMY,positive
176683.0,"Bristol-Myers Squibb, Moffitt Cancer Center Report Entering Into of Collab Deal Related to Rare Population Malignancy Program",2015-09-25 08:00:00-04:00,BMY,negative
176684.0,Bristol-Myers Squibb's Kidney Opportunity Is Bigger Than Some Thought,2015-09-22 14:48:00-04:00,BMY,positive
176685.0,Fast Money Picks For September 21,2015-09-21 06:38:00-04:00,BMY,neutral
176686.0,Make The World A Better Place With...Stock Picks?,2015-09-18 15:13:00-04:00,BMY,positive
176687.0,Bristol-Myers Squibb Foundation Awards Additional Grants to Promote Cervical Cancer Screenings and Services for Women Living with HIV in Tanzania,2015-09-18 08:01:00-04:00,BMY,positive
176688.0,Filing from Bristol-Myers Shows Registration for Automatic Mixed Securities Shelf Offering,2015-09-17 16:39:00-04:00,BMY,positive
176689.0,Cramer's Stock To Buy After A Fed Rate Hike,2015-09-16 17:00:00-04:00,BMY,neutral
176690.0,Bristol-Myers Squibb's Opdivo Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma,2015-09-16 08:00:00-04:00,BMY,positive
176691.0,"Jim Cramer Shares His Thoughts On Home Depot, Bristol-Myers Squibb, Marathon Oil, Exelixis",2015-09-16 06:34:00-04:00,BMY,positive
176692.0,Amgen And Biogen Lead Short Interest Surge In Biotechs,2015-09-14 16:01:00-04:00,BMY,positive
176693.0,Biotechs Coming Off One Of The Busiest Weeks In Recent Memory,2015-09-14 13:44:00-04:00,BMY,neutral
176694.0,Fast Money Picks For September 10,2015-09-10 06:56:00-04:00,BMY,neutral
176695.0,Mike Khouw Sees Unusual Options Activity In Bristol-Myers Squibb,2015-09-10 06:55:00-04:00,BMY,neutral
176696.0,"Bristol-Myers, Pfizer Report Enrollment of First Patient in Phase 4 AUGUSTUS Trial for Evaluation of Safety of Eliquis",2015-09-09 08:02:00-04:00,BMY,positive
176697.0,"BMY Announces CheckMate -017, -063 Trials Evaluating Opdivo in Previously Treated Squamous NSCLC Show Sustained Survival Benefit",2015-09-07 16:42:00-04:00,BMY,positive
176698.0,BMY Announces Opdivo+Yervoy Dosing Schedules Showed Acceptable Tolerability Profile,2015-09-07 15:56:00-04:00,BMY,positive
176699.0,Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC) Highlights,2015-09-02 16:16:00-04:00,BMY,negative
176700.0,U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients,2015-09-02 08:03:00-04:00,BMY,negative
176701.0,"It's Not Shopping, It's Market Research: Talking Investing Trends With TD Ameritrade's Nicole Sherrod",2015-09-01 14:40:00-04:00,BMY,neutral
176702.0,U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies,2015-09-01 07:30:00-04:00,BMY,positive
176703.0,"Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic Diseases",2015-08-31 08:30:00-04:00,BMY,positive
176704.0,"Benzinga's M&A Chatter for Thursday August 27, 2015",2015-08-27 19:15:00-04:00,BMY,neutral
176705.0,Hearing Unconfirmed Market Chatter of Gilead Deal to Acquire BMY,2015-08-27 10:29:00-04:00,BMY,negative
176706.0,Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University,2015-08-27 04:31:00-04:00,BMY,neutral
176707.0,Morgan Stanley Lists Stocks With $5B in Market Cap Possessing Best 1 Year Opportunity,2015-08-24 10:13:00-04:00,BMY,positive
176708.0,"Piper Jaffray Upgrades Bristol-Myers Squibb, Sees Valuation As Fair",2015-08-24 08:45:00-04:00,BMY,positive
176709.0,"Bristol-Myers, Pfizer Will Present New Data on Eliquis at ESC Congress '15",2015-08-24 08:15:00-04:00,BMY,neutral
176710.0,"Piper Jaffray Upgrades Bristol-Myers Squibb to undefined, Maintains $61.00 PT",2015-08-24 04:47:00-04:00,BMY,neutral
176711.0,Bristol-Myers Squibb Announces Health Canada Approves Daklinza for Treatment of Chronic Hepatitis C Infection Across Multiple Genotypes Including Genotype 3,2015-08-20 06:06:00-04:00,BMY,positive
176712.0,Buy The Dip On Bristol-Myers Squibb: J.P. Morgan,2015-08-18 10:24:00-04:00,BMY,neutral
176713.0,"R-Pharm Acquires Ixempra From Bristol-Myers Squibb, Launches U.S. Commercial Operations",2015-08-17 08:31:00-04:00,BMY,neutral
176714.0,Credit Suisse: Top 11 Large-Cap Growth Stocks,2015-08-14 12:24:00-04:00,BMY,positive
176715.0,"Bristol-Myers Squibb Reports FDA Approval of US Product Labeling Update for Sprycel, Will Include Five-Year First-Line, Sever-Year Second-Line Efficacy, Safety Data",2015-08-13 08:02:00-04:00,BMY,positive
176716.0,U.S. FDA Extends Action Date for Supplemental Biologics License Application for Opdivo  in Previously Untreated Advanced Melanoma,2015-08-12 16:16:00-04:00,BMY,positive
176717.0,uniQure Receives Additional $53M from Bristol-Myers Squibb for Target Selection Payment and Additional Equity Investment,2015-08-10 05:03:00-04:00,BMY,neutral
176718.0,Hearing Renewed Unconfirmed Market Chatter of Pfizer Interest in Bristol-Myers,2015-07-31 09:55:00-04:00,BMY,positive
176719.0,"European Medicines Agency Validates, Grants Accelerated Assessment of Marketing Authorization Application for Empliciti For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies",2015-07-27 07:02:00-04:00,BMY,positive
176720.0,Daklinza Approved By FDA For Hepatitis C Genotype 3 Infections Treatment,2015-07-24 13:52:00-04:00,BMY,positive
176721.0,"Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls",2015-07-23 16:01:00-04:00,BMY,neutral
176722.0,From Conf Call: Bristol Myers Says Lung Business to Eclipse Melanoma Business,2015-07-23 11:28:00-04:00,BMY,neutral
176723.0,"Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast",2015-07-23 09:32:00-04:00,BMY,positive
176724.0,"Bristol-Myers Squibb Raises FY15 Adj. EPS from $1.60-$1.70 to $1.70-$1.80 vs $1.77 Est., Sales $15.5B-$15.9B vs $15.42B Est.",2015-07-23 07:38:00-04:00,BMY,neutral
176725.0,"Bristol-Myers Squibb Reports Q2 EPS $0.53 Vs Est $0.36, Sales $4.2B",2015-07-23 07:31:00-04:00,BMY,neutral
176726.0,"US Stock Futures Rise Ahead Of General Motors, McDonald's Earnings",2015-07-23 06:55:00-04:00,BMY,neutral
176727.0,European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe,2015-07-23 06:33:00-04:00,BMY,positive
176728.0,Bristol Myers Announces EMA Validates Two Parallel Type II Variation Applications to Extend Opdivo Indication in Europe,2015-07-23 06:33:00-04:00,BMY,positive
176729.0,"Earnings Scheduled For July 23, 2015",2015-07-23 04:46:00-04:00,BMY,neutral
176730.0,What's Coming For Large-Cap Pharma Stocks This Earnings Season?,2015-07-22 16:13:00-04:00,BMY,neutral
176731.0,"Did McDonald's, Caterpillar & Amazon Lose Sizzle To Strong Dollar?",2015-07-22 13:59:00-04:00,BMY,positive
176732.0,"Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development",2015-07-21 14:00:00-04:00,BMY,positive
176733.0,Bristol-Myers Squibb Given U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients,2015-07-21 09:02:00-04:00,BMY,positive
176734.0,Bristol-Myers Announces European Commission Has Approved Nivolumab BMS in Europe,2015-07-20 12:09:00-04:00,BMY,positive
176735.0,"CheckMate -025, a Pivotal Phase III Opdivo Renal Cell Cancer Trial, Stopped Early",2015-07-20 08:01:00-04:00,BMY,negative
176736.0,Bristol-Myers' HIV-1 Drug Approved In Europe,2015-07-16 12:07:00-04:00,BMY,positive
176737.0,European Commission Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults,2015-07-16 09:21:00-04:00,BMY,positive
176738.0,Benzinga's Weekend M&A Chatter,2015-07-12 20:44:00-04:00,BMY,neutral
176739.0,Hearing Unconfirmed Market Chatter of Potential Pfizer Bid for Bristol Myers Squibb; Rumored Offer is $80+,2015-07-10 10:17:00-04:00,BMY,negative
176740.0,CNBC's Meg Tirrel Speculates About Gilead's New Acquisiton,2015-07-10 06:52:00-04:00,BMY,neutral
176741.0,Fast Money Picks For July 7,2015-07-07 06:47:00-04:00,BMY,neutral
176742.0,Fast Money Picks For June 30,2015-06-30 07:23:00-04:00,BMY,neutral
176743.0,Bristol-Myers Shares Spike Higher,2015-06-26 11:15:00-04:00,BMY,positive
176744.0,"Portola, Bristol-Myers Squibb, Pfizer Announce Complete Phae 3 ANNEXA-A Studya Results",2015-06-22 08:47:00-04:00,BMY,neutral
176745.0,Allied-Bristol Life Sciences Licenses Intellectual Property from Harvard University,2015-06-22 03:47:00-04:00,BMY,positive
176746.0,"European Commission Approves Bristol-Myers Squibb's Opdivo, the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients",2015-06-19 11:38:00-04:00,BMY,positive
176747.0,The Note Moving Pharma Giants Today,2015-06-17 16:06:00-04:00,BMY,neutral
176748.0,Benzinga's Top Initiations,2015-06-17 09:29:00-04:00,BMY,positive
176749.0,Piper Jaffray Initiates Bristol-Myers Squibb With Underperform,2015-06-17 08:09:00-04:00,BMY,neutral
176750.0,"Piper Jaffray Initiates Coverage on Bristol-Myers Squibb at Underperform, Announces $60.00 PT",2015-06-17 06:11:00-04:00,BMY,neutral
176751.0,Morgan Stanley's Positive Comments On Bristol-Myers Squibb,2015-06-15 16:30:00-04:00,BMY,positive
176752.0,"Morgan Stanley Issues Positive Comments on Bristol-Myers, Models Opdivo 2015 Sales At $1.1B Growing To $9.7B In 2020",2015-06-15 11:29:00-04:00,BMY,positive
176753.0,PeptiDream Announces Milestone in Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb,2015-06-11 04:09:00-04:00,BMY,neutral
176754.0,New Post Hoc Breakdown of Phase 3b Data Examine Treatment with Orencia (abatacept) Plus Methotrexate (MTX) in Patients with Early Moderate to Severe Rheumatoid Arthritis (RA) and Markers of Poor Prognosis,2015-06-09 18:02:00-04:00,BMY,negative
176755.0,2 M&A Rumors Moving The Market,2015-06-04 15:29:00-04:00,BMY,neutral
176756.0,Pfizer Issues Statement Related Bristol-Myers Chatter: Co. 'Does Not Comment on Market Rumor or Speculation',2015-06-04 13:10:00-04:00,BMY,neutral
176757.0,Bristol-Myers Squibb Spokesperson Declines Comment on Chatter of Co. Deal with Pfizer,2015-06-04 11:27:00-04:00,BMY,neutral
176758.0,Option Alert: Bristol Myers June 5 $66 Call; 1220 Contract Trade above Ask @$0.38,2015-06-04 10:53:00-04:00,BMY,positive
176759.0,Hearing Unconfirmed Market Chatter of Potential Pfizer Bid for Bristol Myers Squibb,2015-06-04 10:52:00-04:00,BMY,negative
176760.0,Bristol-Myers Squibb to Report Data from 14 Abstracts on Orencia  at the European League Against Rheumatism  2015 Annual Meeting,2015-06-03 08:04:00-04:00,BMY,neutral
176761.0,Genmab Gains Exclusive License from Bristol-Myers Squibb for Human Antibodies against CD19 Target for $4M,2015-06-02 04:24:00-04:00,BMY,positive
176762.0,16 Biotech Stocks Moving Off The ASCO Conference,2015-06-01 15:51:00-04:00,BMY,neutral
176763.0,Options Outlook: Market In 'Headline' And 'Sentiment' Mode,2015-06-01 12:59:00-04:00,BMY,neutral
176764.0,U.S. FDA Supplemental Biologics License Application for Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma,2015-06-01 07:45:00-04:00,BMY,positive
176765.0,Bristol-Myer Opdivo Demonstrates Superior Survival Compared to Ocetaxel for Previously-Treated Squamous NSCLC in Phase 3 Trial,2015-05-31 17:50:00-04:00,BMY,positive
176766.0,Bristol-Myers Announced Positive Results of Phase III Trial Evaluating Opdivo+Yervoy Regimen,2015-05-31 16:01:00-04:00,BMY,positive
176767.0,Bristol-Myers Shares Spike Lower Following Results of Phase I/II Opdivo Trial,2015-05-29 14:15:00-04:00,BMY,neutral
176768.0,Phase I/II Opdivo (nivolumab) Trial Displays Bristol-Myers Squibb's PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma,2015-05-29 14:03:00-04:00,BMY,positive
176769.0,Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Better Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial,2015-05-29 14:02:00-04:00,BMY,positive
176770.0,Fast Money Picks For May 27,2015-05-26 20:58:00-04:00,BMY,neutral
176771.0,uniQure Report Closing of Strategic Partnership with Bristol-Myers Squibb to Develop  Cardiovascular Disease  Gene Therapies,2015-05-26 09:30:00-04:00,BMY,neutral
176772.0,"Bristol-Myers Squibb Given Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients",2015-05-22 07:33:00-04:00,BMY,positive
176773.0,CHMP Grants Positive Opinion for Bristol-Myers' Nivolumab BMS,2015-05-22 07:05:00-04:00,BMY,positive
176774.0,EMA Recommends Approval of Bristol-Myers Squibb HIV Drug Evotaz,2015-05-22 07:03:00-04:00,BMY,positive
176775.0,Bristol-Myers Squibb Granted Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen,2015-05-20 09:00:00-04:00,BMY,positive
176776.0,Berenberg Initiates Bristol-Myers Squibb With Hold,2015-05-14 09:30:00-04:00,BMY,neutral
176777.0,Benzinga's Top Initiations,2015-05-14 09:19:00-04:00,BMY,positive
176778.0,Benzinga's Top #PreMarket Losers,2015-05-14 08:18:00-04:00,BMY,negative
176779.0,Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology from its Broad Immuno-Oncology Portfolio Across Solid Tumors (Last Night),2015-05-14 07:56:00-04:00,BMY,positive
176780.0,"Berenberg Initiates Coverage on Bristol-Myers Squibb at Hold, Announces $70.00 PT",2015-05-14 05:46:00-04:00,BMY,neutral
176781.0,"Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers",2015-05-05 08:51:00-04:00,BMY,positive
176782.0,Report Bristol-Myers Has Been Rejected by US Supreme Court Related to Baraclude Patent,2015-05-04 09:34:00-04:00,BMY,positive
176783.0,Bristol-Myers Reports FDA Acceptance Supplemental BLA for Opdivo in Patients with Previously-Untreated Advanced Melanoma,2015-04-29 17:01:00-04:00,BMY,positive
176784.0,Bristol-Myers Squibb's Next 8 Months: What To Expect,2015-04-29 08:23:00-04:00,BMY,neutral
176785.0,Bristol-Myers Raises FY15 Adj. EPS Outlook from $1.55-$1.70 to $1.60-$1.70 vs $1.71 Est.,2015-04-28 07:31:00-04:00,BMY,neutral
176786.0,"Bristol-Myers Squibb Reports Q1 Adj. EPS $0.71 vs. Est.$0.50, REv. $4.041B vs. Est. $3.80B",2015-04-28 07:31:00-04:00,BMY,neutral
176787.0,"Earnings Scheduled For April 28, 2015",2015-04-28 04:35:00-04:00,BMY,neutral
176788.0,Bristol-Myers Squibb Earnings: Experts & Crowd Expect 10% EPS Growth,2015-04-27 16:27:00-04:00,BMY,positive
176789.0,"Bristol-Myers Reports ALLY-1 Trial Showed Investigational Daclatasvir-Based Regimen Cures 94% of Post-Live Transplant Patients, Met Primary Endpoint",2015-04-27 08:15:00-04:00,BMY,neutral
176790.0,Benzinga's Weekend M&A Chatter,2015-04-26 19:17:00-04:00,BMY,neutral
176791.0,"U.S. Tech, Dollar & Health Care ETFs To Watch This Week",2015-04-26 10:52:00-04:00,BMY,positive
176792.0,Why A Bristol-Myers Squibb Bid On Celgene Is Plausible,2015-04-24 13:31:00-04:00,BMY,neutral
176793.0,"SunTrust Biotech Analyst On Bristol-Myers Squibb, Celgene Rumor-""Is It Possible? Yes It Could Be, All Biotech Names In Play For Large Pharma Looking For Cancer Assets""",2015-04-24 12:03:00-04:00,BMY,positive
176794.0,Hearing Unconfirmed Market Chatter of Bristol Myers Bid for Celgene of $138/Share,2015-04-24 10:21:00-04:00,BMY,negative
176795.0,Bristol-Myers Receives Positive CHMP Opinion in EU for Opdivo for Treatment of Advance Melanoma,2015-04-24 07:47:00-04:00,BMY,positive
176796.0,EMA Recommends Approval of Bristol-Myers Squibb Melanoma Drug Nivolumab,2015-04-24 07:08:00-04:00,BMY,positive
176797.0,Benzinga's Top Upgrades,2015-04-21 12:35:00-04:00,BMY,positive
176798.0,"Morgan Stanley Says 'Buy The Leader In IO,' Upgrades Bristol-Myers To Overweight",2015-04-21 08:28:00-04:00,BMY,negative
176799.0,"Morgan Stanley Upgrades Bristol-Myers Squibb to Overweight, Raises PT to $80.00",2015-04-21 04:27:00-04:00,BMY,negative
176800.0,CAR-T Therapy Stocks Hit Hard Following AACR Data,2015-04-20 13:44:00-04:00,BMY,negative
176801.0,Bristol-Myers Squibb Reports First Randomized Study Evaluating Opdivo+Yervoy Regimen Shows Superior Efficacy Related to Yervoy Alone,2015-04-20 08:31:00-04:00,BMY,positive
176802.0,It's A Big Weekend For Biotech,2015-04-17 16:31:00-04:00,BMY,neutral
176803.0,Why Bristol-Myers Squibb Ending A Drug Trial Early Is A Good Thing,2015-04-17 13:47:00-04:00,BMY,positive
176804.0,"With Bristol-Myers Trial Stopped Early, 'What's Next?'",2015-04-17 11:23:00-04:00,BMY,negative
176805.0,Bristol-Myers Up Big After Drug Study Stopped Early,2015-04-17 10:23:00-04:00,BMY,negative
176806.0,Bristol-Myers Squibb Announces CheckMate -057 Trial Stopped Early,2015-04-17 09:00:00-04:00,BMY,negative
176807.0,Bristol-Myers Squibb Announces CheckMate -057 Trial Stopped Early,2015-04-17 08:56:00-04:00,BMY,negative
176808.0,"Lilly, Bristol-Myers Squibb Restructure Erbitux Pact In North America; Lilly Gets Full Commercialization Rights While Bristol-Myers Gets Tiered Royalties On Product Sales",2015-04-16 12:18:00-04:00,BMY,neutral
176809.0,Morgan Stanley's Major Pharma Q1 Preview,2015-04-14 16:47:00-04:00,BMY,neutral
176810.0,"Benzinga's M&A Chatter for Monday April 13, 2015",2015-04-13 17:48:00-04:00,BMY,neutral
176811.0,Option Alert: Bristol-Myers Squibb Apr $66.5 Call; 1500 Contract Trade at Ask @$0.24,2015-04-13 13:41:00-04:00,BMY,positive
176812.0,Hearing Renewed Unconfirmed Market Chatter of Pfizer Interest in Bristol-Myers,2015-04-13 10:24:00-04:00,BMY,positive
176813.0,Hearing Unconfirmed Market Chatter of Bristol-Myers Stake in Coronado Biosciences,2015-04-08 11:03:00-04:00,BMY,negative
176814.0,Bristol-Myers Squibb Reports Closing of Previously-Announced Purchase of Flexus Biosciences,2015-04-08 08:02:00-04:00,BMY,neutral
176815.0,3 Pharma Stories JPMorgan Is Watching,2015-04-06 18:18:00-04:00,BMY,neutral
176816.0,Benzinga's Volume Movers,2015-04-06 10:16:00-04:00,BMY,neutral
176817.0,Stocks Hitting 52-Week Highs,2015-04-06 10:04:00-04:00,BMY,neutral
176818.0,Morning Market Gainers,2015-04-06 09:41:00-04:00,BMY,neutral
176819.0,UPDATE: uniQure Share Rise 53% Premarket Following Announcement of Deal With Bristol-Myers Squibb,2015-04-06 08:27:00-04:00,BMY,positive
176820.0,Benzinga's Top #PreMarket Gainers,2015-04-06 08:05:00-04:00,BMY,positive
176821.0,"uniQure Share Rise 14% Premarket on Light Trading, Following Announcement of Deal With Bristol-Myers Squibb,",2015-04-06 07:38:00-04:00,BMY,positive
176822.0,"UPDATE: uniQure to Receive $50M Upfront Payment at Close of Transaction; Bristol-Myers-Squibb to Acquire Additional 5% Ownership Before December 31, 2015 at 10% Premium",2015-04-06 07:37:00-04:00,BMY,neutral
176823.0,"Bristol-Myers Squibb, uniQure Report Deal Providing Bristol Exclusive Access to uniQure's Gene Therapy Technology Platform for Multiple Targets in CV Diseases",2015-04-06 07:33:00-04:00,BMY,positive
176824.0,Bristol-Myers Squibb Is Re-Testing Its Breakout Level,2015-03-30 10:50:00-04:00,BMY,neutral
176825.0,Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for  Discovery Research Program on Autoimmune Diseases,2015-03-24 08:00:00-04:00,BMY,positive
176826.0,"SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms",2015-03-23 12:21:00-04:00,BMY,neutral
176827.0,Bristol-Myers Says FDA Approves Re-submission Of Daclatasvir NDA For Hep C Treatment,2015-03-12 15:07:00-04:00,BMY,positive
176828.0,18 Biotech Stocks These Wall Street Analysts Are Tracking,2015-03-11 12:04:00-04:00,BMY,neutral
176829.0,8 Healthcare Names Cowen & Co Are Talking About,2015-03-10 18:02:00-04:00,BMY,neutral
176830.0,Fast Money Halftime Report Final Trade From March 5,2015-03-05 15:26:00-05:00,BMY,neutral
176831.0,What Analysts Said After Bristol-Myers' Quick Lung Drug Approval,2015-03-05 09:35:00-05:00,BMY,positive
176832.0,Bristol-Myers Squibb Hits All-Time High Off FDA Approval For Expanded Use Of Opvido,2015-03-04 14:33:00-05:00,BMY,positive
176833.0,Shares of Rigel Pull Back on Report They are Not Partners with Bristol Myers on Opdivo for Lung Cancer,2015-03-04 13:49:00-05:00,BMY,negative
176834.0,Bristol-Myers Opdivo Expanded Use Approved To Treat Lung Cancer,2015-03-04 13:31:00-05:00,BMY,neutral
176835.0,Bristol-Myers Squibb to Pay Bavarian Nordic Up to $975M for PROSTVAC License,2015-03-04 04:47:00-05:00,BMY,negative
176836.0,Bristol-Myers Squibb Canada Announces Hepatitis C Cure Rate of 97% in Study of Patients Co-infected with HIV Given 12-week Combination Treatment of Daclatasvir and Sofosbuvir in ALLY-2 Trial,2015-03-03 06:22:00-05:00,BMY,neutral
176837.0,UPDATE: USDA Approves Supplimental Biologics License,2015-03-02 09:28:00-05:00,BMY,positive
176838.0,USDA Accepts Supplemental Biologics License Application for Yervoy As Adjuvant Treatment for Patients with Stage 3 Melanoma Who Are at High Risk of Recurrence,2015-03-02 09:27:00-05:00,BMY,positive
176839.0,BMY Announced ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12-Week Regimen of Daclatasvir and Sofosbuvir,2015-02-26 15:18:00-05:00,BMY,neutral
176840.0,Bristol Myers Reports Data Supporting Clinical Development Of BMS-955176,2015-02-26 08:35:00-05:00,BMY,positive
176841.0,"Bristol-Myers Has Said BMS-955176 Supports Candidate as Viable Compound, Expecting to Begin Phase 2b Studies in Q2, Primary Endpoint of Change in HIV-1 Met",2015-02-25 16:32:00-05:00,BMY,positive
176842.0,Bristol-Myers Squibb Launches Phase III Trial Of HIV Drug,2015-02-25 12:57:00-05:00,BMY,neutral
176843.0,Bristol Myers Announces Data From Phase IIb Trial of BMS-663068,2015-02-25 08:33:00-05:00,BMY,neutral
176844.0,Morning Market Gainers,2015-02-23 09:44:00-05:00,BMY,neutral
176845.0,Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications,2015-02-23 08:04:00-05:00,BMY,negative
176846.0,"Bristol-Myers Reports Deal to Purchase Flexus Biosciences for Total Consideration $1.25B, Including $800M Upfront, Development Milestones Which Could Total as Much as ~$450M",2015-02-23 08:02:00-05:00,BMY,neutral
176847.0,Evercore ISI Technical Analysis: The 'Single Best Idea',2015-02-23 07:34:00-05:00,BMY,positive
176848.0,"Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices",2015-02-20 13:10:00-05:00,BMY,positive
176849.0,FDA Approves Bristol-Myers Squibb's Evotaz,2015-01-29 17:24:00-05:00,BMY,positive
176850.0,Bristol-Myers Announces FDA Has Approved Evotaz for Treatment of HIV-1 Infection for Adults,2015-01-29 17:22:00-05:00,BMY,positive
176851.0,"Celldex Therapeutics, Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo",2015-01-29 08:05:00-05:00,BMY,neutral
176852.0,"Tuesday Morning Movers: Microsoft, Procter & Gamble Tumble Following Earnings",2015-01-27 09:19:00-05:00,BMY,neutral
176853.0,"UPDATE: Bristol-Meyers Squibb Posts Upbeat Q4 Results, Issues Downbeat Forecast",2015-01-27 08:39:00-05:00,BMY,neutral
176854.0,"Bristol-Myers Sees FY15 Adj. EPS $1.55-$1.70 vs $1.73 Est., Sales $14.4-$15B vs $15.64B Est.",2015-01-27 07:33:00-05:00,BMY,neutral
176855.0,"Bristol-Myer Squibb Reports Q4 EPS $0.46 Vs. Est. $0.41, Revenues Of $4.26B Vs. $4.03B",2015-01-27 07:31:00-05:00,BMY,neutral
176856.0,"Earnings Scheduled For January 27, 2015",2015-01-27 04:34:00-05:00,BMY,neutral
176857.0,"Bristol-Myers Squibb Names Caforio CEO, Andreotti To Become Chairman",2015-01-20 17:09:00-05:00,BMY,neutral
176858.0,"Bristol-Myers Squibb Appoints Giovanni Caforio As CEO; Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman",2015-01-20 16:31:00-05:00,BMY,positive
176859.0,10 Biotech Stories You Might've Missed This Week,2015-01-15 13:18:00-05:00,BMY,negative
176860.0,Bloomberg Reporting That Bristol-Myers' Ulocuplumab Treatment Granted FDA Orphan Status,2015-01-13 14:10:00-05:00,BMY,positive
176861.0,"Fast Money Picks For January 13: SanDisk, Tiffany & Co., Frontline, Bristol-Myers Squibb",2015-01-13 06:47:00-05:00,BMY,neutral
176862.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,BMY,neutral
176863.0,Morning Market Gainers,2015-01-12 09:42:00-05:00,BMY,neutral
176864.0,4 Stocks Trending On Social Media This Monday,2015-01-12 09:38:00-05:00,BMY,neutral
176865.0,Seattle Genetics and Bristol Myers Announces Collaboration on Two Drugs,2015-01-12 08:02:00-05:00,BMY,neutral
176866.0,Bristol-Myers Announces Phase 3 Study of Opdivo vs Docetaxel in Patients with Second-Line Squamous Cell NSCLC Met Endpoint,2015-01-11 21:28:00-05:00,BMY,neutral
176867.0,Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2015,2015-01-11 12:59:00-05:00,BMY,positive
176868.0,What Investors Should Expect From Portola Pharmaceutical's Upcoming Data Readouts,2015-01-09 12:43:00-05:00,BMY,neutral
176869.0,Jim Cramer Advises His Viewers On Wynn Resorts And Second Sight Medical Products,2015-01-06 07:53:00-05:00,BMY,neutral
176870.0,Bristol-Myers Squibb and California Institute for Biomedical Research Sign Worldwide Research Collaboration and License Agreement Focused on New Treatment Approaches for Fibrotic Diseases,2015-01-05 08:01:00-05:00,BMY,positive
176871.0,Bristol-Myers Squibb Receives Accelerated Approval Of Opdivo,2014-12-22 17:22:00-05:00,BMY,positive
176872.0,Bristol-Myers Nivolumab Opdivo Cleared BY FDA For Advanced Melanoma,2014-12-22 14:15:00-05:00,BMY,positive
176873.0,Fitch Revises Bristol-Myers Squibb's Outlook to Stable; Affirms IDR at 'A-',2014-12-11 14:50:00-05:00,BMY,positive
176874.0,US Stock Futures Edge Lower Ahead Of Federal Budget,2014-12-10 07:01:00-05:00,BMY,negative
176875.0,"Ono Pharmaceutical, Bristol-Myers Squibb, Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo and Mogamulizumab in Advanced Solid Tumors",2014-12-10 06:02:00-05:00,BMY,positive
176876.0,Bristol-Myers Declares Raised Qtr. Dividend from $0.36 to $0.37/Share,2014-12-09 16:31:00-05:00,BMY,neutral
176877.0,"Bristol-Myers, Pfizer Report Results of First-Human Study Evaluating Reversal of Anticoagulant Effect of Eliquis: Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects",2014-12-08 13:39:00-05:00,BMY,positive
176878.0,BMS Reports Opdivo Demonstrates Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma,2014-12-06 17:31:00-05:00,BMY,neutral
176879.0,UPDATE: Pfizer Declines Comment on Rumored Bid for Bristol-Myers Squibb,2014-12-05 12:45:00-05:00,BMY,neutral
176880.0,UPDATE: Bristol-Myers Squibb Spokesperson Declines Comment on Rumored Talks with Pfizer,2014-12-05 12:14:00-05:00,BMY,neutral
176881.0,"Option Alert: Bristol-Myers Squibb Dec 5 $59.5 Call; 3,167 Contracts Traded vs 130 OI; Currently $59.59",2014-12-05 10:05:00-05:00,BMY,positive
176882.0,UPDATE: Hearing Unconfirmed Market Chatter of Potential $70-$72 Bid for Bristol-Myers Squibb  by Pfizer,2014-12-05 09:56:00-05:00,BMY,negative
176883.0,Hearing Unconfirmed Market Chatter of Potential Pfizer Bid for Bristol Myers Squibb,2014-12-05 09:54:00-05:00,BMY,negative
176884.0,"Jefferies Maintains Hold on Bristol-Myers Squibb Company, Raises PT to $54.00",2014-12-04 08:00:00-05:00,BMY,neutral
176885.0,Bristol-Myers Receives CRL Letter From FDA; Requesting Added Data For Daclatasvir,2014-11-26 11:38:00-05:00,BMY,neutral
176886.0,Bristol-Myers Squibb Receives CRL from FDA for Daclatasvir,2014-11-26 11:37:00-05:00,BMY,neutral
176887.0,Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration,2014-11-24 08:59:00-05:00,BMY,positive
176888.0,Allied-Bristol Life Sciences Announces Strategic Partnership with Synergy Partners R&D Solutions,2014-11-18 04:57:00-05:00,BMY,positive
176889.0,"UPDATE: Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)",2014-11-17 08:13:00-05:00,BMY,positive
176890.0,"Portola , Bristol-Myers Squibb, Pfizer Report Statistically Significant Results from First Part of Phase 3 ANNEXA-A Studies of Andexanet Alfa with Eliquis",2014-11-17 08:03:00-05:00,BMY,positive
176891.0,Bristol-Myers Squibb Reports CheckMate -066 Study Met Primary Endpoint of Overall Survival,2014-11-16 07:08:00-05:00,BMY,neutral
176892.0,"Bristol-Myers Squibb to Construct Large-Scale Biologics Manufacturing Facility In Cruiserath, Ireland; Will Create 300-400 Manufacturing Jobs",2014-11-14 06:09:00-05:00,BMY,positive
176893.0,Morgan Stanley Downgrades Bristol-Myers On Valuation,2014-11-13 09:01:00-05:00,BMY,neutral
176894.0,"Bristol-Myers Squibb Reports High Cure Rates For Genotype 3 Hepatitis C Using Combination Of Daclatasvir, Sofosbuvir in ALLY-3 Trial",2014-11-13 06:03:00-05:00,BMY,neutral
176895.0,"Morgan Stanley Downgrades Bristol-Myers Squibb Company to Equal-weight, Maintains $60.00 PT",2014-11-13 04:37:00-05:00,BMY,neutral
176896.0,Bristol-Myers Squibb Announces Late-Breaking Data from ALLY Trial,2014-11-08 18:31:00-05:00,BMY,neutral
176897.0,Traders Highlighting Section in Tekmira Earnings/Corporate Update Release Related to Expiration of Collaboration with Bristol-Myers Squibb,2014-11-06 15:50:00-05:00,BMY,neutral
176898.0,Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor ,2014-11-03 08:37:00-05:00,BMY,positive
176899.0,#Premarket Prep Technical Update - Bristol-Myers Squibb Trading Finds Resistance,2014-10-31 14:06:00-04:00,BMY,neutral
176900.0,Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb Co,2014-10-31 07:49:00-04:00,BMY,neutral
176901.0,#Premarket Prep Technical Update - Bristol-Myers Squibb Makes New All Time High,2014-10-30 15:22:00-04:00,BMY,neutral
176902.0,Bristol-Myers Squibb & Lonza Announce Multi-year Manufacturing Agreement Expansion ,2014-10-30 13:04:00-04:00,BMY,positive
176903.0,"Bristol-Myers Squibb Announces Results From CheckMate -063, a Phase 2 single-arm, Open-Label Study of Opdivo ",2014-10-30 09:02:00-04:00,BMY,neutral
176904.0,Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy ,2014-10-28 07:02:00-04:00,BMY,positive
176905.0,"#PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line With Expectations",2014-10-27 08:19:00-04:00,BMY,negative
176906.0,"From Conf Call: Bristol-Myer Says Encouraged By Clincal Trial Data from ""069"" Melanoma Trial of Combo Of Yervoy, Opdivo Immuno-Oncology Drugs",2014-10-24 11:13:00-04:00,BMY,positive
176907.0,UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates,2014-10-24 08:59:00-04:00,BMY,positive
176908.0,"#PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets",2014-10-24 07:47:00-04:00,BMY,negative
176909.0,Bristol-Myers Squibb Company Sees FY2014 Sales $15.20B-15.80B vs $15.59B Est,2014-10-24 07:30:00-04:00,BMY,neutral
176910.0,Bristol-Myers Squibb Company Reports Q3 EPS of $0.45 vs $0.42 Est; Revenue of $3.92B vs $3.80B Est,2014-10-24 07:30:00-04:00,BMY,neutral
176911.0,"Earnings Scheduled For October 24, 2014",2014-10-24 04:51:00-04:00,BMY,neutral
176912.0,Must Watch Stocks for Today,2014-10-24 04:06:00-04:00,BMY,neutral
176913.0,Drug ETFs Attractive Buys On Pullback,2014-10-22 17:10:00-04:00,BMY,positive
176914.0,Benzinga Weekly Preview: Earnings Season Is In Full Swing,2014-10-19 10:19:00-04:00,BMY,neutral
176915.0,"BMO Capital Upgrades Bristol-Myers Squibb Company to Outperform, Maintains $55.00 PT",2014-10-16 06:08:00-04:00,BMY,neutral
176916.0,Markets Debut Week On Negative Note; S&P 500 Falls Through Key Level,2014-10-13 16:57:00-04:00,BMY,negative
176917.0,"Jefferies Maintains Hold on Bristol-Myers Squibb Company, Raises PT to $50.00",2014-10-13 08:27:00-04:00,BMY,neutral
176918.0,5 Companies That Could Develop An Enterovirus Treatment,2014-10-13 08:07:00-04:00,BMY,neutral
176919.0,"Bristol-Myers, Pharmacyclics, Janssen Report Clinical Collaboration of Evaluate OPDIVO, IMBRUVICA in NHL",2014-10-13 08:01:00-04:00,BMY,neutral
176920.0,Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S ,2014-10-08 08:02:00-04:00,BMY,neutral
176921.0,Shares of Achillion Pharm Edging Into Positive Territory as Hearing UBS Commenting on Bristol-Myers Squibb Look Into Strategic Assets as Boding Well for Co.,2014-10-07 12:03:00-04:00,BMY,positive
176922.0,"Bristol-Myers Squibb Statement About Asunaprevir In The US, WIthdraws NDA",2014-10-07 08:32:00-04:00,BMY,neutral
176923.0,2 Mutual Funds Holding Hospital Stocks ,2014-10-06 10:38:00-04:00,BMY,neutral
176924.0,Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia and Hematologic Malignancies ,2014-10-06 08:03:00-04:00,BMY,negative
176925.0,"Novartis, Bristol-Myers Squibb Collaborate on Novel Immunotherapy in Combination Treatments for NSCLC ",2014-10-06 05:24:00-04:00,BMY,positive
176926.0,What Are The Best-Selling Drugs Of 2014?,2014-10-03 11:34:00-04:00,BMY,neutral
176927.0,NeurOp Receives Milestone Payment As Bristol-Myers Squibb Nominates NMDA Receptor Compound As Candidate For Drug Development ,2014-10-02 15:16:00-04:00,BMY,neutral
176928.0,Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly Over Next Several Months,2014-10-02 10:15:00-04:00,BMY,neutral
176929.0,"Guggenheim Securities Initiates Coverage on Bristol-Myers Squibb Company at Neutral, Announces $57.00 PT",2014-10-02 06:10:00-04:00,BMY,positive
176930.0,"UPDATE: Bristol-Myers Says No Added Cash Contributions by Co. Are Required, No Change to Monthly Retirement Benefit Payment",2014-09-30 17:04:00-04:00,BMY,negative
176931.0,Bristol-Myers Squibb to Transfer $1.4 Billion in U.S. Pension Obligations to Prudential ,2014-09-30 17:00:00-04:00,BMY,neutral
176932.0,"Fast Money Picks For September 29 - Yahoo! Inc., Exxon Mobil Corporation And More",2014-09-29 09:15:00-04:00,BMY,neutral
176933.0,Bristol-Myers Squibb Presents Positive Phase 3 Data for Opdivoin Advanced Melanoma Patients Previously Treated with Yervoy,2014-09-29 05:04:00-04:00,BMY,positive
176934.0,Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo In U.S & EU,2014-09-26 16:19:00-04:00,BMY,neutral
176935.0,Bristol-Myers Announces Health Canada Approves Yervoy for First-Line Treatment of Adults With Metastatic Melanoma,2014-09-16 06:02:00-04:00,BMY,positive
176936.0,"Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug",2014-09-05 16:04:00-04:00,BMY,negative
176937.0,Shares of Bristol-Myers Edge Off Session Lows as Bloomberg Reporting Co. Has Filed Suit Against Merck Related to Patent for Immunotherapy Drugs,2014-09-05 10:57:00-04:00,BMY,positive
176938.0,Merck Wins FDA Approval For Pembrolizumab In Melanoma,2014-09-04 14:27:00-04:00,BMY,positive
176939.0,"Bristol-Myers, Pfizer Announce Eliquis Significantly Reduced Risk of All-Cause Hospitalization vs Placebo in Patients With VTE",2014-08-30 09:10:00-04:00,BMY,negative
176940.0,Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend,2014-08-27 17:17:00-04:00,BMY,negative
176941.0,FDA Site Shows Teva Has Received Approval for Generic Version of Bristol-Myer's Baraclude as of Aug. 26th,2014-08-27 15:07:00-04:00,BMY,positive
176942.0,"Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold",2014-08-27 12:32:00-04:00,BMY,neutral
176943.0,US Stock Futures Edge Higher Ahead Of Tiffany Earnings,2014-08-27 07:07:00-04:00,BMY,neutral
176944.0,"Deutsche Bank Initiates Coverage on Bristol-Myers Squibb Company at Hold, Announces $52.00 PT",2014-08-27 06:41:00-04:00,BMY,neutral
176945.0,EC Approves Bristol-Myers Squibb's Daklinza Across Multiple Genotypes for Treatment of Chronic Hepatitis C Infection ,2014-08-27 05:19:00-04:00,BMY,positive
176946.0,"Bristol, Pfizer Report Eliquis Approved for DVT, PE by FDA",2014-08-21 13:32:00-04:00,BMY,positive
176947.0,Bristol-Myers And Celgene Announce Clinical Collaboration For an Immunotherapy and Chemotherapy Combination,2014-08-20 08:01:00-04:00,BMY,neutral
176948.0,Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments,2014-08-11 16:46:00-04:00,BMY,positive
176949.0,FDA Site Shows Bristol-Myer's Nivolumab Has Won FDA Orphan Drug Designation,2014-08-08 10:03:00-04:00,BMY,positive
176950.0,"Leica Biosystems, Bristol-Myers Squibb to Collaborate on Companion Diagnostics That Support Targeted Therapies",2014-08-07 11:03:00-04:00,BMY,positive
176951.0,"Allied Minds, Bristol-Myers Squibb form Allied-Bristol Life Sciences",2014-08-04 05:03:00-04:00,BMY,neutral
176952.0,Achillion Pharmaceuticals Shares Move Higher on Unconfirmed Market Chatter of Potential Bid from Bristol-Myers Squibb,2014-08-01 10:54:00-04:00,BMY,positive
176953.0,Bristol Myers and Pfizer Announces European Approval of Eliquis,2014-07-29 07:01:00-04:00,BMY,positive
176954.0,Thursday Morning Earnings Reports,2014-07-24 12:14:00-04:00,BMY,neutral
176955.0,Bristol-Myers Squibb Company Sees FY2014 EPS $1.70-1.80 vs $1.77 Est,2014-07-24 07:50:00-04:00,BMY,neutral
176956.0,Bristol-Myers Squibb Company Reports Q2 EPS of $0.48 vs $0.44 Est,2014-07-24 07:32:00-04:00,BMY,neutral
176957.0,"Earnings Scheduled For July 24, 2014",2014-07-24 05:31:00-04:00,BMY,neutral
176958.0,Galectin Therapeutics Reports First Patient Dosed in Cohort 1 of Phase 1B Clincial Trial of GR-MD-02 in Combo with Ipilimumab in Metastatic Melanoma,2014-07-22 08:32:00-04:00,BMY,neutral
176959.0,Benzinga Weekly Preview: Earnings Season Continues With Geopolitical Tensions As A Backdrop,2014-07-18 16:47:00-04:00,BMY,negative
176960.0,"Bristol-Myers, Pfizer Report First-Patient Enrollment Phase IV EMANATE Trial for Assessment of Eliquis",2014-07-17 08:06:00-04:00,BMY,neutral
176961.0,Sarepta Declines Comment on Rumored Partnership with Bristol-Myers Squibb ,2014-07-15 13:03:00-04:00,BMY,neutral
176962.0,Hearing Merger Market Says Bristol-Meyers Interested in DMD Partnership with Sarepta,2014-07-15 12:28:00-04:00,BMY,positive
176963.0,Dow Sets New Intraday High; Citigroup Impresses With Earnings,2014-07-14 16:44:00-04:00,BMY,positive
176964.0,Bristol-Myers Announces Plans To File Biologics License Application For Opdivo in Q3,2014-07-10 07:30:00-04:00,BMY,neutral
176965.0,Markets Little Changed Ahead Of 4th Of July Break,2014-07-02 16:34:00-04:00,BMY,neutral
176966.0,Barclays Downgrades Pharmaceutical Sector,2014-07-02 15:31:00-04:00,BMY,neutral
176967.0,"UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target By 41%",2014-07-02 10:06:00-04:00,BMY,negative
176968.0,Benzinga's Top Downgrades,2014-07-02 08:01:00-04:00,BMY,positive
176969.0,"Barclays Downgrades Bristol-Myers Squibb Company to Equal-weight, Lowers PT to $46.00",2014-07-02 06:28:00-04:00,BMY,negative
176970.0,"Ex-Dividends For July 1, 2014",2014-07-01 09:44:00-04:00,BMY,neutral
176971.0,"Bristol-Myers Reports Issuance of Voluntary Recall of COUMADIN for Injection, Cites Presence of Particulate Matter",2014-06-30 13:25:00-04:00,BMY,neutral
176972.0,"Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments",2014-06-27 09:36:00-04:00,BMY,positive
176973.0,US Stock Futures Drop Ahead Of Consumer Sentiment Report,2014-06-27 07:41:00-04:00,BMY,negative
176974.0,Phiser and Bristol's Eliquis Gets Positive Opinion From EMA,2014-06-27 07:04:00-04:00,BMY,positive
176975.0,Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment of Chronic Hepatitis C in the European Union,2014-06-27 07:01:00-04:00,BMY,positive
176976.0,"UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped Early, Showed Superior Overall Survival vs Davarbazine",2014-06-24 16:46:00-04:00,BMY,positive
176977.0,"Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped Early, Showed Superior Overall Survival vs Davarbazine",2014-06-24 16:45:00-04:00,BMY,positive
176978.0,Bristol-Myers Announces Expansion of Access to Clinical Trial Data Through Collaboration with Academic Research Institute,2014-06-24 08:00:00-04:00,BMY,neutral
176979.0,Edward Jones Reinstates Hold on Bristol-Myers Squibb Company,2014-06-19 15:48:00-04:00,BMY,neutral
176980.0,"Pennsylvania Supreme Court Has Vacated $28M Judgement Related to Drug Pricing of Bristol-Myers, 13 Other Drug Cos. - Bloomberg",2014-06-17 15:02:00-04:00,BMY,positive
176981.0,"Benzinga's M&A Chatter for Monday June 16, 2014",2014-06-16 20:53:00-04:00,BMY,neutral
176982.0,Bristol-Myers Has Lost Appeals Court Ruling Related to Baraclude Patent - Bloomberg,2014-06-12 11:05:00-04:00,BMY,negative
176983.0,Takeover Whispers Add To Achillion Pharmaceuticals' Momentum,2014-06-11 16:22:00-04:00,BMY,neutral
176984.0,"Hearing Leering Says JNJ, AbbVie, Bristol-Myers Squibb Could Target Achillion Pharmaceuticals",2014-06-09 13:25:00-04:00,BMY,neutral
176985.0,ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy,2014-06-04 14:08:00-04:00,BMY,positive
176986.0,ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?,2014-06-04 13:58:00-04:00,BMY,neutral
176987.0,"Bristol-Myers, Syngene Extend Drug Discovery, Development Collaboration in India by Five Years",2014-06-03 07:07:00-04:00,BMY,positive
176988.0,Phase 3 Study Evaluating Yervoy® (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival,2014-06-02 07:38:00-04:00,BMY,neutral
176989.0,#Premarket Prep Technical Update - Bristol-Myers Squibb Trading Higher,2014-05-29 14:36:00-04:00,BMY,neutral
176990.0,"Bristol-Myers Squibb, CytomX Therapeutics Announce Worldwide Collaborations ",2014-05-27 07:07:00-04:00,BMY,neutral
176991.0,"Bristol-Myers Squibb, Incyte Enter Clinical Collaboration Agreement ",2014-05-27 07:04:00-04:00,BMY,positive
176992.0,13G Filing from Alder Biopharma on Bristol Myers Shows 5.35% Stake,2014-05-19 16:26:00-04:00,BMY,neutral
176993.0,Breaking Biotech: Bristol Does It Again,2014-05-19 13:19:00-04:00,BMY,neutral
176994.0,"Bristol-Myers, AbbVie Will Receive FDA Breakthrough Therapy for Elotuzumab",2014-05-19 08:00:00-04:00,BMY,neutral
176995.0,"#PreMarket Primer: Friday, May 16: Wall Street Giants Take Up Positions In Telecom Sector",2014-05-16 06:58:00-04:00,BMY,neutral
176996.0,Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss,2014-05-15 16:41:00-04:00,BMY,negative
176997.0,Mid-Afternoon Market Update: Markets Remain Red Despite Slight Recovery; Zendesk IPO Goes Off Without A Hitch,2014-05-15 15:45:00-04:00,BMY,neutral
176998.0,Mid-Day Market Update: Dow Drops Over 200 Points; Cisco Shares Jump On Upbeat Results,2014-05-15 12:41:00-04:00,BMY,positive
176999.0,UPDATE: BMO Downgrades Bristol-Myers Squibb,2014-05-15 10:37:00-04:00,BMY,neutral
177000.0,Mid-Morning Market Update: Markets Tumble; Wal-Mart Posts Lower Profit,2014-05-15 10:18:00-04:00,BMY,positive
177001.0,UPDATE: Morgan Stanley Reiterates On Bristol-Myers Squibb On Disappointing Combo Data,2014-05-15 09:51:00-04:00,BMY,negative
177002.0,Morning Market Losers ,2014-05-15 09:47:00-04:00,BMY,negative
177003.0,Benzinga's Top #PreMarket Losers,2014-05-15 08:22:00-04:00,BMY,negative
177004.0,Benzinga's Top Downgrades,2014-05-15 07:52:00-04:00,BMY,positive
177005.0,"Barclays, Cowen, Leerink, and William Blair Maintain Outperform/Overweight Ratings on Bristol Myers Squibb",2014-05-15 06:43:00-04:00,BMY,neutral
177006.0,Redburn Maintains Neutral on Bristol-Myers Squibb Company,2014-05-15 06:36:00-04:00,BMY,neutral
177007.0,"Bernstein Maintains Market Perform on Bristol-Myers Squibb Company, Maintains $48.00 PT",2014-05-15 06:36:00-04:00,BMY,neutral
177008.0,"BMO Capital Downgrades Bristol-Myers Squibb Company to Market Perform, Lowers PT to $55.00",2014-05-15 06:36:00-04:00,BMY,negative
177009.0,Bristol-Myers Squibb Announces Nivolumab in Combo with Yervoy in Phase 2 and 1b Trials Shows Anti-Tumor Activity,2014-05-14 17:13:00-04:00,BMY,neutral
177010.0,"Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab",2014-05-14 17:03:00-04:00,BMY,neutral
177011.0,Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab ,2014-05-14 08:17:00-04:00,BMY,neutral
177012.0,"Bristol-Myers, Celldex Therapeutics Reports Clinical Trial Collaboration",2014-05-14 08:02:00-04:00,BMY,neutral
177013.0,#Premarket Prep Technical Update - Bristol-Myers Squibb Trading Higher,2014-05-12 15:32:00-04:00,BMY,neutral
177014.0,"ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, TWTR)",2014-04-29 09:48:00-04:00,BMY,neutral
177015.0,UPDATE: Bristol-Myers Posts Higher Q1 Profit,2014-04-29 08:44:00-04:00,BMY,positive
177016.0,Bristol-Myers Squibb Company Reports Q1 EPS of $0.46 vs $0.43 Est,2014-04-29 07:30:00-04:00,BMY,neutral
177017.0,"US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data",2014-04-29 07:29:00-04:00,BMY,positive
177018.0,"Bristol-Myers Squibb Acquires iPierian for $175M, Potential Milestone Payments of $550M",2014-04-29 07:08:00-04:00,BMY,neutral
177019.0,"Earnings Scheduled For April 29, 2014",2014-04-29 05:16:00-04:00,BMY,neutral
177020.0,"Stocks To Watch For April 29, 2014",2014-04-29 04:23:00-04:00,BMY,neutral
177021.0,"Earnings Expectations For The Week Of April 28: Big Oil, Big Pharma And More",2014-04-27 11:58:00-04:00,BMY,neutral
177022.0,Benzinga Weekly Preview: Earnings Season Continues As Biotech & Pharmaceutical Companies Report,2014-04-25 16:41:00-04:00,BMY,neutral
177023.0,"Bristol-Myers Squibb, Samsung BioLogics Expand Manufacturing Agreement ",2014-04-22 19:06:00-04:00,BMY,positive
177024.0,UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo Tablet for Atazanavir Sulfate with Cobicistate,2014-04-14 08:08:00-04:00,BMY,neutral
177025.0,Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo Tablet for Atazanavir Sulfate with Cobicistate for People Living with HIV-1,2014-04-14 08:01:00-04:00,BMY,neutral
177026.0,Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients ,2014-04-10 07:08:00-04:00,BMY,neutral
177027.0,"Bristol-Myers Announces NDAS Submitted for Daclatasvir, Asunaprevir",2014-04-07 08:01:00-04:00,BMY,neutral
177028.0,Innate Pharma Announces Bristol-Myers Squibb Conducting Phase I Trial with Lirilumab and Nivolumab in Selected Solid Tumors ,2014-03-31 05:40:00-04:00,BMY,positive
177029.0,"Bristol-Myers Squibb, Pfizer Announce Found Consistent Results for Eliquis as Warfarin",2014-03-27 08:16:00-04:00,BMY,neutral
177030.0,Bristol-Myers Squibb Announces 12 Abstracts have been Accepted for Presentation at ILC,2014-03-24 05:46:00-04:00,BMY,positive
177031.0,Hearing Unconfirmed Market Chatter of Icahn Stake in Bristol-Myers Squibb ,2014-03-21 09:53:00-04:00,BMY,negative
177032.0,US Stock Futures Jump Ahead Of Economic Data,2014-03-17 07:10:00-04:00,BMY,neutral
177033.0,"Five Prime Therapeutics, Bristol-Myers Squibb Announce Collaboration Agreement ",2014-03-17 07:07:00-04:00,BMY,positive
177034.0,FDA Approves Eliquis to Reduce Risk of Blood Clots Following Hip or Knee Replacement Surgery ,2014-03-14 13:01:00-04:00,BMY,positive
177035.0,Bristol-Myers Squibb Trading Lower,2014-03-06 15:41:00-05:00,BMY,negative
177036.0,Market Wrap For February 25: Markets End The Day Relatively Flat,2014-02-25 16:38:00-05:00,BMY,neutral
177037.0,Market Wrap For February 24: Markets Showing Strength To Start The Week,2014-02-24 16:46:00-05:00,BMY,positive
177038.0,Bristol-Myers Receives US FDA Breakthrough Therapy Designation for Daclatasvir Regimen for Chronic Hep C,2014-02-24 08:32:00-05:00,BMY,neutral
177039.0,"Britsol-Meyers, Pfizer Report Eliquis Reduced Risk of Stroke and Demonstrated Fewer Major Bleeding Events vs Warfarin",2014-02-21 11:09:00-05:00,BMY,negative
177040.0,UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on More Positive Outlook,2014-02-10 10:02:00-05:00,BMY,positive
177041.0,"BMO Capital Upgrades Bristol-Myers Squibb Company to Outperform, Raises PT to $60.00",2014-02-10 07:32:00-05:00,BMY,neutral
177042.0,Bristol-Myers Squibb Completes Sale of Global Diabetes Business to AstraZeneca ,2014-02-03 05:45:00-05:00,BMY,neutral
177043.0,"#PreMarket Primer: Monday, January 27: Markets Open The Week On Edge",2014-01-27 07:16:00-05:00,BMY,neutral
177044.0,Top Earnings-Related Movers for Week of Jan. 20th,2014-01-24 18:19:00-05:00,BMY,positive
177045.0,Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment,2014-01-24 15:21:00-05:00,BMY,negative
177046.0,"UPDATE: Bristol-Myers Spikes Lower; 29,170 Contract Sale in Feb $60 Call",2014-01-24 11:08:00-05:00,BMY,negative
177047.0,"From Bristol-Myers Call: Reaffirms FY Outlook, Sees Gross Margin Slightly Above 75%",2014-01-24 10:51:00-05:00,BMY,negative
177048.0,Bristol Meyers Sqiubb Spikes to Low,2014-01-24 10:51:00-05:00,BMY,negative
177049.0,Bristol-Myers Squibb Company Reports Q4 EPS of $0.51 vs $0.43 Est; Revenue of $4.44B vs $4.29B Est,2014-01-24 07:30:00-05:00,BMY,neutral
177050.0,"#PreMarket Primer: Friday, January 24: Growth Fears Drag Down Emerging Markets",2014-01-24 07:07:00-05:00,BMY,negative
177051.0,"Earnings Scheduled For January 24, 2014",2014-01-24 04:35:00-05:00,BMY,neutral
177052.0,"Stocks To Watch For January 24, 2014",2014-01-24 04:03:00-05:00,BMY,neutral
177053.0,UPDATE: Galectin Therapeutics Supports Investigational New Drug Application for its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma,2014-01-15 07:55:00-05:00,BMY,positive
177054.0,Bristol-Myers CEO Andreotti at JP Morgan Healthcare Conf. Says Buybacks Are Possible,2014-01-14 12:22:00-05:00,BMY,positive
177055.0,"Portola Pharma Announces Second Clinical Pact with Bristol-Myers, Will Study Andexanet Alfa with Eliquis, Will Receive Upfront, Milestone Payments",2014-01-13 08:05:00-05:00,BMY,neutral
177056.0,"Barclays Upgrades Bristol-Myers Squibb Company to Overweight, Raises PT to $65.00",2014-01-10 08:55:00-05:00,BMY,negative
177057.0,"AstraZeneca, Bristol-Myers Report FDA Approval of Farxiga",2014-01-08 17:12:00-05:00,BMY,positive
177058.0,Market Wrap For January 8: Fed Minutes Released,2014-01-08 16:39:00-05:00,BMY,neutral
177059.0, FDA Approves Farxiga to Treat Type 2 Diabetes,2014-01-08 11:54:00-05:00,BMY,positive
177060.0,Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by EMA,2014-01-08 07:03:00-05:00,BMY,positive
177061.0,"From Bristol-Myers Presentation: CEO Says Co. Will Use Cash on Dividends, Will Reconsider a Buyback Plan",2014-01-07 10:44:00-05:00,BMY,neutral
177062.0,"Bristol-Myers CEO Andreotti Speaking at Goldman Conference: Says Opportunities for Top Line, Sees Improvements in Cost of Goods, SG&A Lines",2014-01-07 10:39:00-05:00,BMY,positive
177063.0,Benzinga's Top #PreMarket Losers,2013-12-24 08:14:00-05:00,BMY,negative
177064.0,Fitch Affirms Bristol-Myers; Lowers Outlook to Negative,2013-12-23 13:35:00-05:00,BMY,negative
177065.0,Benzinga's Top #PreMarket Losers,2013-12-23 08:18:00-05:00,BMY,negative
177066.0,Market Wrap For December 20: Markets Gain On GDP Data ,2013-12-20 16:44:00-05:00,BMY,positive
177067.0,UPDATE: Credit Suisse Reiterates on Bristol-Myers Squibb on Divestiture of Stake in Diabetes Joint Venture,2013-12-20 09:17:00-05:00,BMY,positive
177068.0,"Credit Suisse Maintains Outperform on Bristol-Myers Squibb Company, Raises PT to $60.00",2013-12-20 06:32:00-05:00,BMY,positive
177069.0,"Bristol-Myers, Pfizer Announces FDA Acceptance for Review Eliquis sNDA to Treat DVT",2013-12-19 17:02:00-05:00,BMY,positive
177070.0,Market Wrap For December 18: Markets Flat During Day One Post Fed Taper,2013-12-19 16:47:00-05:00,BMY,neutral
177071.0,"From Bristol-Myers Call: CEO Says Will Look for Deals in Core Therapy Area, Won't Do Deals in Primary Care",2013-12-19 08:59:00-05:00,BMY,positive
177072.0,"Bristol-Myers, AstraZeneca Shares Higher Following Confirmation AstraZeneca Will Buy JV Diabetes Stake for Up to $4.3B",2013-12-19 07:57:00-05:00,BMY,positive
177073.0,WSJ Reporting Bristol Myers Could Be Near a Deal to Sell Diabetes JV Stake to AstraZeneca in $3B Deal,2013-12-18 18:23:00-05:00,BMY,neutral
177074.0,FDA Panel Votes 10-4 Dapagliflozin's Heart Risk Acceptable; ,2013-12-12 16:29:00-05:00,BMY,positive
177075.0,"Bloomberg First Word Reporting Bristol Myers, AstraZeneca Have Won FDA Panel Support for Metreleptin in Lipodystrophy",2013-12-11 16:21:00-05:00,BMY,positive
177076.0,"Bloomberg Reporting Express Scripts' Miller in Phone Interview Said Aiming to Cut Costs for Hep C Drugs, Planning to Pit Gilead Against Other Drugmakers",2013-12-10 12:09:00-05:00,BMY,negative
177077.0,"Option Alert: Bristol-Myers Squibb January $52.5 Call; 20,098 Contracts Traded Monday vs 6,067 Open Interest; Currently $51.56",2013-12-09 12:11:00-05:00,BMY,positive
177078.0,FDA Posts Staff Review of AstraZeneca/Bristol's Metreleptin on Website,2013-12-09 07:49:00-05:00,BMY,neutral
177079.0,Investing in Companies Developing Promising Immunotherapy Drugs for Melanoma ,2013-11-18 10:42:00-05:00,BMY,positive
177080.0,"Bristol-Myers Squibb Says CFO Bancroft Will Take on Expanded Role in Biz Dev, Strategy Groups, Names Caforio Exec VP, Chief Commercial Officer, Murdo Gordon Named Pres of US",2013-11-13 15:02:00-05:00,BMY,neutral
177081.0,"UPDATE: '$BMY BRISTOL-MYERS SAYS TO CONTINUE FOCUS ON HIV, HEPATITIS B, HEART FAILURE, ONCOLOGY, IMMUNOSCIENCE AND FIBROTIC DISEASES'",2013-11-07 17:03:00-05:00,BMY,negative
177082.0,Colfax Tweet: '$BMY BRISTOL-MYERS ,2013-11-07 17:02:00-05:00,BMY,neutral
177083.0,"Colfax Tweet: 'BMY BRISTOL-MYERS SAYS TO CONTINUE FOCUS ON HIV, HEPATITIS B, HEART FAILURE, ONCOLOGY, IMMUNOSCIENCE AND FIBROTIC DISEASES'",2013-11-07 17:00:00-05:00,BMY,negative
177084.0,Market Wrap for October 28: Investors Push Apple Shares Lower,2013-10-28 17:12:00-04:00,BMY,neutral
177085.0,Mid-Afternoon Market Update: Markets Mixed as JC Penney Rises,2013-10-28 15:46:00-04:00,BMY,neutral
177086.0,Mid-Day Market Update: Burger King Surges On Upbeat Earnings; Sohu Shares Dip,2013-10-28 12:31:00-04:00,BMY,positive
177087.0,Mid-Morning Market Update: Markets Mixed; Merck Profit Beats Estimates,2013-10-28 10:35:00-04:00,BMY,positive
177088.0,UPDATE: Morgan Stanley Upgrades Bristol-Myers Squibb Co. on Potential of New Cancer Drugs,2013-10-28 09:04:00-04:00,BMY,negative
177089.0,Benzinga's Top Upgrades,2013-10-28 08:29:00-04:00,BMY,positive
177090.0,"Credit Suisse Added Bristol-Myers Squibb, Vantiv to 'US Focus List,' ADP, Rowan Companies Removed",2013-10-28 08:25:00-04:00,BMY,positive
177091.0,Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology ,2013-10-28 07:31:00-04:00,BMY,positive
177092.0,"Morgan Stanley Upgrades Bristol-Myers Squibb Company to Overweight, Raises PT to $60.00",2013-10-28 06:37:00-04:00,BMY,negative
177093.0,Bristol-Myers Presents Data on Nivolumab from Lung Cancer Cohort of Phase 1 Study at 15th World Conference on Lung Cancer ,2013-10-26 10:15:00-04:00,BMY,negative
177094.0,"Market Primer: Thursday, October 24: Investors Switch Focus To Earnings",2013-10-24 06:43:00-04:00,BMY,neutral
177095.0,UPDATE: Bristol-Myers Posts Q3 Profit,2013-10-23 08:34:00-04:00,BMY,positive
177096.0,Bristol-Myers Squibb Company Reports Q3 EPS of $0.46 vs $0.44 Est; Revenue of $4.07B vs $4.02B Est,2013-10-23 07:33:00-04:00,BMY,neutral
177097.0,"Market Primer: Wednesday, October 23: Fed Taper Outlook Looking Cloudy",2013-10-23 06:54:00-04:00,BMY,neutral
177098.0,"Earnings Scheduled For October 23, 2013",2013-10-23 04:54:00-04:00,BMY,neutral
177099.0,Earnings Expectations For The Week Of October 21: The Crunch Is On,2013-10-20 12:33:00-04:00,BMY,neutral
177100.0,"Benzinga Weekly Preview: Earnings Season Continues, Delayed US Data To Hit Markets",2013-10-18 16:08:00-04:00,BMY,negative
177101.0,"Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)",2013-10-11 14:33:00-04:00,BMY,neutral
177102.0,"Credit Suisse Starts Pfizer, Bristol-Myers, AbbVie, Allergan at Outperform, Merck, Eli Lilly, Forest Labs at Neutral",2013-10-08 16:57:00-04:00,BMY,positive
177103.0,Bristol-Myers Says Expecting Three-Year Survival Rate of 22% for Yervoy Study ,2013-09-27 16:11:00-04:00,BMY,neutral
177104.0,"AstraZeneca, Bristol-Myers Squibb Announce Positive Phase III Dapagliflozin Data",2013-09-24 06:01:00-04:00,BMY,positive
177105.0,Moody's Affirms Ratings on Bristol-Myers; Outlook Lowered from Stable to Negative,2013-09-23 15:13:00-04:00,BMY,negative
177106.0,Innate Pharma Announces First DSMB Review of Ongoing EffiKIR Phase II Trial with lirilumab ,2013-09-17 05:58:00-04:00,BMY,neutral
177107.0,UPDATE: J.P. Morgan Upgrades Bristol-Myers Squibb Ahead of Multiple Important Catalysts,2013-09-16 09:34:00-04:00,BMY,positive
177108.0,US Stock Futures Mostly Flat; Jobless Claims Data In Focus,2013-09-12 07:15:00-04:00,BMY,neutral
177109.0,Bristol-Myers Squibb Announces Results of Phase 3 Trial of Yervoy,2013-09-12 05:55:00-04:00,BMY,neutral
177110.0,"Bristol-Myers, Pfizer Report Stroke, Systemic Embolism, Major Bleeding Uncommon in Eliquis Phase 3 ARISTOTLE Trial    ",2013-08-31 11:46:00-04:00,BMY,neutral
177111.0,"Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)",2013-08-27 13:29:00-04:00,BMY,positive
177112.0,Benzinga's Weekend M&A Chatter,2013-08-18 18:26:00-04:00,BMY,neutral
177113.0,How Much Does It Cost To Develop A New Drug?,2013-08-14 09:32:00-04:00,BMY,neutral
177114.0,"UPDATE: Albany Molecular Research Shares Down Roughly 20% At $10.27, Fell As Much As 23.3% At Low On Disclosure That Bristol-Myers Squibb Has Canceled Development of Drug With Company",2013-08-12 13:35:00-04:00,BMY,neutral
177115.0,Albany Molecular Files Form 8-K Disclosing Termination Of Development Of BMS-820836 With Bristol-Myers Squibb,2013-08-12 13:15:00-04:00,BMY,neutral
177116.0,"Three Soaring, But Overlooked Health Care ETFs",2013-08-02 14:19:00-04:00,BMY,positive
177117.0,Bristol-Myers Squibb and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship ,2013-07-29 07:31:00-04:00,BMY,neutral
177118.0,"BMO Capital Maintains Market Perform on Bristol-Myers Squibb Company, Lowers PT to $48.00",2013-07-26 09:07:00-04:00,BMY,negative
177119.0,"Benzinga Market Primer: Friday, July 26: Futures Flat On Mixed Global Stocks Overnight",2013-07-26 06:41:00-04:00,BMY,neutral
177120.0,U.S. FDA Acknowledges Receipt of Resubmission of the New Drug Application From AstraZenenca,2013-07-25 17:02:00-04:00,BMY,neutral
177121.0,"Bristol-Myers Call Concludes, Exec Said Working with Pfizer In Order to Improve Sales of Eliquis",2013-07-25 11:36:00-04:00,BMY,positive
177122.0,"From Bristol-Myers Call: CEO Says M&A Strategy Has Not Changed, Continues to Look at Outside Deals",2013-07-25 11:21:00-04:00,BMY,neutral
177123.0,"Bristol-Myers Squibb Company Reports Q2 EPS of $0.44, Inline; Revenue of $4.05B vs $4.05B Est",2013-07-25 07:30:00-04:00,BMY,neutral
177124.0,"Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown",2013-07-25 06:31:00-04:00,BMY,negative
177125.0,"US Stock Futures Down; GM Earnings, Economic Data In Focus",2013-07-25 06:03:00-04:00,BMY,neutral
177126.0,"Earnings Scheduled For July 25, 2013",2013-07-25 04:43:00-04:00,BMY,neutral
177127.0,"Earnings Expectations for the Week of July 22 (AAPL, GM, MCD, NFLX)",2013-07-22 07:29:00-04:00,BMY,neutral
177128.0,"Benzinga's M&A Chatter for Tuesday July 16, 2013",2013-07-16 19:42:00-04:00,BMY,neutral
177129.0,"UPDATE: Amgen, Pfizer, Bristol-Myers Squibb, Gilead Among Companies that May Submit Bids for Onyx, According to Sources",2013-07-16 12:19:00-04:00,BMY,neutral
177130.0,UPDATE: Jefferies Downgrades Bristol-Myers Squibb on Challenges Ahead,2013-07-12 08:47:00-04:00,BMY,positive
177131.0,Benzinga's Top Downgrades,2013-07-12 07:40:00-04:00,BMY,positive
177132.0,"Jefferies Downgrades Bristol-Myers Squibb Company to Hold, Lowers PT to $49.00",2013-07-12 07:31:00-04:00,BMY,negative
177133.0,FDA Accepts Eliquis® (apixaban) Supplemental New Drug Application for Review for Prophylaxis of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery ,2013-07-11 07:31:00-04:00,BMY,positive
177134.0,"Bristol-Myers Squibb IDR Cut to A- from A, Outlook to Stable from Negative - Fitch",2013-07-01 13:34:00-04:00,BMY,negative
177135.0,Spectrum Pharmaceuticals Elects Two New Healthcare Industry Veterans to the Board of Directors ,2013-07-01 07:11:00-04:00,BMY,neutral
177136.0,"Bristol-Myers Squibb, Pfizer Announce Eliquis Meets Primary Efficacy Endpoint ",2013-06-30 18:10:00-04:00,BMY,neutral
177137.0,"Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)",2013-06-26 13:17:00-04:00,BMY,positive
177138.0,"AstraZeneca, Bristol-Myers Squibb, Announce Results from Phase IIa Study Assessing Safety and Tolerability of Dapagliflozin",2013-06-22 11:10:00-04:00,BMY,positive
177139.0,"Bristol-Myers, Otsuka America Announce FDA Approves US Product Labeling Update for Sprycel to Include Three--Year First-Line, Five-Year Second-Line Efficacy, Safety Data in Chronic Myeloid Leukemia in Chronic Phase",2013-06-20 14:11:00-04:00,BMY,positive
177140.0,Bristol's Amylin Named in Suit Realted to Januvia,2013-06-17 10:12:00-04:00,BMY,neutral
177141.0,"Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study ",2013-06-15 11:51:00-04:00,BMY,neutral
177142.0,"Bristol-Myers, Simcere Announce Partnership to Co-Develop, Co-Commercializde Orencia in China",2013-06-14 08:02:00-04:00,BMY,neutral
177143.0,"Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)",2013-06-12 13:29:00-04:00,BMY,positive
177144.0,"Astrazeneca, Bristol-Myers Squibb Release Statement to American Diabetes Association",2013-06-12 13:13:00-04:00,BMY,neutral
177145.0,"FDA Says Considering New Study of Incretin Mimetic Diabetes Drug, Says May Need to Look for Cancer-Link Patterns",2013-06-12 08:18:00-04:00,BMY,neutral
177146.0,A Peek Into The Market Before The Trading Starts,2013-06-12 07:19:00-04:00,BMY,neutral
177147.0,Bristol-Meyers Squibb Announces ORENCIA Shows Comparable Efficacy to Humira in Year Two Ample Study,2013-06-12 06:04:00-04:00,BMY,neutral
177148.0,"Top-Performing Dividend Payers in Health Care with the Most Upside Potential (AET, ENSG, QCOR)",2013-06-08 12:47:00-04:00,BMY,positive
177149.0,UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review,2013-06-07 12:30:00-04:00,BMY,negative
177150.0,"Jefferies Maintains Buy on Bristol-Myers Squibb Company, Lowers PT to $53.00",2013-06-07 07:49:00-04:00,BMY,negative
177151.0,"Bloomberg Reporting Bristol-Myers Health Canada Expands Indications of Abilify, Now Will Treat MDD",2013-06-06 11:04:00-04:00,BMY,positive
177152.0,"U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy ",2013-06-04 09:03:00-04:00,BMY,positive
177153.0,Bristol-Myers Squibb Reports Phase 1 Results from Advanced Melanoma Trial,2013-06-02 12:11:00-04:00,BMY,positive
177154.0,"SunTrust Robinson Humphrey Initiates Coverage on Bristol-Myers Squibb Company at Buy, Announces $55.00 PT",2013-05-29 16:47:00-04:00,BMY,neutral
177155.0,"Short Interest in Vertex Rises, in Biogen Idec Falls",2013-05-29 13:19:00-04:00,BMY,positive
177156.0,UPDATE: Jefferies Raises PT on Bristol Myers Squibb Following SOTP Analysis,2013-05-28 10:44:00-04:00,BMY,neutral
177157.0,"Jefferies Maintains Buy on Bristol-Myers Squibb Company, Raises PT to $53.50",2013-05-28 08:25:00-04:00,BMY,neutral
177158.0,"Market Wrap for Wednesday, May 22: Stocks Pullback As Bernanke Says Bond Buying Could Slow",2013-05-22 16:19:00-04:00,BMY,neutral
177159.0,Benzinga's Top Upgrades,2013-05-22 08:04:00-04:00,BMY,positive
177160.0,"Citigroup Upgrades Bristol-Myers Squibb Company to Buy, Raises PT to $55.00",2013-05-22 07:46:00-04:00,BMY,neutral
177161.0,Bristol-Myers CFO Speaking at UBS Global Healthcare Conference Says Committed to 3% Boost in 2013 Dividend,2013-05-21 08:44:00-04:00,BMY,positive
177162.0,Leerink Swann Upgrades Bristol-Myers Squibb Company to Outperform,2013-05-16 13:21:00-04:00,BMY,neutral
177163.0,Bristol Meyers Moving off Lows on Volume; May be Attributed to Leerink Upgrade to Outperform,2013-05-16 13:17:00-04:00,BMY,negative
177164.0,"Market Wrap for Wednesday, May 15: Bull Market Continues as Dow and S&P Hit New Highs",2013-05-15 16:17:00-04:00,BMY,neutral
177165.0,"Bristol Myers Exec to Speak at BofA Merrill's Health Care Conference at 1PM EDT; Shares Up Nearly 8%, Continuing Higher Following 3% Move Higher on Tuesday, 1% Gain on Monday",2013-05-15 12:51:00-04:00,BMY,positive
177166.0,"Short Interest in Vertex Rises, in Celgene Falls",2013-05-11 10:45:00-04:00,BMY,positive
177167.0,TD Ameritrade's IMX Survey Declines to 5.31 in April,2013-05-06 13:50:00-04:00,BMY,neutral
177168.0,"Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates",2013-05-03 08:02:00-04:00,BMY,neutral
177169.0,Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA  (efavirenz) in HIV-1 Infected Pediatric Patients,2013-05-03 08:01:00-04:00,BMY,neutral
177170.0,Form 8-K Shows Vanda Reported Bristol-Myers Waived Options on Tasimelteon,2013-04-29 07:31:00-04:00,BMY,neutral
177171.0,A Look Ahead: This Week's ETFs to Watch,2013-04-28 17:28:00-04:00,BMY,neutral
177172.0,"Short Sellers Move into Celgene, Regeneron",2013-04-26 13:25:00-04:00,BMY,neutral
177173.0,"Bristol-Myers Squibb Company Reports Q1 EPS of $0.41, Inline; Revenue of $3.83B vs $3.88B Est",2013-04-25 07:33:00-04:00,BMY,neutral
177174.0,"Gilead, Bristol Hepatitis-C Drug Combination Suppresses Virus in Study, Helps Those Who Fail Other Drugs",2013-04-23 07:38:00-04:00,BMY,negative
177175.0,Bristol-Myers Trying to Break Through Triple-Top Resistance at $41.50,2013-04-22 12:59:00-04:00,BMY,neutral
177176.0,ETF Showdown: A Pharma Fight,2013-04-11 16:21:00-04:00,BMY,negative
177177.0,"Bristol-Myers to Expand Massachusetts Biologics Facility, to Invest $250M, Increase Workforce",2013-04-11 10:17:00-04:00,BMY,positive
177178.0,UPDATE: Jefferies Raises PT on Bristol-Myers Squibb on Positive Outlook,2013-04-10 12:10:00-04:00,BMY,positive
177179.0,"UBS Maintains Neutral on Bristol-Myers Squibb Company, Raises PT to $40.00",2013-04-10 09:42:00-04:00,BMY,neutral
177180.0,"Jefferies Maintains Buy on Bristol-Myers Squibb Company, Raises PT to $45.00",2013-04-10 08:01:00-04:00,BMY,neutral
177181.0,These Are the 100 Highest-Paid CEOs in Business Today,2013-04-08 16:30:00-04:00,BMY,neutral
177182.0,UPDATE: BMO Capital Raises PT on Bristol Myers Squibb Co. on 1Q13 Caution,2013-04-08 11:43:00-04:00,BMY,neutral
177183.0,"BMO Capital Maintains Market Perform on Bristol-Myers Squibb Company, Raises PT to $43.00",2013-04-08 07:46:00-04:00,BMY,neutral
177184.0,"Stocks To Watch For April 8, 2013",2013-04-08 04:32:00-04:00,BMY,neutral
177185.0,Bristol-Myers Squibb Names Francis Cuss as New CSO,2013-04-07 16:29:00-04:00,BMY,neutral
177186.0,"Vertex, Bristol-Myers Enter Deal for Phase 2 All-Oral Studies of VX-135",2013-04-05 08:04:00-04:00,BMY,neutral
177187.0,"German Drug Panel Sees Pfizer, Bristol-Myers Eliquis Benefits in Patients 65+",2013-04-02 07:44:00-04:00,BMY,positive
177188.0,A Peek Into The Market Before The Trading Starts,2013-04-01 07:25:00-04:00,BMY,neutral
177189.0,LabCorp Clinical Trials Enters 5-Year Agreement with Bristol-Myers Squibb ,2013-04-01 06:25:00-04:00,BMY,positive
177190.0,The Supreme Court is About to Stick it to Big Pharma,2013-03-26 12:22:00-04:00,BMY,positive
177191.0,EMA Investigating Pancreatic Risks with GLP-1 Diabetes Drugs,2013-03-26 11:19:00-04:00,BMY,negative
177192.0,FDA Approves Zymodenetics Request Regarding Thrombin Topical -Bloomberg,2013-03-20 11:30:00-04:00,BMY,positive
177193.0,FDA Approves Bristol Myers' Unit Request to Supplement BLA -Bloomberg,2013-03-20 11:26:00-04:00,BMY,positive
177194.0,NIRI Appoints Charles Triano to Board of Directors ,2013-03-20 09:39:00-04:00,BMY,neutral
177195.0,S&P Likes a Pair of Low Vol ETFs,2013-03-19 13:44:00-04:00,BMY,positive
177196.0,A Look at a New Super Dividend ETF,2013-03-12 15:03:00-04:00,BMY,positive
177197.0,"NICE Recommending Bristol-Myers' Abatacept, Shares Unaffected",2013-03-08 07:28:00-05:00,BMY,positive
177198.0,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,2013-03-08 06:15:00-05:00,BMY,positive
177199.0,William Blair Initiates Coverage on Bristol-Myers Squibb Company at Outperform,2013-03-06 08:43:00-05:00,BMY,neutral
177200.0,William Blair Initiates Coverage on Bristol-Myers Squibb Company at Outperform,2013-03-05 17:08:00-05:00,BMY,neutral
177201.0,An HIV Cure Is Great News For These Drug Manufacturers,2013-03-04 15:22:00-05:00,BMY,positive
177202.0,UPDATE: Bank of America Downgrades Bristol-Myers Squibb to Neutral on Limited Upside,2013-03-04 07:10:00-05:00,BMY,negative
177203.0,"Bank of America Downgrades Bristol-Myers Squibb Company to Neutral, Raises PO to $39.00",2013-03-04 06:22:00-05:00,BMY,negative
177204.0,"Benzinga's M&A Chatter for Friday March 1, 2013",2013-03-02 10:36:00-05:00,BMY,neutral
177205.0,Bristol Meyers Squibb Reportedly Considered Large Acquisitions of Biogen and Shire,2013-03-01 14:38:00-05:00,BMY,neutral
177206.0,UPDATE: Jefferies Raises PT to $41 on Bristol-Myers Squibb on Long-Term Growth Prospects,2013-02-12 13:48:00-05:00,BMY,positive
177207.0,"Jefferies Maintains Buy on Bristol-Myers Squibb Company, Raises PT to $41.00",2013-02-12 07:37:00-05:00,BMY,neutral
177208.0,A Peek Into The Market Before The Trading Starts,2013-02-12 07:18:00-05:00,BMY,neutral
177209.0,Bristol-Myers Squibb Enters 3-Year Agreement with Reckitt Benckiser Group for Over-the-Counter Medicines ,2013-02-12 07:08:00-05:00,BMY,positive
177210.0,"The Medicines Co., Bristol-Myers Begin Alliance for Recothrom",2013-02-08 10:12:00-05:00,BMY,neutral
177211.0,Novo Spokesperson Says Will Introduce Tresiba in Some EU Countries in First Half - Bloomberg,2013-01-29 11:07:00-05:00,BMY,neutral
177212.0,"UBS Maintains Neutral on Bristol-Myers Squibb Company, Raises PT to $36.00",2013-01-25 11:23:00-05:00,BMY,neutral
177213.0,Bristol-Myers Squibb Company Reports Q4 EPS of $0.47 vs $0.44 Est; Revenue of $4.20B vs $4.14B Est,2013-01-24 07:31:00-05:00,BMY,neutral
177214.0,US Stock Futures Mixed After Disappointing Apple Results,2013-01-24 05:38:00-05:00,BMY,negative
177215.0,"Earnings Scheduled For January 24, 2013",2013-01-24 02:45:00-05:00,BMY,neutral
177216.0,Earnings Expectations for the Week of January 21,2013-01-20 13:14:00-05:00,BMY,neutral
177217.0,EMA Says Bristol-Myers Wins Backing for Extended Komboglyze Use,2013-01-18 07:39:00-05:00,BMY,positive
177218.0,"UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Bristol Myers Squibb Co.",2013-01-16 09:31:00-05:00,BMY,neutral
177219.0,"Jefferies Maintains Buy on Bristol-Myers Squibb Company, Raises PT to $39.00",2013-01-16 08:50:00-05:00,BMY,neutral
177220.0,WSJ Reporting Bristol-Myers Said to Be Holding Talks Related to Hepatits Claims,2013-01-15 14:55:00-05:00,BMY,neutral
177221.0,From Slides Ahead of JPMorgan Healthcare Conference: Bristol-Myers Sees Raising Dividend by 3% for 2013,2013-01-08 12:39:00-05:00,BMY,neutral
177222.0,"Bristol-Myers Said to Plan Experimental Migraine Drug, Awaiting Study Results on BMS-927711",2013-01-07 13:57:00-05:00,BMY,neutral
177223.0,A Peek Into The Market Before The Trading Starts,2013-01-04 07:23:00-05:00,BMY,neutral
177224.0,Tranzyme Completes Drug Discovery Collaboration With Bristol-Myers Squibb ,2013-01-04 06:05:00-05:00,BMY,neutral
177225.0,J.P. Morgan Reiterates Neutral Rating on Bristol Myers Squibb Co.,2012-12-31 10:28:00-05:00,BMY,neutral
177226.0,Benzinga's Top Upgrades,2012-12-31 10:02:00-05:00,BMY,positive
177227.0,Benzinga's Top Upgrades,2012-12-31 10:01:00-05:00,BMY,positive
177228.0,"Bristol, Pfizer Win FDA Approval for Eliquis -Bloomberg",2012-12-28 16:32:00-05:00,BMY,positive
177229.0,"ELIQUIS Receives Approval In Japan for Prevention of Stroke, Systemic Embolism In Patients with Nonvalvular Atrial Fibrillation ",2012-12-26 07:41:00-05:00,BMY,positive
177230.0,Aegerion Pharmaceuticals Wins Approval for Cholesterol Drug,2012-12-24 13:01:00-05:00,BMY,positive
177231.0,"UPDATE: Goldman Sachs Reiterates Buy Rating, Lowers PT on Bristol-Myers Squibb Co.",2012-12-19 10:34:00-05:00,BMY,negative
177232.0,"Goldman Sachs Maintains CL-Buy on Bristol-Myers Squibb Company, Lowers PT to $39.00",2012-12-19 08:19:00-05:00,BMY,negative
177233.0,"The Medicines Company, Bristol-Myers Squibb Announce Global Alliance for Recothrom",2012-12-12 07:50:00-05:00,BMY,neutral
177234.0," Bristol-Myers, Abbott Announce Results from Phase 2 Multiple Myeloma Study",2012-12-09 19:31:00-05:00,BMY,neutral
177235.0,"Bristol-Myers, Pfizer Announce Positive Phase 3 Trial Results for ELIQUIS",2012-12-08 15:53:00-05:00,BMY,positive
177236.0,"Citigroup Reiterates Neutral Rating, $33 PT on Bristol Myers Squibb",2012-12-07 13:09:00-05:00,BMY,neutral
177237.0,Bristol-Myers Raises Qtr. Dividend from $0.34 to $0.35/Share,2012-12-04 16:31:00-05:00,BMY,neutral
177238.0,Bristol Myers to Terminate Avagacestat Clinical Development - Bloomberg,2012-12-03 13:38:00-05:00,BMY,neutral
177239.0,UPDATE: Bristol Myers Says Study Data Didn't Warrant Phase 3 Study,2012-12-03 13:38:00-05:00,BMY,neutral
177240.0,"CORRECTION: Citi Initiates Coverage on Bristol-Myers Squibb Company at Neutral, Announces $33.00 PT",2012-11-29 16:27:00-05:00,BMY,neutral
177241.0,"Bristol-Myers, Pfizer's Eliquis Approved in Europe for Prevention of Stroke",2012-11-20 13:55:00-05:00,BMY,positive
177242.0,"Bristol-Myers, AstraZeneca's Forxiga Wins EU Approval for Treatment of Type 2 Diabetes",2012-11-14 11:56:00-05:00,BMY,positive
177243.0,Bristol-Myers Squibb's Investigational Hepatitis C Compounds Lambda and   Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study,2012-11-12 15:33:00-05:00,BMY,neutral
177244.0,"Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)",2012-11-12 13:24:00-05:00,BMY,positive
177245.0,"UPDATE: BMO Capital Markets Downgrades Bristol-Myers Squibb to Market Perform, Lowers PT",2012-11-12 11:19:00-05:00,BMY,negative
177246.0,New Head-to-Head Patient Reported Outcomes Data for Orencia,2012-11-12 09:03:00-05:00,BMY,neutral
177247.0,"BMO Capital Markets Downgrades Bristol-Myers Squibb from Outperform to Market Perform, Lowers PT from $38 to $37",2012-11-12 07:48:00-05:00,BMY,negative
177248.0,A Peek Into The Market Before The Trading Starts,2012-11-12 07:17:00-05:00,BMY,neutral
177249.0,Bristol-Myers Squibb  Presents Phase II Hepatitis C Data,2012-11-12 06:19:00-05:00,BMY,neutral
177250.0,"Moves in Smaller Health Care Stocks (GMED, SEM, UAM, VRTX)",2012-11-03 10:07:00-04:00,BMY,positive
177251.0,Bristol-Myers Squibb Receives Positive Decision from NIH for YERVOY,2012-11-01 20:07:00-04:00,BMY,positive
177252.0,UPDATE: Bristol-Myers Says FDA Willing to Reconsider Benefit/Risk for Dapaglifozin,2012-10-24 10:48:00-04:00,BMY,neutral
177253.0,UPDATE: Bristol-Myers Says Ready to Launch Eliquis on Approval; May Take Hep C Treatment to Phase 3 in 2014,2012-10-24 10:36:00-04:00,BMY,positive
177254.0,Bristol-Myers Says Strategy Has Not Changed; Sanofi Restructure Minimal in 2013; Abilify Performance Was Table in Line with View,2012-10-24 10:18:00-04:00,BMY,neutral
177255.0,Bristol-Myers Guides FY Adj. EPS Upper End of $1.90-2.00 vs $1.93 Est.,2012-10-24 07:42:00-04:00,BMY,neutral
177256.0,Bristol-Myers Squibb Reports Q3 EPS $0.41 vs $0.42 Est; Revenues $3.74B vs $3.98B Est,2012-10-24 07:41:00-04:00,BMY,neutral
177257.0,US Stock Futures Up Ahead Of Boeing Earnings,2012-10-24 06:05:00-04:00,BMY,neutral
177258.0,"Earnings Scheduled For October 24, 2012",2012-10-24 04:12:00-04:00,BMY,neutral
177259.0,Earnings Expectations for the Week of October 22,2012-10-22 08:15:00-04:00,BMY,neutral
177260.0,"Bristol-Myers Says FDA Approves Labeling Update for Baraclude; Includes Data on African Americans, Liver Transplant Recipients",2012-10-15 15:51:00-04:00,BMY,positive
177261.0,Bristol-Myers Says 88% of Patients Who Took Drugs for 12 Weeks Cleared Hep C Virus,2012-10-15 11:36:00-04:00,BMY,positive
177262.0,"From Earlier: Fate Therapeutics Names Weyer President, CEO",2012-10-15 09:21:00-04:00,BMY,neutral
177263.0,Eli Lilly Says Ending Partnership with Amylin Wasn't Easy; Broad Diabetes Pipeline is Advantage; End of Amylin Deal Was Bet on Dulaglutide,2012-10-08 09:54:00-04:00,BMY,negative
177264.0,Bristol-Myers Squibb Says Orencia Approved by EU,2012-10-05 11:03:00-04:00,BMY,positive
177265.0,From Earlier: Sanofi Says Lyxumia Dose Isn't Issue for Regulators; Lyxumia Isn't At All Like Byetta,2012-10-04 09:15:00-04:00,BMY,negative
177266.0,"Morgan Stanley Maintains Bristol-Myers Squibb at Equal-weight, Lowers PT from $36 to $35",2012-10-04 07:06:00-04:00,BMY,negative
177267.0,"From Earlier: Bristol-Myers Squibb, Sanofi Will Restructure Alliance; Sanofi Will Get Rights to Plavix and Avapro",2012-10-03 08:37:00-04:00,BMY,neutral
177268.0,ELIQUIS Reduces Stroke and Systemic Embolism Compared to Warfarin in  ARISTOTLE trial,2012-10-01 21:03:00-04:00,BMY,neutral
177269.0,Deutsche Bank Transfers Coverage of Bristol-Myers Squibb,2012-10-01 16:26:00-04:00,BMY,neutral
177270.0, Bristol-Myers Presents 4 and 5-Year Survival Data for YERVOY in Treatment-Naïve and Previously-Treated Metastatic Melanoma,2012-09-29 07:34:00-04:00,BMY,neutral
177271.0,FDA Acknowledges Receipt of Resubmission of the ELIQUIS,2012-09-26 17:02:00-04:00,BMY,neutral
177272.0,Vanderbilt University and Bristol-Myers Squibb Sign Collaboration Agreement to Develop Novel Treatments for Parkinson's Disease,2012-09-21 08:31:00-04:00,BMY,positive
177273.0,Life Technologies Will Partner with Bristol-Myers Squibb,2012-09-17 07:34:00-04:00,BMY,neutral
177274.0,UPDATE: Vical Rises 10% Pre-Market on Licensing Pact with  Bristol-Myers Squibb,2012-09-13 08:13:00-04:00,BMY,neutral
177275.0,Benzinga's Top Pre-Market Gainers,2012-09-13 08:12:00-04:00,BMY,positive
177276.0,A Peek Into The Market Before The Trading Starts,2012-09-13 07:17:00-04:00,BMY,neutral
177277.0,Vical Signs Licensing Pact with Bristol-Myers Squibb for DNA Immunization Technology,2012-09-13 06:35:00-04:00,BMY,neutral
177278.0,Bristol-Myers Squibb Foundation Announces Five New Grants to Advance Cancer Nursing Skills in Central and Eastern Europe,2012-09-11 09:02:00-04:00,BMY,negative
177279.0,UPDATE: Goldman Sachs Upgrades Bristol-Myers Squibb to CL-Buy on Catalysts  ,2012-09-11 07:25:00-04:00,BMY,neutral
177280.0,"Goldman Sachs Upgrades Bristol-Myers Squibb from Buy to CL-Buy, Raises PT from $38 to $40",2012-09-11 06:15:00-04:00,BMY,neutral
177281.0,"Credit Suisse Reinstates Coverage on Bristol-Myers Squibb at Neutral, Announces PT of $36",2012-09-11 06:07:00-04:00,BMY,positive
177282.0,Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb,2012-08-27 08:16:00-04:00,BMY,neutral
177283.0,"UPDATE: Bank of America Merrill Lynch Upgrades Bristol-Myers Squibb to Buy, Reiterates $36 PT",2012-08-24 12:05:00-04:00,BMY,neutral
177284.0,Bristol-Myers' Trash is Gilead Sciences' Treasure,2012-08-24 09:16:00-04:00,BMY,positive
177285.0,Bristol-Myers Slapped With $1.8B Charge on Failed Hepatitis C Drug,2012-08-24 07:45:00-04:00,BMY,negative
177286.0,"Bank of America Upgrades Bristol-Myers Squibb from Neutral to Buy, Announces PO of $36",2012-08-24 07:13:00-04:00,BMY,negative
177287.0,"Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C ",2012-08-23 20:12:00-04:00,BMY,neutral
177288.0,Synergy Pharma Buys FV-100 Drug from Bristol-Myers,2012-08-23 16:46:00-04:00,BMY,neutral
177289.0,Hearing Unconfirmed Takeover Chatter in Regeneron,2012-08-23 10:52:00-04:00,BMY,negative
177290.0,Idenix Shares Plunge After Hepatitis Drug Study Put on Hold ,2012-08-17 09:43:00-04:00,BMY,positive
177291.0,Bristol-Myers Squibb Announces Specialty Pharmacy Patient Management Programs For Sprycel,2012-08-15 08:02:00-04:00,BMY,neutral
177292.0,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,2012-08-13 00:25:00-04:00,BMY,positive
177293.0,Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb's Acquisition of Amylin   ,2012-08-09 07:47:00-04:00,BMY,neutral
177294.0,"Bristol-Myers Squibb Completes Acquisition of Amylin Pharmaceuticals, Inc.   ",2012-08-09 07:30:00-04:00,BMY,neutral
177295.0,"Bristol-Myers Squibb Announces Successful Completion of Cash Tender Offer for Shares of Amylin Pharmaceuticals, Inc.   ",2012-08-08 07:32:00-04:00,BMY,positive
177296.0,Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb,2012-08-06 10:18:00-04:00,BMY,positive
177297.0,UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb from $39 to $38,2012-08-06 09:34:00-04:00,BMY,negative
177298.0,"Jefferies & Company  Maintains Bristol-Myers Squibb at Buy, Lowers PT from $39 to $38",2012-08-06 06:02:00-04:00,BMY,negative
177299.0,Bristol-Myers Executive Charged with Insider Trading ,2012-08-02 15:44:00-04:00,BMY,negative
177300.0,Call Activity in Bristol-Myers,2012-08-02 15:28:00-04:00,BMY,neutral
177301.0,"UBS Maintains Bristol-Myers Squibb at Neutral, Lowers PT from $36 to $34",2012-08-02 12:05:00-04:00,BMY,negative
177302.0,UPDATE: SEC Charges Bristol-Myers Squibb Executive With Insider Trading in Stock Options of Potential Acquisition Targets,2012-08-02 12:02:00-04:00,BMY,negative
177303.0,Barclays Downgrades Bristol-Myers Squibb from Overweight to Equal-weight,2012-08-02 11:55:00-04:00,BMY,negative
177304.0,Leerink Swann Downgrades Bristol-Myers Squibb from Outperform to Market Perform,2012-08-02 07:22:00-04:00,BMY,neutral
177305.0,Prosetta Antiviral Inc Enters into Multi-year Antiviral Drug Development Collaboration with Bristol-Myers Squibb   ,2012-07-31 15:05:00-04:00,BMY,neutral
177306.0,Bristol-Myers Said to Sell Bonds at Record-Low Coupons -Bloomberg,2012-07-26 16:36:00-04:00,BMY,neutral
177307.0,Bristol-Meyers in Call Says It Forecasts $2.7B in Sales for Plavix,2012-07-25 10:47:00-04:00,BMY,neutral
177308.0,Bristol-Myers Squibb Reports Q2 EPS $0.48 vs $0.48 Est; Revenues $4.44B vs $4.45B Est,2012-07-25 07:31:00-04:00,BMY,neutral
177309.0,US Stock Futures Mixed; Apple Shares Drop In Pre-Market Trading,2012-07-25 06:29:00-04:00,BMY,neutral
177310.0,Earnings Scheduled For July 25,2012-07-25 04:26:00-04:00,BMY,neutral
177311.0,Earnings Expectations for the Week of July 23,2012-07-23 07:07:00-04:00,BMY,neutral
177312.0,Bristol Considering Options for Brivanib Development Program; Says Study Doesn't Meet Primary Objective,2012-07-19 16:44:00-04:00,BMY,neutral
177313.0,BRISK-FL Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Does Not Meet Overall Survival Primary Endpoint  ,2012-07-19 16:33:00-04:00,BMY,neutral
177314.0,"Morgan Stanley Maintains Bristol-Myers Squibb at Equal-weight, Raises PT from $34 to $36",2012-07-18 06:09:00-04:00,BMY,neutral
177315.0,Popular Drug Manufacturing Stocks Among Hedge Funds,2012-07-17 07:47:00-04:00,BMY,positive
177316.0,"Jefferies & Company Maintains Bristol-Myers Squibb at Buy, Raises PT from $38 to $39",2012-07-13 07:00:00-04:00,BMY,neutral
177317.0,Best & Worst Sector ETFs & Mutual Funds,2012-07-11 20:05:00-04:00,BMY,neutral
177318.0,"Dendreon, Pharmacyclics and Other Biotech Takeover Targets",2012-07-10 14:07:00-04:00,BMY,neutral
177319.0,These Are Four of the Hottest Biotechs in the Market Right Now,2012-07-05 13:19:00-04:00,BMY,neutral
177320.0,Bristol-Myers to Acquire Amylin,2012-07-02 13:45:00-04:00,BMY,neutral
177321.0,"Trading the Trend: Regeneron, Alexion, TripAdvisor, Expedia All Pushing Higher ",2012-07-02 13:17:00-04:00,BMY,neutral
177322.0,Benzinga's Top Pre-Market Gainers,2012-07-02 08:06:00-04:00,BMY,positive
177323.0,Amylin Pharmaceuticals Rises 9% Pre-Market on Bristol-Myers Acquisition,2012-07-02 07:30:00-04:00,BMY,neutral
177324.0,"Financial Breakfast: Morning News Summary for July 2, 2012",2012-07-02 07:22:00-04:00,BMY,neutral
177325.0,US Stock Futures Mixed; Dollar Rises Against Euro,2012-07-02 06:33:00-04:00,BMY,neutral
177326.0,"Deutsche Bank Maintains Bristol-Myers Squibb at Buy, Raises PT from $37.50 to $39",2012-07-02 06:27:00-04:00,BMY,neutral
177327.0,Stocks To Watch For July 2,2012-07-02 01:58:00-04:00,BMY,neutral
177328.0,"Benzinga's M&A Chatter for Friday June 29, 2012",2012-06-30 10:52:00-04:00,BMY,neutral
177329.0,Bristol-Myers Squibb to Acquire Amylin Pharmaceuticals for $31/Share,2012-06-30 09:11:00-04:00,BMY,neutral
177330.0,"Benzinga's M&A Chatter for Tuesday June 26, 2012",2012-06-26 18:04:00-04:00,BMY,neutral
177331.0,Bristol-Myers Squibb Announces the Authorization of an Additional $3 billion for Share Repurchase Program,2012-06-26 16:30:00-04:00,BMY,positive
177332.0,Spokesperson for Amylin Pharmaceuticals Won't Comment on Rumor of Bids from Pharma Companies,2012-06-26 13:17:00-04:00,BMY,neutral
177333.0,Amylin Pharmaceuticals Spiking to Highs on Earlier Bid Reports,2012-06-26 11:57:00-04:00,BMY,neutral
177334.0,"Novartis, Sanofi, Merck, Bristol, AstraZeneca Weigh Amylin Final Bids; Amylin Expects Final Bids Starting End of the Week -Reuters ",2012-06-26 11:38:00-04:00,BMY,neutral
177335.0,"Ahead of Obamacare Ruling, S&P Likes Health Care SPDR",2012-06-25 14:02:00-04:00,BMY,positive
177336.0,"Social Media Outlook for Monday June 25 (TEVA, MNTA, BMY, XOM)",2012-06-25 11:25:00-04:00,BMY,neutral
177337.0,Benzinga's Top Pre-Market Losers,2012-06-25 08:18:00-04:00,BMY,negative
177338.0,Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. Food and Drug Administration for ELIQUIS   ,2012-06-25 07:30:00-04:00,BMY,neutral
177339.0,UPDATE: Citigroup Reiterates Buy on Bristol-Myers Squibb,2012-06-22 09:50:00-04:00,BMY,neutral
177340.0,UPDATE: Bank of America Merrill Lynch Raises PT to $36 for Bristol-Myers Squibb ,2012-06-21 11:14:00-04:00,BMY,neutral
177341.0,UPDATE: Citi Reiterates Buy on Bristol-Myers Squibb ,2012-06-21 10:42:00-04:00,BMY,neutral
177342.0,"Bank of America Maintains Bristol-Myers Squibb at Neutral, Raises PO from $34 to $36",2012-06-21 07:06:00-04:00,BMY,negative
177343.0,Six-Year Follow-Up Data for SPRYCEL 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib ,2012-06-15 14:09:00-04:00,BMY,neutral
177344.0,Bristol-Myers Comments on Nulojix Trials,2012-06-04 14:32:00-04:00,BMY,neutral
177345.0,The US Economy and the United Nations: Bold Strategies Needed - Tax Reform and Benefits Reform,2012-06-04 12:16:00-04:00,BMY,positive
177346.0,UPDATE: JP Morgan Raises PT to $35 on Bristol-Myers Squibb on ASCO Update  ,2012-06-04 07:38:00-04:00,BMY,positive
177347.0,"Benzinga's M&A Chatter for  Friday June 1, 2012",2012-06-03 10:47:00-04:00,BMY,neutral
177348.0,Teva Spikes Higher as Chairman Purchases One Million Shares,2012-06-02 11:23:00-04:00,BMY,positive
177349.0,Financial Astrology: The Key to Future Investing,2012-05-30 14:13:00-04:00,BMY,neutral
177350.0,"Amylin Shares Jump as Sanofi, Merck Sumbit Bids",2012-05-25 15:15:00-04:00,BMY,positive
177351.0,"Amylin Said to Get First-Round Bids from Sanofi, Merck -Bloomberg",2012-05-25 14:01:00-04:00,BMY,neutral
177352.0,"BMO Capital Markets Initiates Coverage on Bristol-Myers Squibb at Outperform, Announces PT of $39",2012-05-18 07:57:00-04:00,BMY,neutral
177353.0,U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility ,2012-05-15 11:01:00-04:00,BMY,positive
177354.0,German Panel: Bristol--Myers Drug Helped Melanoma Patients,2012-05-02 08:11:00-04:00,BMY,neutral
177355.0,FDA Considering Letting Patients Purchase Drugs Without Prescriptions,2012-04-30 12:09:00-04:00,BMY,neutral
177356.0,Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe,2012-04-26 12:29:00-04:00,BMY,neutral
177357.0,"Earnings Recap for April 26, 2012",2012-04-26 09:50:00-04:00,BMY,neutral
177358.0,UPDATE: Bristol-Myers Posts Rise In Q1 Profit,2012-04-26 08:00:00-04:00,BMY,positive
177359.0,Bristol-Myers Squibb Reports Q1 EPS $0.64 vs $0.63 Est; Revenues $5.3B vs $5.26B Est,2012-04-26 07:30:00-04:00,BMY,neutral
177360.0,"US Stock Futures Down Ahead Of Earnings, Jobless Claims",2012-04-26 06:28:00-04:00,BMY,neutral
177361.0,Earnings Scheduled For April 26,2012-04-26 03:33:00-04:00,BMY,neutral
177362.0,"Benzinga's M&A Chatter for Monday April 23, 2012",2012-04-23 17:32:00-04:00,BMY,neutral
177363.0,Hearing Amylin Considering Sale -Reuters,2012-04-22 18:22:00-04:00,BMY,neutral
177364.0,Bristol-Meyers Reports 77% of Patients Cured 24 Weeks After Treatment,2012-04-19 12:00:00-04:00,BMY,neutral
177366.0,Why our portfolio is John Deere green,2012-04-18 05:46:00-04:00,BMY,neutral
177367.0,"Bristol-Myers Still Eyeing Amylin; Amylin Rejected Bristol's $22/Share Offer; Amylin Not Running A Sale Process; Carl Icahn Urged Amylin To Pursue Sale  -WSJ, Sources",2012-04-05 15:52:00-04:00,BMY,negative
177368.0,Carl Ichan: 'Everyone Said Bristol Meyers Offered $22 for Amylin and They Didn't Deny It',2012-04-03 17:26:00-04:00,BMY,positive
177369.0,Convatec Said to be Among Potential Bidders for Montagu's BSN -Bloomberg,2012-04-03 08:26:00-04:00,BMY,neutral
177370.0,Amylin Shares Active on Monday; Stock Down 4%,2012-04-02 13:05:00-04:00,BMY,positive
177371.0,Biographical Profiles in Investing: Dr. Phillip Frost,2012-04-02 07:33:00-04:00,BMY,neutral
177372.0,"Benzinga's M&A Chatter for Wednesday March 28, 2012",2012-03-28 20:31:00-04:00,BMY,neutral
177373.0,"Trading Ideas: Stocks to Watch for Thursday (AMLN, SABA, ANGI, RHT, LGF, AE) ",2012-03-28 19:39:00-04:00,BMY,neutral
177374.0,Amylin Rejected $3.5 Billion Offer; Stock Soars,2012-03-28 13:07:00-04:00,BMY,negative
177375.0,Amylin Spokesperson Won't Comment on Rejection of Bristol Meyers Offer,2012-03-28 09:45:00-04:00,BMY,positive
177376.0,Amylin Pharmaceuticals Spikes 42% Higher on Rejection of Bristol-Meyers Squib Offer ,2012-03-28 09:25:00-04:00,BMY,negative
177377.0,Bristol-Myers Squibb and Meso Scale Discovery Enter Agreement to Develop Diagnostic Assays for Alzheimer's Disease   ,2012-03-28 08:02:00-04:00,BMY,positive
177378.0,Bristol-Myers Squibb and Meso Scale Discovery Enter Agreement to Develop Diagnostic Assays for Alzheimer's Disease,2012-03-28 08:01:00-04:00,BMY,positive
177379.0,"A Look At The New Russell High Yield ETF (HDIV, ABT, KFT)",2012-03-15 14:55:00-04:00,BMY,neutral
177380.0,"Fresh Del Monte, BlackRock and Other Stocks Insiders Are Buying",2012-03-08 06:41:00-05:00,BMY,positive
177381.0,Radiation Blast Could Turbocharge Bristol-Myers Melanoma Drug -Bloomberg,2012-03-07 17:02:00-05:00,BMY,neutral
177382.0,Deutsche Bank: Bristol-Myers Squibb's Cardiorenal Meeting Removed from FDA Website,2012-03-07 14:11:00-05:00,BMY,neutral
177383.0,"Pfizer Analyst: Delay in Eliquis Approval Would Not be Terribly Material to Bristol-Myers or Pfizer in Our View.  However, This Could Cut into Sales Forecasts Slightly.",2012-03-01 15:48:00-05:00,BMY,positive
177384.0,From Earlier: Bristol-Myers Squibb and Pfizer Announce FDA Extends Action Date for ELIQUIS® (apixaban) by Three Months  ,2012-03-01 07:42:00-05:00,BMY,positive
177385.0,FDA Approves Important Safety Label Changes For The Class Of Cholesterol-Lowering Drugs Known As Statins -Reuters,2012-02-28 13:20:00-05:00,BMY,positive
177386.0,"Benzinga's M&A Chatter for Monday February 27, 2012",2012-02-27 17:37:00-05:00,BMY,neutral
177387.0,Positive Rumors Circulate About Vertex Pharmaceuticals,2012-02-27 10:16:00-05:00,BMY,positive
177388.0,Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish,2012-02-17 12:30:00-05:00,BMY,negative
177389.0,Bristol Myers Squibb Says Gob Sunpoena in January for Ambilify Info,2012-02-17 08:54:00-05:00,BMY,neutral
177390.0,"Benzinga's M&A Chatter for Tuesday February 14, 2012",2012-02-14 18:32:00-05:00,BMY,neutral
177391.0,Hearing Renewed Takeover Chatter in Vertex Pharmaceuticals,2012-02-14 09:56:00-05:00,BMY,neutral
177392.0,Trovagene: Built on Experience and Ready to Move Higher,2012-02-09 13:08:00-05:00,BMY,positive
177393.0,"Benzinga's M&A Chatter for Wednesday February 8, 2012",2012-02-08 19:59:00-05:00,BMY,neutral
177394.0,Positive Rumors Circulate About Vertex Pharmaceuticals,2012-02-08 11:40:00-05:00,BMY,positive
177395.0,From Earlier: Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex  ,2012-02-08 08:20:00-05:00,BMY,negative
177396.0,"Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc.",2012-02-03 07:30:00-05:00,BMY,neutral
177397.0,Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex   ,2012-02-03 07:30:00-05:00,BMY,neutral
177398.0,Two Biotechs That Continue to Attract Positive Attention From Investors,2012-02-01 08:50:00-05:00,BMY,positive
177399.0,Bristol-Myers CEO Andreotti Says Not Making Decisions on Diabetes Salesforce Cuts; Planning to Talk to FDA on Forward Path for Drug -Bloomberg,2012-01-30 08:17:00-05:00,BMY,negative
177400.0,UPDATE: Bristol-Myers Squibb Reports Rise In Q4 Earnings,2012-01-26 09:05:00-05:00,BMY,neutral
177401.0,Bristol-Myers Squibb Reports Q4 EPS $0.53 vs $0.55 Est; Revenues $5.45B vs $5.51B Est			 ,2012-01-26 07:30:00-05:00,BMY,neutral
177402.0,Earnings Scheduled For January 26,2012-01-26 01:33:00-05:00,BMY,neutral
177403.0,"Bristol-Meyers, Pfizer Receive Positive Mad Money/Jim Cramer Mention -CNBC",2012-01-24 18:20:00-05:00,BMY,positive
177404.0,BioLineRx Surges after Hep C License Agreement,2012-01-24 10:23:00-05:00,BMY,positive
177405.0,Earnings Expectations for the Week of January 23,2012-01-22 14:13:00-05:00,BMY,neutral
177406.0,Morgan Stanley Downgrades Bristol Myers-Squibb to Equal-weight,2012-01-19 10:16:00-05:00,BMY,neutral
177407.0,Achillion's Hep C Pipeline Likely Can't Compete,2012-01-19 09:03:00-05:00,BMY,neutral
177408.0,From Earlier: Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin  ,2012-01-19 07:10:00-05:00,BMY,neutral
177409.0,"Hearing 6 Potential Buyers Bid on Inhibitex, 2 at $26.00/Share",2012-01-17 14:24:00-05:00,BMY,neutral
177410.0,S&P Lukewarm On New Low Volatility ETFs,2012-01-17 13:23:00-05:00,BMY,negative
177411.0,UPDATE: McNicoll Lewis & Vlak Downgrades Inhibitex to Hold ,2012-01-13 12:58:00-05:00,BMY,neutral
177412.0,Bristol-Myers Squibb Begins Tender Offer to Acquire Inhibitex,2012-01-13 07:30:00-05:00,BMY,neutral
177413.0,San Francisco Health Care Conferences Provide Plenty of Buzz and Chatter,2012-01-13 06:26:00-05:00,BMY,positive
177414.0,Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target?,2012-01-10 14:54:00-05:00,BMY,neutral
177415.0,"Benzinga's M&A Chatter for Monday January 9, 2012",2012-01-09 18:40:00-05:00,BMY,neutral
177416.0,Just What The Doctor Ordered: 4 ETFs For Biotech M&A,2012-01-09 15:49:00-05:00,BMY,neutral
177417.0,"Forget Dendreon, Inhibitex is the New Biotech Success Story",2012-01-09 13:26:00-05:00,BMY,positive
177418.0,Bank of America Raises PO on Idenix Pharmaceuticals to $18,2012-01-09 10:14:00-05:00,BMY,negative
177419.0,Morning Market Movers,2012-01-09 09:49:00-05:00,BMY,neutral
177420.0,Option Alert: Inhibitex January 15.00 Call Gains 5900% on Takeover,2012-01-09 09:42:00-05:00,BMY,positive
177421.0,Benzinga's Top Pre-Market Gainers,2012-01-09 08:10:00-05:00,BMY,positive
177422.0,"Financial Breakfast: Morning News Summary for January 9, 2012",2012-01-09 07:26:00-05:00,BMY,neutral
177423.0,Bristol-Myers Squibb to Acquire Inhibitex for $26/Share in Cash,2012-01-09 06:57:00-05:00,BMY,neutral
177424.0,Brean Murray Raises PT on Inhibitex to $26,2012-01-09 06:55:00-05:00,BMY,neutral
177425.0,Bristol-Myers To Acquire Inhibitex For $2.5B,2012-01-09 06:53:00-05:00,BMY,neutral
177426.0,Stocks To Watch For January 9,2012-01-09 06:43:00-05:00,BMY,neutral
177427.0,US Stock Futures Flat; Alcoa Earnings In Focus,2012-01-09 06:39:00-05:00,BMY,neutral
177428.0,Inhibitex Rises 156% Pre-Market on Bristol-Myers Squibb Acquisition ,2012-01-09 06:35:00-05:00,BMY,neutral
177429.0,Bristol-Myers To Acquire Inhibitex For $2.5B,2012-01-09 04:28:00-05:00,BMY,neutral
177430.0,Stocks To Watch For January 9,2012-01-09 03:27:00-05:00,BMY,neutral
177431.0,Bristol-Myers Squibb to Acquire Inhibitex for $26/Share,2012-01-07 23:07:00-05:00,BMY,neutral
177432.0,8 High-Yielding Stocks That Are Showing Strong Momentum,2012-01-04 16:01:00-05:00,BMY,positive
177433.0,Bank of America Merrill Lynch Provides Update on Bristol-Myers Squibb,2012-01-04 09:17:00-05:00,BMY,neutral
177434.0,From Earlier: Teva Pharmaceutical CEO to Retire in May; Dr. Jeremy Levin To Succeed Shlomo Yanai as CEO  ,2012-01-03 08:36:00-05:00,BMY,positive
177435.0,Bristol-Myers Squibb Hits 52-Week High of $35.35,2011-12-30 09:34:00-05:00,BMY,neutral
177436.0,Goldman Sachs Positive on Onyx Pharmaceuticals After Brivanib Failure,2011-12-23 09:36:00-05:00,BMY,positive
177437.0,BRISK-PS Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Completed   ,2011-12-22 16:31:00-05:00,BMY,neutral
177438.0,Bristol-Myers Squibb and the Gladstone Institutes Enter Three-Year Discovery Partnership in Alzheimer's Disease   ,2011-12-22 13:07:00-05:00,BMY,neutral
177439.0,Bristol-Myers Squibb Hits 52-Week High of $35.30,2011-12-22 12:52:00-05:00,BMY,neutral
177440.0,Merck Hands Exelixis $12 Million Up Front For a Preclinical Compound Program,2011-12-21 11:28:00-05:00,BMY,neutral
177441.0,Bristol-Myers Squibb Hits 52-Week High of $35.22,2011-12-21 10:44:00-05:00,BMY,neutral
177442.0,Bristol-Myers Squibb Hits 52-Week High of $34.69,2011-12-20 09:57:00-05:00,BMY,neutral
177443.0,"Benzinga's M&A Chatter for Monday December 19, 2011",2011-12-19 16:40:00-05:00,BMY,neutral
177444.0,Hearing Unconfirmed Takeover Chatter in Elan with Bristol Meyers Squibb Rumored Buyer at $16/Share,2011-12-19 10:22:00-05:00,BMY,negative
177445.0,Bristol-Myers Squibb Hits 52-Week High of $34.51,2011-12-19 09:59:00-05:00,BMY,neutral
177446.0,Bristol-Myers Squibb Hits 52-Week High of $34.44,2011-12-16 09:30:00-05:00,BMY,neutral
177447.0,Bristol-Myers Squibb Hits 52-Week High of $33.97,2011-12-15 09:30:00-05:00,BMY,neutral
177448.0,Bristol-Myers Squibb Hits 52-Week High of $33.73,2011-12-14 11:54:00-05:00,BMY,neutral
177449.0,NeurOp Announces Extension to Drug Discovery Collaboration with Bristol-Myers Squibb   ,2011-12-14 07:45:00-05:00,BMY,neutral
177450.0,Five Biotech Stocks to Watch Going into Big Doctors' Meeting,2011-12-09 13:06:00-05:00,BMY,neutral
177451.0,"BofA Reiterates Neutral, $34 PT On Bristol-Myers",2011-12-08 14:09:00-05:00,BMY,neutral
177452.0,A Peek Into The Market Before The Trading Start,2011-12-08 07:39:00-05:00,BMY,neutral
177453.0,"Astra, Bristol-Myers Report Phase 3 Dapagliflozin Results",2011-12-08 06:34:00-05:00,BMY,neutral
177454.0,Bristol-Myers Squibb Hits 52-Week High of $33.36,2011-12-07 10:51:00-05:00,BMY,neutral
177455.0,Bristol-Myers Squibb Announces Increase in Dividend; Boosts Dividend to $0.34/Share from $0.33/Share,2011-12-06 17:15:00-05:00,BMY,positive
177456.0,Bristol-Myers Squibb Hits 52-Week High of $33.28,2011-12-06 14:40:00-05:00,BMY,neutral
177457.0,Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals for Phase II Combination Study in Patients Chronically Infected with Hepatitis C   ,2011-12-02 07:30:00-05:00,BMY,neutral
177458.0,"Mad Money Lightning Round: Cramer Dislikes Microsoft, Radioshack",2011-12-01 05:52:00-05:00,BMY,negative
177459.0,Bank of America Reiterates Neutral on Bristol-Myers Squibb ,2011-11-29 11:08:00-05:00,BMY,neutral
177460.0,Deutsche Bank Reiterates Buy on Bristol-Myers Squibb  ,2011-11-29 10:55:00-05:00,BMY,neutral
177461.0,FDA Accepts ELIQUIS New Drug Application for Review,2011-11-29 07:30:00-05:00,BMY,positive
177462.0,ONGLYZA Approved for Use in Europe as Combination Therapy With Insulin in Adults,2011-11-28 08:00:00-05:00,BMY,positive
177463.0,Mad Money Lightning Round: Cramer Likes Waste Management,2011-11-22 04:33:00-05:00,BMY,negative
177464.0,Hep-C Stocks Soar On M&A News,2011-11-21 13:14:00-05:00,BMY,neutral
177465.0,FDA Approves Erwinaze To Treat A Form Of Leukemia,2011-11-18 09:34:00-05:00,BMY,positive
177466.0,"End-of-Day Market Summary for November 16, 2011",2011-11-16 16:15:00-05:00,BMY,neutral
177467.0, Bristol-Myers Squibb and AstraZeneca Announce Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients with Type 2 Diabetes  ,2011-11-16 16:06:00-05:00,BMY,positive
177468.0,Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients,2011-11-16 16:03:00-05:00,BMY,positive
177469.0,Morgan Stanley Maintains Overweight Rating on Bristol-Myers Squibb ,2011-11-14 09:35:00-05:00,BMY,negative
177470.0,ISI Group Publishes Report on Bristol-Myers Squibb ,2011-11-14 08:00:00-05:00,BMY,neutral
177471.0,"Financial Breakfast: Morning News Summary for November 14, 2011",2011-11-14 07:48:00-05:00,BMY,neutral
177472.0,Bank of America Merrill Lynch Neutral on Bristol-Myers Squibb ,2011-11-14 07:44:00-05:00,BMY,neutral
177473.0,New Data Presented on Phase 3 Trial of ELIQUIS in Prevention of Venous Thromboembolism in Patients with Acute Medical Illness,2011-11-13 13:21:00-05:00,BMY,negative
177474.0,Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz in Brazil   ,2011-11-11 09:05:00-05:00,BMY,positive
177475.0,Dako Enters New Collaboration With Bristol-Myers Squibb on Pharmacodiagnostics  ,2011-11-09 06:49:00-05:00,BMY,neutral
177476.0,Bristol-Myers Squibb Company Phase IIIb Comparison of BARACLUDE Monotherapy Versus BARACLUDE Plus Tenofovir Combination Shows No Statistical Difference Between Study Arms   ,2011-11-08 11:00:00-05:00,BMY,negative
177477.0,A Peek Into The Market Before The Trading Starts,2011-11-08 07:29:00-05:00,BMY,neutral
177478.0,Tranzyme Pharma Announces the Extension of Its Chemistry-Based Drug Discovery Collaboration With Bristol-Myers Squibb  ,2011-11-08 06:57:00-05:00,BMY,neutral
177479.0,FDA Approves Erbitrux to Treat Late-Stage Head And Neck Cancer; Erbitux Marketed by Bristol-Myers Squibb,2011-11-07 14:13:00-05:00,BMY,neutral
177480.0,A Peek Into The Market Before The Trading Starts,2011-11-04 07:28:00-04:00,BMY,neutral
177481.0,"Pharmasset and Bristol-Myers Squibb Announce New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir for HCV Genotype 1 ",2011-11-04 07:02:00-04:00,BMY,neutral
177482.0,Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals?,2011-11-02 08:46:00-04:00,BMY,neutral
177483.0,A Look at The New DRGS ETN,2011-10-31 13:34:00-04:00,BMY,neutral
177484.0,Higher Profit for Bristol-Myers Squibb Company,2011-10-27 10:09:00-04:00,BMY,positive
177485.0,"Pfizer Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-27 09:37:00-04:00,BMY,neutral
177486.0,"Financial Breakfast: Morning News Summary for October 27, 2011",2011-10-27 07:55:00-04:00,BMY,neutral
177487.0,Bristol-Myers Squibb Reports Q3 EPS $0.61 vs $0.58 Est; Revenues $5.35B vs $5.30B Est		,2011-10-27 07:30:00-04:00,BMY,neutral
177488.0,Bristol-Myers Squibb and AstraZeneca Announce U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months  ,2011-10-26 16:10:00-04:00,BMY,positive
177489.0,Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV   ,2011-10-26 08:30:00-04:00,BMY,positive
177490.0,"Earnings Preview: Vertex Pharmaceuticals' EPS, Revenue Expected to Rise",2011-10-25 13:50:00-04:00,BMY,neutral
177491.0,"Merck Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-25 12:10:00-04:00,BMY,neutral
177492.0,"Celgene Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-25 12:10:00-04:00,BMY,neutral
177493.0,"Biogen Idec Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-25 11:48:00-04:00,BMY,neutral
177494.0,"Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS",2011-10-24 10:16:00-04:00,BMY,negative
177495.0,"Gilead Sciences Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-24 08:46:00-04:00,BMY,neutral
177496.0,Earnings Expectations for the Week of October 24,2011-10-23 13:40:00-04:00,BMY,neutral
177497.0,"Court Cuts Apotex Payment To Sanofi, Bristol In Plavix Case",2011-10-18 12:35:00-04:00,BMY,negative
177498.0,"Eli Lilly Earnings Preview: Analysts Expect Rising Revenue, Falling EPS",2011-10-17 08:40:00-04:00,BMY,negative
177499.0,"Abbott Laboratories Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-14 17:54:00-04:00,BMY,neutral
177500.0,Bristol-Myers Squibb Foundation Announces Collaboration with World Health Organization,2011-10-11 09:01:00-04:00,BMY,neutral
177501.0,Bristol-Myers and Quidel to Open Near 52-Week Highs,2011-10-06 07:37:00-04:00,BMY,neutral
177502.0,Bank of America Raises PO on Bristol-Myers Squibb to $34,2011-10-05 06:12:00-04:00,BMY,negative
177503.0,Bristol Myers Squibb Entered $1.5B Credit Pact,2011-10-04 16:42:00-04:00,BMY,positive
177504.0,"Bristol-Meyers CEO Says Plans to Continue Growing Company, Deals Have to be Strategic",2011-10-04 08:38:00-04:00,BMY,positive
177505.0,UPDATE: Deutsche Bank Raises PT on Bristol-Myers Squibb to $37.50,2011-09-26 08:06:00-04:00,BMY,neutral
177506.0,Bears at Work  09-22-2011,2011-09-22 18:27:00-04:00,BMY,neutral
177507.0,UPDATE: Goldman Sachs Upgrades Bristol-Myers Squibb to Buy,2011-09-22 09:18:00-04:00,BMY,neutral
177508.0,Bristol-Myers Squibb and Ambrx Announce Collaboration for Novel Biologics Programs in Diabetes and Heart Failure,2011-09-22 08:02:00-04:00,BMY,negative
177509.0,"Goldman Sachs Upgrades Bristol-Myers Squibb to Buy, PT Raised to $37",2011-09-22 07:27:00-04:00,BMY,neutral
177510.0,Bristol-Myers Squibb and Saladax Biomedical Expand Collaboration for Diagnostic Assays for Alzheimer's Disease,2011-09-20 11:00:00-04:00,BMY,positive
177511.0,VIX Pops 10%,2011-09-19 15:34:00-04:00,BMY,neutral
177512.0,Stocks Hitting 52-Week Highs,2011-09-19 10:03:00-04:00,BMY,neutral
177513.0,UPDATE: Jefferies Upgrades Bristol-Myers Squibb to Buy,2011-09-19 09:28:00-04:00,BMY,neutral
177514.0,Benzinga's Top Upgrades,2011-09-19 07:32:00-04:00,BMY,positive
177515.0,A Peek Into The Market Before The Trading Starts,2011-09-19 07:26:00-04:00,BMY,neutral
177516.0,"Jefferies Upgrades Bristol-Myers Squibb to Buy, PT Raised to $35",2011-09-19 06:04:00-04:00,BMY,neutral
177517.0,Bristol-Myers Squibb and AstraZeneca Announce ONGLYZA When Added to Insulin in Adults with Type 2 Diabetes Maintained Reductions in Blood Sugar Levels Over 52 Weeks in Investigational Study Extension  ,2011-09-16 07:02:00-04:00,BMY,neutral
177518.0,Goldman Sachs Suggests Searching for Yield Through Options,2011-09-07 09:21:00-04:00,BMY,neutral
177519.0,A Peek Into The Market Before The Trading Starts,2011-08-30 07:31:00-04:00,BMY,neutral
177520.0,ICON Selected as a Preferred Provider for Early Phase Clinical Development by Bristol-Myers Squibb  ,2011-08-30 06:49:00-04:00,BMY,neutral
177521.0,J.P. Morgan Maintains Neutral on Bristol-Myers Squibb,2011-08-29 09:40:00-04:00,BMY,neutral
177522.0,Bank of America Raises PO On Bristol-Myers Squibb To $32,2011-08-29 05:54:00-04:00,BMY,negative
177523.0,Friday's Biotech/Pharma Stocks Trading,2011-08-15 11:48:00-04:00,BMY,neutral
177524.0,GNS Healthcare Announces Collaboration With Bristol-Myers Squibb ,2011-08-10 08:31:00-04:00,BMY,neutral
177525.0,"Citi Reiterates Buy on Bristol Myers Squibb, Raises PT to $39",2011-08-02 07:33:00-04:00,BMY,neutral
177526.0,Citigroup Raises PT On Bristol-Myers Squibb To $39,2011-08-02 06:07:00-04:00,BMY,neutral
177527.0,Thursday's S&P Sector Recap,2011-07-28 17:50:00-04:00,BMY,neutral
177528.0,Pfizer Earnings Preview: Analysts Expect Falling EPS,2011-07-28 15:40:00-04:00,BMY,negative
177529.0,Earnings Roundup,2011-07-28 08:42:00-04:00,BMY,neutral
177530.0,"Bristol-Myers Squibb's Profit Falls, Still Tops Estimates",2011-07-28 08:38:00-04:00,BMY,positive
177531.0,"UPDATE: Bristol-Myers Reports Upbeat Q2 Earnings, Raises 2011 Forecast",2011-07-28 08:10:00-04:00,BMY,neutral
177532.0,Bristol-Myers Guides Year EPS Higher to $2.20-2.30; Guides FY 2013 EPS $1.95,2011-07-28 07:43:00-04:00,BMY,neutral
177533.0,Bristol-Myers Squibb Reports Q2 EPS $0.56 vs $0.55 Est; Revenues $5.43B vs $5.04B Est        ,2011-07-28 07:31:00-04:00,BMY,neutral
177534.0,"US Stock Futures Slightly Up Ahead Of Earnings, Jobless Claims Data",2011-07-28 06:26:00-04:00,BMY,neutral
177535.0,Earnings Scheduled For July 28,2011-07-28 05:02:00-04:00,BMY,neutral
177536.0,"Earnings Preview: Merck EPS, Revenue Expected to Rise from Previous Quarter",2011-07-26 13:00:00-04:00,BMY,neutral
177537.0,"Celgene Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter",2011-07-25 14:20:00-04:00,BMY,negative
177538.0,"Vertex Pharmaceuticals Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter",2011-07-25 13:49:00-04:00,BMY,negative
177539.0,"Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter",2011-07-25 12:45:00-04:00,BMY,negative
177540.0,Earnings Expectations for the Week of July 25,2011-07-24 09:40:00-04:00,BMY,neutral
177541.0,Biogen IDEC Earnings Preview: Analysts Expect Falling Revenue Over Last Quarter,2011-07-21 13:43:00-04:00,BMY,negative
177542.0,"Earnings Preview: Gilead Sciences EPS, Revenue Expected to Rise from Previous Quarter",2011-07-21 13:12:00-04:00,BMY,neutral
177543.0,Jefferies Reports FDA Votes Against BMY Dapagliflozin Approval,2011-07-20 07:47:00-04:00,BMY,positive
177546.0,Jefferies Lowers PT On Bristol-Myers Squibb To $27,2011-07-18 07:12:00-04:00,BMY,negative
177547.0,FDA Says Bristol-Astrazeneca Diabetes Drug is Effective,2011-07-15 08:07:00-04:00,BMY,positive
177548.0,FDA Posts Staff Review of Bristol-Astrazeneca Drug for Diabetes,2011-07-15 07:56:00-04:00,BMY,neutral
177549.0,"10 High Yield, High Momentum Stocks",2011-07-12 00:20:00-04:00,BMY,neutral
177550.0,Citi Maintains Buy on Bristol-Myers Squibb,2011-07-11 08:11:00-04:00,BMY,neutral
177551.0,Bristol-Myers Squibb and Innate Pharma Announce Global License Agreement for an Investigational Immuno-Oncology Biologic   ,2011-07-06 14:32:00-04:00,BMY,positive
177552.0,Morgan Stanley Provides Color on Bristol Myers Squibb,2011-06-30 08:46:00-04:00,BMY,neutral
177553.0,"Q&A with Aethlon Medical CEO, Jim Joyce; The Potential for the Hemopurifier® Medical Device in Cancer Immunotherapy",2011-06-28 12:21:00-04:00,BMY,negative
177554.0,Tuesday's Mid-Day Options Volume Leaders,2011-06-28 11:26:00-04:00,BMY,neutral
177555.0,Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz® (atazanavir sulfate) in sub-Saharan Africa and India ,2011-06-28 10:00:00-04:00,BMY,positive
177556.0,Goldman Sachs Reiterates Neutral on Bristol Myers Squibb and AstraZeneca,2011-06-27 08:12:00-04:00,BMY,neutral
177557.0,Morgan Stanley Provides Color on Bristol Myers Squibb,2011-06-27 08:03:00-04:00,BMY,neutral
177558.0,Stocks to Watch for 6/24/11: Fresh 52 Week Highs and Lows,2011-06-24 04:30:00-04:00,BMY,positive
177559.0,Market Battles Back  06-23-2011,2011-06-23 19:00:00-04:00,BMY,negative
177560.0,Thursday's S&P Sector Recap 6/23/11,2011-06-23 17:43:00-04:00,BMY,neutral
177561.0,Critical Levels Broken  06-23-2011,2011-06-23 14:44:00-04:00,BMY,negative
177562.0,Thursday's Mid-Day Options Volume Leaders,2011-06-23 12:26:00-04:00,BMY,neutral
177563.0,J.P. Morgan Maintains Neutral on Bristol Myers Squibb,2011-06-23 09:44:00-04:00,BMY,neutral
177564.0,UPDATE: Bristol Myers Squibb Trading Over 6% Higher on Positive Phase 3 Results,2011-06-23 08:58:00-04:00,BMY,positive
177565.0,UPDATE: Bristol Myers Squibb Trading Over 6% Higher on Positive Phase 3 Results,2011-06-23 08:50:00-04:00,BMY,positive
177566.0,Deutsche Bank Discusses Apixaban From Bristol-Myers Squibb,2011-06-23 08:38:00-04:00,BMY,neutral
177567.0,Benzinga's Top Upgrades,2011-06-23 08:21:00-04:00,BMY,positive
177568.0,"Morgan Stanley Upgrades Bristol Myers Squibb to Overweight, Raises PT to $34",2011-06-23 08:19:00-04:00,BMY,negative
177569.0,Jefferies Anticipates Next Key Event in the Oral Anticoagulant Space,2011-06-23 08:09:00-04:00,BMY,neutral
177570.0,ELIQUIS Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study ,2011-06-23 08:04:00-04:00,BMY,neutral
177571.0,"Morgan Stanley Upgrades Bristol-Myers Squibb To Overweight, Raises PT To $34",2011-06-23 06:15:00-04:00,BMY,negative
177572.0,Bristol-Myers Squibb,2011-06-22 19:19:00-04:00,BMY,neutral
177573.0,Biotech/Pharma Stocks; Take A New Approach to Cancer,2011-06-20 13:40:00-04:00,BMY,negative
177574.0,Bristol-Myers Squibb Announces FDA Approves NULOJIX,2011-06-16 14:49:00-04:00,BMY,positive
177575.0,Citi Reports On FDA Approval For BMY,2011-06-16 07:39:00-04:00,BMY,positive
177576.0,Goldman Sachs Suggests Buying Puts on Bristol-Myers Squibb,2011-06-08 09:43:00-04:00,BMY,neutral
177577.0,Technical Trading Summary 6/7/2011,2011-06-07 17:40:00-04:00,BMY,neutral
177578.0,J.P. Morgan Provides Color on Bristol Myers Squibb and Pfizer,2011-06-07 06:39:00-04:00,BMY,neutral
177579.0,J.P. Morgan Maintains Neutral on Bristol-Myers Squibb,2011-06-06 07:35:00-04:00,BMY,neutral
177580.0,Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement to Conduct Combination Studies with YERVOY and Vemurafenib   ,2011-06-02 07:04:00-04:00,BMY,positive
177581.0,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",2011-06-01 12:13:00-04:00,BMY,positive
177582.0,Hapoalim Cutting Ocverage On Multitude Of Names,2011-06-01 11:48:00-04:00,BMY,negative
177583.0,Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest ROE,2011-06-01 01:12:00-04:00,BMY,positive
177584.0,"Pharmasset Announces All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated ",2011-05-26 06:58:00-04:00,BMY,neutral
177585.0,AMRI to Receive Milestone Payment from Bristol-Myers Squibb for the Initiation of a Phase II Study,2011-05-25 08:02:00-04:00,BMY,neutral
177586.0,Diabetes Device Market to Reach $24 Billion by 2017 ,2011-05-24 09:11:00-04:00,BMY,neutral
177587.0,Top Healthcare and Major Drugs stocks to watch- Sector Performance,2011-05-22 14:55:00-04:00,BMY,positive
177588.0,Pfizer's and  Bristol-Myers Squibb's ELIQUIS Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement   ,2011-05-20 10:43:00-04:00,BMY,positive
177589.0,GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term,2011-05-18 06:29:00-04:00,BMY,neutral
177590.0,Bank Of America Ups PT To $29 On BMY,2011-05-16 07:22:00-04:00,BMY,neutral
177591.0,"Benzinga's Top Downgrades (NSM, SNHY, BMY, RIMM)",2011-05-11 08:30:00-04:00,BMY,positive
177592.0,Goldman Sachs Switches Top New Product Story From BMY To JNJ,2011-05-11 08:09:00-04:00,BMY,positive
177593.0,"Goldman Sachs Downgrades Bristol-Myers Squibb To Neutral, $32 PT",2011-05-11 05:54:00-04:00,BMY,neutral
177594.0,"TOP 15 Stocks To Watch this week- AAPL, BRK-A, BRK-B, BJ, C, F, GM, GPRO, IP, KND, N, NRTLQ, ONTY, SPPI, YRCW",2011-05-02 04:48:00-04:00,BMY,positive
177595.0,"Earnings Roundup For April 28 (XOM, AZN, HST, PEP, POT, PG, IP, DOW, S, AET, BMY, VIA, CL, EQT, CCE, OXY)",2011-04-28 08:40:00-04:00,BMY,neutral
177596.0,UPDATE: Bristol-Myers Squibb Reports Better-Than-Expected Q1 Results,2011-04-28 07:54:00-04:00,BMY,neutral
177597.0,Bristol-Myers Squibb Reports EPS of $0.58 vs. $0.53 Estimate; Revenues $5.01B vs. $4.95B Estimate (BMY),2011-04-28 07:30:00-04:00,BMY,neutral
177598.0,"US Stock Futures Mixed As Investors Await GDP Data, Earnings Reports",2011-04-28 06:26:00-04:00,BMY,positive
177599.0,"Earnings Scheduled For April 28 (MSFT, AET, VIA, XOM, CL, PEP, BMY, MMI, TWC, PG, DOW, S, TYC, CCE, SWY, HOT, EK, EXPE, D, VRSN, EMN)",2011-04-28 02:33:00-04:00,BMY,neutral
177600.0,"Earnings Preview for Bristol Myers Squibb Company (BMY, CTIC)",2011-04-27 16:15:00-04:00,BMY,neutral
177601.0,Jefferies Comments On Bristol-Myers Squibb,2011-04-26 09:41:00-04:00,BMY,neutral
177602.0,Don't Fall For The 'Defensive Portfolio' Hype,2011-04-18 12:37:00-04:00,BMY,neutral
177603.0,Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and Ribavirin Achieved Up to 92% Sustained Virologic Response in Phase II Dose-Ranging Study,2011-03-31 10:32:00-04:00,BMY,neutral
177604.0,Jefferies Downgrades BMY To Hold,2011-03-31 08:28:00-04:00,BMY,neutral
177605.0,"Benzinga's Top Upgrades (CAVM, EMR, ARMH, BMY)",2011-03-31 08:20:00-04:00,BMY,positive
177606.0,Jefferies Downgrades Bristol-Myers Squibb To Hold,2011-03-31 07:04:00-04:00,BMY,neutral
177607.0,Jefferies Ups BMY To Hold,2011-03-31 05:57:00-04:00,BMY,neutral
177608.0,"Biotech/Pharma Snapshot; Advances in Cancer Immunotherapy, Dendreon Corporation",2011-03-29 11:57:00-04:00,BMY,negative
177609.0,Is Approval of Bristol-Myers Squibb's Yervoy Start of New Chapter at FDA?,2011-03-28 13:08:00-04:00,BMY,positive
177610.0,"Pharma/Biotech Stock News: FDA Approves YERVOY (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer",2011-03-28 09:00:00-04:00,BMY,negative
177611.0,"Pharma/Biotech Stock News: FDA Approves YERVOY (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer",2011-03-28 09:00:00-04:00,BMY,negative
177612.0,Deutsche Bank Updates On BMY Yervoy Approval,2011-03-28 08:02:00-04:00,BMY,positive
177613.0,UPDATE: Goldman Sachs Raises PT on Bristol-Myers Squibb to $32 (BMY),2011-03-28 07:15:00-04:00,BMY,neutral
177614.0,Did Bristol-Myers Just Find A Cure For Melanoma? (BMY),2011-03-25 13:25:00-04:00,BMY,neutral
177615.0,FDA Approves Bristol-Myers Squibb Drug Yervoy To Treat Melanoma,2011-03-25 12:44:00-04:00,BMY,positive
177616.0,FDA Approves Bristol Myers Squibb's Drug Yermoy To Treat Melanoma (BMY),2011-03-25 12:08:00-04:00,BMY,positive
177617.0,Bristol Myers Squibb Receives Positive FDA News (BMY),2011-03-25 12:04:00-04:00,BMY,positive
177618.0,Goldman Sachs Says Buy Bristol-Myers Squibb Company (BMY),2011-03-25 08:53:00-04:00,BMY,neutral
177619.0,Goldman Sachs Anticipates BMY Melanoma Drug Approval,2011-03-25 07:58:00-04:00,BMY,positive
177620.0,Goldman Sachs Maintains Buy on Bristol-Myers Squibb (BMY),2011-03-22 09:43:00-04:00,BMY,neutral
177622.0,Biotech Sector Snapshot HIV Drug Development,2011-03-18 14:13:00-04:00,BMY,neutral
177623.0,Biotech/Pharma Sector Close-Up;  Drug Resistance Potential for HIV Drugs; Can Medical Devices take over when drugs fail?,2011-03-17 14:22:00-04:00,BMY,negative
177624.0,Bristol-Myers Squibb to Present at Barclays Capital Global Healthcare Conference   ,2011-03-09 10:02:00-05:00,BMY,neutral
177625.0,KineMed Extends Collaboration With Bristol-Myers Squibb,2011-03-09 08:14:00-05:00,BMY,positive
177626.0,FDA Accepts New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes   ,2011-03-08 08:03:00-05:00,BMY,positive
177627.0,Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility   ,2011-03-07 08:01:00-05:00,BMY,neutral
177628.0,"Fast Money Picks For March 7th (BMY, PGH, GM, STJ)",2011-03-04 20:01:00-05:00,BMY,neutral
177629.0,Slow Grind Squeezes Shorts  03-03-2011,2011-03-03 15:34:00-05:00,BMY,neutral
177630.0,Goldman Sachs Suggests Buying Calls on Bristol-Myers Squibb (BMY),2011-03-03 09:11:00-05:00,BMY,neutral
177631.0,Bristol-Myers Squibb Names Elliott Sigal to Board of Directors   ,2011-03-01 11:42:00-05:00,BMY,neutral
177632.0,Bristol-Myers Squibb's BARACLUDE Approved by the European Commission for the Treatment of Chronic Hepatitis B ,2011-03-01 08:09:00-05:00,BMY,positive
177633.0,"Mad Money Lightning Round: Cramer Advises Investors To Buy Apache (BMY, AAPL, APA, IBN, FCX, BHP)",2011-02-23 02:58:00-05:00,BMY,negative
177634.0,Citi On BMY Product Trends For The Week Ending 2/11,2011-02-22 08:53:00-05:00,BMY,neutral
177635.0,Two ETFs for the Recovery in Big Pharma,2011-02-11 14:59:00-05:00,BMY,neutral
177636.0,Jefferies Comments On BMY Financials,2011-02-08 09:26:00-05:00,BMY,neutral
177637.0,FDA Approves Labeling Update for REYATAZ Capsules to Include Data Supporting the Recommended Adult Dose for HIV-1 Infected Pregnant Women ,2011-02-07 10:40:00-05:00,BMY,positive
177638.0,Cowen Ups BMY To Outperform,2011-02-07 06:51:00-05:00,BMY,neutral
177639.0,Roche Misses on Tamiflu Decline - Analyst Blog,2011-02-03 08:31:00-05:00,BMY,negative
177640.0,Roche Misses on Tamiflu Decline - Analyst Blog,2011-02-03 08:15:00-05:00,BMY,negative
177641.0,"Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab ",2011-02-02 09:43:00-05:00,BMY,negative
177642.0,"Company News for January 28, 2011 - Corporate Summary",2011-01-28 10:01:00-05:00,BMY,neutral
177643.0,Hapoalim Securities Reiterates Sell Rating on Bristol-Myers Squibb (BMY),2011-01-28 09:54:00-05:00,BMY,positive
177644.0,"Company News for January 28, 2011 - Corporate Summary",2011-01-28 09:29:00-05:00,BMY,neutral
177645.0,BMY Misses by a Penny in Q4 - Analyst Blog,2011-01-27 13:31:00-05:00,BMY,negative
177646.0,BMY Misses by a Penny in Q4 - Analyst Blog,2011-01-27 13:00:00-05:00,BMY,negative
177647.0,Bristol-Myers Squibb Reports 47 Cent EPS (BMY),2011-01-27 08:12:00-05:00,BMY,neutral
177648.0,A Peek Into The Market Before The Trading Starts,2011-01-27 07:47:00-05:00,BMY,neutral
177649.0,Bristol-Myers Squibb Reports Q4 EPS of $.47 vs. $.48,2011-01-27 07:31:00-05:00,BMY,neutral
177650.0,"Earnings Scheduled For January 27 (CAT, MSFT, PG, T, BMY, LLY, AMZN, AZN, TWC, SNDK, NOK, CB, JBLU, VRSN, PMCS, CL, MSI, KLAC)",2011-01-27 03:44:00-05:00,BMY,neutral
177651.0,Earnings Preview: Bristol-Myers - Analyst Blog,2011-01-26 13:01:00-05:00,BMY,neutral
177652.0,Earnings Preview: Bristol-Myers - Analyst Blog,2011-01-26 12:15:00-05:00,BMY,neutral
177653.0,Abbott Labs Tops 4Q Estimates - Analyst Blog,2011-01-26 10:01:00-05:00,BMY,negative
177654.0,Abbott Labs Tops 4Q Estimates - Analyst Blog,2011-01-26 09:29:00-05:00,BMY,negative
177655.0,Bristol-Myers Squibb and sanofi-aventis Announce FDA Decision to Grant Pediatric Exclusivity For PLAVIX,2011-01-25 12:00:00-05:00,BMY,positive
177656.0,Earnings Preview: Abbott Labs - Analyst Blog,2011-01-25 09:01:00-05:00,BMY,neutral
177657.0,Earnings Preview: Abbott Labs - Analyst Blog,2011-01-25 08:30:00-05:00,BMY,neutral
177658.0,AstraZeneca Responds to FDA Letter - Analyst Blog,2011-01-24 16:01:00-05:00,BMY,neutral
177659.0,AstraZeneca Responds to FDA Letter - Analyst Blog,2011-01-24 15:40:00-05:00,BMY,neutral
177660.0,Jefferies Previews Q4 and FY2010 Earnings for Bristol-Myers Squibb (BMY),2011-01-21 09:54:00-05:00,BMY,neutral
177661.0,Bleeding Risk with MRK's Candidate  - Analyst Blog,2011-01-20 11:01:00-05:00,BMY,negative
177662.0,Pfizer Inks Deal With Theraclone - Analyst Blog,2011-01-20 11:01:00-05:00,BMY,neutral
177663.0,Pfizer Inks Deal With Theraclone - Analyst Blog,2011-01-20 10:45:00-05:00,BMY,neutral
177664.0,Bleeding Risk with MRK's Candidate  - Analyst Blog,2011-01-20 10:30:00-05:00,BMY,negative
177665.0,Merck's Blood Thinner in Trouble - Analyst Blog,2011-01-14 16:31:00-05:00,BMY,negative
177666.0,Merck's Blood Thinner in Trouble - Analyst Blog,2011-01-14 16:01:00-05:00,BMY,negative
177667.0,Morgan Stanley Lowers BMY 2011e EPS To $2.23 From $2.30,2011-01-13 10:08:00-05:00,BMY,negative
177668.0,Bristol-Myers Inks Deal - Analyst Blog,2011-01-11 14:31:00-05:00,BMY,neutral
177669.0,Bristol-Myers Inks Deal - Analyst Blog,2011-01-11 14:17:00-05:00,BMY,neutral
177670.0,Bristol-Myers Squibb and Pharmasset Enter into a Clinical Collaboration Agreement,2011-01-10 07:40:00-05:00,BMY,positive
177671.0,Label Expansion for Roche's Actemra - Analyst Blog,2011-01-06 17:00:00-05:00,BMY,neutral
177672.0,Label Expansion for Roche's Actemra - Analyst Blog,2011-01-06 16:38:00-05:00,BMY,neutral
177673.0,"Goldman Sachs Healthcare CEO's Conference (BMY, MRK, CELG)",2011-01-06 11:14:00-05:00,BMY,neutral
177674.0,Bayer Seeks Approval for Xarelto - Analyst Blog,2011-01-06 10:03:00-05:00,BMY,positive
177675.0,Bayer Seeks Approval for Xarelto - Analyst Blog,2011-01-06 09:45:00-05:00,BMY,positive
177676.0,Bristol-Myers Outlook Mixed - Analyst Blog,2011-01-04 15:03:00-05:00,BMY,neutral
177677.0,Bristol-Myers Outlook Mixed - Analyst Blog,2011-01-04 14:32:00-05:00,BMY,neutral
177678.0,10 Companies 'Less Valuable' Than Facebook,2011-01-03 15:01:00-05:00,BMY,positive
177679.0,J&J to Bring Cancer Test to Market,2011-01-03 10:16:00-05:00,BMY,negative
177680.0,Stocks Going Ex Dividend the First Week of January,2010-12-27 16:05:00-05:00,BMY,neutral
177681.0,Another Setback for AstraZeneca  - Analyst Blog,2010-12-22 09:03:00-05:00,BMY,neutral
177682.0,Another Setback for AstraZeneca  - Analyst Blog,2010-12-22 08:15:00-05:00,BMY,neutral
177683.0,Big Pharma in Frenzy of Drug Deals,2010-12-21 11:34:00-05:00,BMY,negative
177684.0,"Bristol-Myers Squibb Co. Officer Sells 10,000 Shares of BMY",2010-12-20 16:34:00-05:00,BMY,positive
177685.0,S&P 500 Buybacks: Top Q4 Earnings-Boost Stocks,2010-12-20 13:41:00-05:00,BMY,positive
177686.0,Bristol-Myers Squibb and Oncolys BioPharma Announce Global Licensing Agreement for Investigational HIV Compound   ,2010-12-20 08:04:00-05:00,BMY,positive
177687.0,Regulatory Setback for AstraZeneca - Analyst Blog,2010-12-17 19:03:00-05:00,BMY,neutral
177688.0,Regulatory Setback for AstraZeneca - Analyst Blog,2010-12-17 18:21:00-05:00,BMY,neutral
177689.0,"Stocks To Watch For December 15 (BRCM, BMY, JOYG, YHOO, ADSK)",2010-12-15 05:05:00-05:00,BMY,neutral
177690.0,Bristol Myers-Squibb Lifts Dividend,2010-12-14 19:54:00-05:00,BMY,neutral
177691.0,Bristol-Myers Squibb Increases Dividend by 3.1% to $.33   ,2010-12-14 16:47:00-05:00,BMY,neutral
177692.0,Bob Doll's Picks ,2010-12-14 14:36:00-05:00,BMY,neutral
177693.0,Best Stocks For Creating A Passive Income Stream,2010-12-09 11:00:00-05:00,BMY,positive
177694.0,Phase III Data on PFE's Bosutinib - Analyst Blog,2010-12-08 11:33:00-05:00,BMY,neutral
177695.0,Phase III Data on PFE's Bosutinib - Analyst Blog,2010-12-08 10:48:00-05:00,BMY,neutral
177696.0,Good News for Bristol-Myers - Analyst Blog,2010-12-07 14:00:00-05:00,BMY,positive
177697.0,Good News for Bristol-Myers - Analyst Blog,2010-12-07 13:54:00-05:00,BMY,positive
177698.0,Citigroup On BMY's Sprycel,2010-12-07 08:49:00-05:00,BMY,neutral
177699.0,FDA Accepts Bristol-Myers Squibb's Application for Subcutaneous Formulation of ORENCIA® ,2010-12-06 15:25:00-05:00,BMY,positive
177700.0,Bristol-Myers Squibb Set to Present Sprycel Data (BMY),2010-11-30 09:09:00-05:00,BMY,neutral
177701.0,Gilead Files NDA for Combo HIV Drug - Analyst Blog,2010-11-24 18:00:00-05:00,BMY,neutral
177702.0,Gilead Files NDA for Combo HIV Drug - Analyst Blog,2010-11-24 18:00:00-05:00,BMY,neutral
177703.0,Gilead Files NDA for Combo HIV Drug - Analyst Blog,2010-11-24 12:18:00-05:00,BMY,neutral
177704.0,Gilead Files NDA for Combo HIV Drug - Analyst Blog,2010-11-24 12:18:00-05:00,BMY,neutral
177705.0,"Zacks Analyst Blog Highlights: Gap Inc., Pfizer, Bristol-Myers Squibb, Johnson and Johnson and Bayer    - Press Releases",2010-11-22 10:30:00-05:00,BMY,neutral
177706.0,"Zacks Analyst Blog Highlights: Gap Inc., Pfizer, Bristol-Myers Squibb, Johnson and Johnson and Bayer    - Press Releases",2010-11-22 05:01:00-05:00,BMY,neutral
177707.0,Another Pipeline Setback for Pfizer - Analyst Blog,2010-11-19 08:33:00-05:00,BMY,neutral
177708.0,Deutsche Bank Has Buy Rating On Bristol Myers Squibb (BMY),2010-11-19 07:33:00-05:00,BMY,neutral
177709.0,Another Pipeline Setback for Pfizer - Analyst Blog,2010-11-19 02:48:00-05:00,BMY,neutral
177710.0,Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Up to $750 Million,2010-11-18 11:42:00-05:00,BMY,neutral
177711.0,Simcere Beats on Top & Bottom Line  - Analyst Blog,2010-11-18 11:42:00-05:00,BMY,positive
177712.0,Bristol-Myers Squibb Sued for Denying Overtime Pay  ,2010-11-18 09:47:00-05:00,BMY,negative
177713.0,Simcere Beats on Top & Bottom Line  - Analyst Blog,2010-11-18 05:55:00-05:00,BMY,positive
177714.0,Boost for Bayer - Analyst Blog,2010-11-16 14:33:00-05:00,BMY,positive
177715.0,"Zacks Analyst Blog Highlights: Isis Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson and Genzyme      - Press Releases",2010-11-16 10:36:00-05:00,BMY,neutral
177716.0,Unconfirmed Rumors that Delcath Systems Inc. (DCTH)is in talks with Bristol-Myers Squibb Company (BMY) on possible takeover in low $20s.,2010-11-12 12:29:00-05:00,BMY,negative
177717.0,"Zacks Analyst Blog Highlights: DuPont, Bristol Meyers, Wal-Mart, Chesapeake and EnCana    - Press Releases",2010-11-11 10:33:00-05:00,BMY,neutral
177718.0,Trade Deficit Improves a Bit - Analyst Blog,2010-11-10 13:03:00-05:00,BMY,neutral
177719.0,Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews,2010-11-09 17:03:00-05:00,BMY,neutral
177720.0,Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook,2010-11-09 17:03:00-05:00,BMY,neutral
177721.0,Pharma and Biotech Industry Outlook - Nov. 2010 - Industry Outlook,2010-11-09 17:03:00-05:00,BMY,neutral
177722.0,"Zacks Analyst Blog Highlights: Toyota Motor Corp.,  King Pharmaceuticals Inc., Bristol-Myers Squibbs', Johnson & Johnson and Pfizer - Press Releases",2010-11-09 10:33:00-05:00,BMY,neutral
177723.0,Jefferies Likes Bristol Myers' Pipeline (BMY),2010-11-08 07:10:00-05:00,BMY,positive
177724.0,Deutsche Bank Has Note On Bristol-Myers Squibb (BMY),2010-11-03 07:33:00-04:00,BMY,neutral
177725.0,Bristol-Myers Waiting On Ipilimumab Approval From FDA,2010-11-03 06:55:00-04:00,BMY,positive
177726.0,Bristol-Myers Squibb Announces that FDA Has Extended the Review Timeline for the Ipilimumab Biologics ,2010-11-02 16:15:00-04:00,BMY,neutral
177727.0,"Friday's Put/Call Ratio Leaders (NWL, RYL, NVS, QSII, BMY)",2010-10-29 12:52:00-04:00,BMY,neutral
177728.0,"Zacks Analyst Blog Highlights:  United States Steel, Bristol-Myers Squibb, AstraZeneca plc, BHP Billiton and Wyndham Worldwide   - Press Releases",2010-10-27 15:33:00-04:00,BMY,positive
177729.0,Citi Raises Estimates On Bristol-Myers Squibb (BMY),2010-10-27 07:06:00-04:00,BMY,neutral
177730.0,Earnings Were Solid 10-26-2010,2010-10-26 18:57:00-04:00,BMY,positive
177731.0,Current OX Put/Call Ratio 10-26-2010,2010-10-26 18:55:00-04:00,BMY,neutral
177732.0,Hapoalim Securities Reiterates Sell On Bristol Myers (BMY),2010-10-26 13:46:00-04:00,BMY,positive
177733.0,Bristol-Myers Squibb Warned by FDA ,2010-10-26 09:53:00-04:00,BMY,negative
177734.0,"Bristol-Myers Squibb Third Quarter Featured Solid Operating Performance, EPS of $.59",2010-10-26 07:32:00-04:00,BMY,positive
177735.0,"Earnings Scheduled For October 26 (DD, DV, BMY, COH, MCK, AFL, DWA, FIS, X, F, NBR, VLO, MHP, SHW, LXK, BRCM, KMB, WU, UA)",2010-10-26 04:39:00-04:00,BMY,neutral
177736.0,"Stocks To Watch For October 26 (F, TXN, DD, AMGN, BMY)",2010-10-26 04:37:00-04:00,BMY,neutral
177737.0,Earnings Preview: Bristol-Myers  - Analyst Blog,2010-10-22 13:00:00-04:00,BMY,neutral
177738.0,Label Expansion at Bristol-Myers  - Analyst Blog,2010-10-19 14:39:00-04:00,BMY,neutral
177739.0,U.S. Food and Drug Administration Approves Bristol-Myers Squibb's  BARACLUDE as a Treatment for Chronic Hepatitis B,2010-10-18 10:07:00-04:00,BMY,positive
177740.0,Coverage Discontinued On ZymoGenetics,2010-10-14 07:32:00-04:00,BMY,neutral
177741.0,"Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc. at $9.75 per Share  ",2010-10-12 16:58:00-04:00,BMY,positive
177742.0,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)",2010-10-12 04:16:00-04:00,BMY,positive
177743.0,"Benzinga's Top Pre-Market NASDAQ Gainers (HRBN, RVSN, EXEL, SMTX)",2010-10-11 08:55:00-04:00,BMY,positive
177744.0,Jon Najarian Is Watching Delcath Systems (DCTH) And Savient Pharmaceuticals (SVNT)  ,2010-10-07 20:13:00-04:00,BMY,neutral
177745.0,Unconfirmed Chatter that Bristol-Myers Squibb Company (BMY) will Acquire Delcath Systems Inc. (DCTH) at $15.00 a share,2010-10-07 09:41:00-04:00,BMY,positive
177746.0,Citi Has Buy Rating On Bristol-Myers Squibb (BMY),2010-10-05 07:07:00-04:00,BMY,neutral
177747.0,Bristol Myers at Neutral - Analyst Blog,2010-10-04 23:21:00-04:00,BMY,neutral
177748.0,Morgan Stanley Downgrades Bristol-Myers Squibb,2010-10-04 10:11:00-04:00,BMY,neutral
177749.0,BMY ZGEN Deal; HSR Period Expires,2010-09-28 09:25:00-04:00,BMY,neutral
177750.0,A Peek Into The Market Before The Trading Starts,2010-09-28 08:53:00-04:00,BMY,neutral
177751.0,Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics,2010-09-28 07:38:00-04:00,BMY,neutral
177752.0,"The Rapid Growth Of Layoffs In Pharma, As Industry Despairs Of Its Future (BMY, ABT, PFE, MRK)",2010-09-24 11:49:00-04:00,BMY,negative
177753.0,"Benzinga's Top Downgrades (NOA, SHAW, NSC, BMY)",2010-09-24 08:48:00-04:00,BMY,positive
177754.0,Bristol-Myers Downgraded To Sell,2010-09-24 08:41:00-04:00,BMY,neutral
177755.0,PT Raised For BMY By Deutsche Bank,2010-09-22 08:09:00-04:00,BMY,neutral
177756.0,BMY's Diabetes Candidate Encourages - Analyst Blog,2010-09-21 14:33:00-04:00,BMY,positive
177757.0,"Mad Money Lightning Round: Cramer Loves HJ Heinz, Considers Eastman Kodak As Mere Speculations (HNZ, BMY, NANO, EK, BAC, NAT)",2010-09-17 07:00:00-04:00,BMY,positive
177758.0,Pharmaceutical Stocks Worth Owning For The Dividend Alone,2010-09-15 20:06:00-04:00,BMY,neutral
177759.0,Pharmaceutical Stocks Worth Owning For The Dividend Alone,2010-09-15 20:06:00-04:00,BMY,neutral
177760.0,"Bristol-Myers Squibb Begins Tender Offer to Acquire ZymoGenetics, Inc. (BMY, ZGEN)",2010-09-10 07:38:00-04:00,BMY,neutral
177761.0,"Zacks Analyst Blog Highlights: Bristol-Myers Squibb, ZymoGenetics, Family Dollar Stores, Wal-Mart Stores and Dollar General Corporation     - Press Releases",2010-09-09 07:45:00-04:00,BMY,neutral
177762.0,BMY to Acquire ZymoGenetics - Analyst Blog,2010-09-09 07:21:00-04:00,BMY,neutral
177763.0,"Most Active NASDAQ Stocks Today (ZGEN, INTC, SIRI, JASO, AMAT)",2010-09-08 13:03:00-04:00,BMY,positive
177764.0,"Vincent Wong Announces an Investigation into the Possible Breaches of Fiduciary Duty by the Board of ZymoGenetics, Inc",2010-09-08 12:45:00-04:00,BMY,neutral
177765.0,Bristol-Myers Squibb to Present at Global Healthcare Unplugged Conference   ,2010-09-08 12:01:00-04:00,BMY,neutral
177766.0,BMY to Acquire ZGEN for $9.75/Share,2010-09-08 11:32:00-04:00,BMY,neutral
177767.0,"Mid-Day Market Movers (ZGEN, EDAP, QXM, HDY)",2010-09-08 10:55:00-04:00,BMY,neutral
177768.0,ZymoGenetics Advances On Acquisition News,2010-09-08 09:58:00-04:00,BMY,neutral
177769.0,Piper Jaffray Reiterates Neutral Rating on ZymoGenetics (ZGEN),2010-09-08 09:52:00-04:00,BMY,neutral
177770.0,"Company News for September 8, 2010 - Corporate Summary",2010-09-08 09:39:00-04:00,BMY,neutral
177771.0,"Benzinga's Top Pre-Market NASDAQ Gainers (ZGEN, TUNE, ARMH, JASO)",2010-09-08 08:41:00-04:00,BMY,positive
177772.0," Protalix BioTherapeutics And PROLOR Biotech May Rise On ""Protein Acquistion""  (PBTH, PLX)",2010-09-08 07:59:00-04:00,BMY,neutral
177773.0,"Citi Likes Bristol-Myers Acquisition Of Zymogenetics (BMY, ZGEN)",2010-09-08 07:37:00-04:00,BMY,positive
177774.0, Bristol-Myers Squibb to Acquire ZymoGenetics,2010-09-07 17:28:00-04:00,BMY,neutral
177775.0,"Bristol-Myers Squibb To Acquire ZymoGenetics For $9.75 Per Share (BMY, ZGEN)",2010-09-07 17:28:00-04:00,BMY,positive
177776.0,"Bristol-Myers Squibb to Acquire ZymoGenetics (BMY, ZGEN)",2010-09-07 17:27:00-04:00,BMY,neutral
177777.0,Gilead Files MAA for HIV Drug - Analyst Blog,2010-09-07 17:03:00-04:00,BMY,neutral
177778.0,Bristol-Myers Squibb Announces Dividend of $.32 ,2010-09-07 16:43:00-04:00,BMY,neutral
177779.0,Wells Fargo Securities Reiterates Outperform Rating on Bristol-Myers (BMY),2010-09-01 08:49:00-04:00,BMY,positive
177780.0,Bristol-Myers Squibb Boosted by Blood Thinner Study ,2010-08-31 14:05:00-04:00,BMY,positive
177781.0,Goldman Sachs Introduces And Adjusts Estimates For Major Pharmaceuticals,2010-08-30 11:20:00-04:00,BMY,neutral
177782.0,ZGEN's HCV Candidate Progresses - Analyst Blog,2010-08-27 08:36:00-04:00,BMY,neutral
177783.0,GDP Next Big Number to Watch 08-26-2010,2010-08-26 18:59:00-04:00,BMY,positive
177784.0,Reverse Head & Shoulders Pattern  08-26-2010,2010-08-26 14:55:00-04:00,BMY,neutral
177785.0,Hapoalim Securities Has Positive Thoughts On Bristol Myers (BMY),2010-08-25 11:19:00-04:00,BMY,positive
177786.0,Generic Risk For Gilead's Hepsera  - Analyst Blog,2010-08-23 08:21:00-04:00,BMY,negative
177787.0,Good News for BMY Pipeline - Analyst Blog,2010-08-19 15:34:00-04:00,BMY,positive
177788.0,"Top 4 Large-Cap Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)",2010-08-17 04:57:00-04:00,BMY,positive
177789.0,All Is Not Well In The Pharmaceutical Industry,2010-08-13 14:14:00-04:00,BMY,negative
177790.0,"U.S. Probing Pharmaceutical Corruption (GSK, PFE, BMY, LLY)",2010-08-13 10:57:00-04:00,BMY,neutral
177791.0,Amgen's Vectibix Disappoints  - Analyst Blog,2010-08-12 14:40:00-04:00,BMY,negative
177792.0,Bristol-Myers Has PT Raised By Jefferies Int'l,2010-08-12 09:54:00-04:00,BMY,neutral
177793.0,"Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (LLY, GSK, BMY, PFE)",2010-08-11 05:58:00-04:00,BMY,positive
177794.0,"Fast Money Picks For August 6th (JPM, RTP, KO, BBY, BMY)",2010-08-05 18:56:00-04:00,BMY,neutral
177795.0,Corporate Catalysts For The Week Starting July 26 ,2010-07-26 06:51:00-04:00,BMY,neutral
177796.0,Bristol-Myers Squibb Misses Revenue Estimates (BMY) ,2010-07-22 07:51:00-04:00,BMY,negative
177797.0,"Bristol-Myers Squibb Posts In-Line Q2 Net Income, Revenue Falls Short",2010-07-22 07:50:00-04:00,BMY,neutral
177798.0,"Ryan Recommends Bristol-Myers and Merck (BMY, MRK, PFE)",2010-07-14 16:48:00-04:00,BMY,positive
177799.0,"Zacks Analyst Blog Highlights: Intel, Kraft Foods, Bristol Myers, Wal-Mart and Target  - Press Releases",2010-07-14 08:07:00-04:00,BMY,neutral
177800.0,"Miller Tabak Likes Bristol Myers Squibb (BMY), Novartis (NVS) And Merck (MRK)",2010-07-13 14:30:00-04:00,BMY,positive
177801.0,Jefferies Raises Estimates and Price Target for Bristol-Myers Squibb (BMY),2010-07-08 11:11:00-04:00,BMY,neutral
177802.0,Top Yielding Big Pharmaceutical Stocks,2010-07-08 00:02:00-04:00,BMY,positive
177803.0,"Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (AZN, LLY, GSK, BMY)",2010-06-30 05:58:00-04:00,BMY,positive
177804.0,"""Mad Money Lightning Round:"" Jim Says BMY Better Than PFE At The Moment",2010-06-29 07:12:00-04:00,BMY,negative
177805.0,Citi (C) Has A Price Target Of $30 For Bristol Myers Squibb  (BMY) ,2010-06-28 14:36:00-04:00,BMY,neutral
177806.0,"Fast Money Picks For June 23rd (STD, JEF, KR, BMY)",2010-06-22 18:46:00-04:00,BMY,neutral
177807.0,Fast Money's Trades For Wednesday,2010-06-22 18:38:00-04:00,BMY,neutral
177808.0,"Citi's Outlook For U.S. Pharmaceuticals (TEVA, BMY, ABT, MCK)",2010-06-21 12:01:00-04:00,BMY,neutral
177809.0,"Benzinga’s Top Pre-Market Gainers (AIPC, EXEL, CRUS, GXDX)",2010-06-21 08:35:00-04:00,BMY,positive
177810.0,Calls Bought on Bristol Myers Squibb (BMY),2010-06-11 10:30:00-04:00,BMY,neutral
177811.0,"Benzinga's After Hours Gainers (WEN, BMY, PFE) ",2010-06-10 18:56:00-04:00,BMY,neutral
177812.0,"Analyst Buys Bristol-Myers, Shorts Apple (AAPL, CMG, TOL, BMY, CAG)",2010-06-08 11:05:00-04:00,BMY,neutral
177813.0,Using the Euro as a Barometer  06-07-2010,2010-06-07 15:03:00-04:00,BMY,neutral
177814.0,"Monday Morning’s Options Volume Leaders (C, BAC, AAPL, BP, BMY, SPY, GS)",2010-06-07 12:00:00-04:00,BMY,neutral
177815.0,BMY’s Sprycel and ipilimumab Have Blockbuster Sales Potential,2010-06-07 10:58:00-04:00,BMY,positive
177816.0,"Company News for June 7, 2010 - Corporate Summary",2010-06-07 09:36:00-04:00,BMY,neutral
177817.0,"Benzinga’s Top Upgrades (SYMC, NILE, AMB, BMY, CSCO)",2010-06-07 07:41:00-04:00,BMY,positive
177818.0,BMY Upgraded To Buy At Goldman,2010-06-07 06:31:00-04:00,BMY,neutral
177819.0,Jefferies Gives Bristol-Myers Squibb A Hold Rating (BMY) ,2010-06-04 11:45:00-04:00,BMY,neutral
177820.0,Calls Bought on Bristol Myers (BMY),2010-06-04 10:14:00-04:00,BMY,neutral
177821.0,Bristol-Myers Squibb Shows Healthy Trends (BMY),2010-06-01 15:19:00-04:00,BMY,positive
177822.0,"Citigroup Outlook For U.S. Major Pharmaceuticals (MRK, PFE, BMY)",2010-05-27 12:39:00-04:00,BMY,neutral
177823.0,Daniel Peris Feels Investors Are Turning To Dividend Stocks ,2010-05-26 15:32:00-04:00,BMY,neutral
177824.0,"Bristol-Myers Squibb Gets “Hold” Rating (BMY, C)",2010-05-25 17:53:00-04:00,BMY,neutral
177825.0,Bristol-Myers Expects Positive Results On Drug-Trials (BMY) ,2010-05-24 18:10:00-04:00,BMY,positive
177826.0,"Citi Says DMARDs ""Not Immune to Tough Economy"" (JNJ, MRK, BMY, AMGN, ABT)",2010-05-24 14:08:00-04:00,BMY,negative
177827.0,Stocks Under Pressure  05-19-2010,2010-05-19 18:37:00-04:00,BMY,negative
177828.0,Market Jittery  05-19-2010,2010-05-19 16:18:00-04:00,BMY,neutral
177829.0,Traders Sell Out of BMY Calls (BMY),2010-05-19 10:14:00-04:00,BMY,neutral
177830.0,Bristol (BMY) Unfazed By Healthcare Reform ,2010-04-29 15:11:00-04:00,BMY,neutral
177831.0,Bristol Myers Squibb Co. (BMY) Up After Reporting First-Quarter Results,2010-04-29 12:21:00-04:00,BMY,neutral
177832.0,"News Summary (PALM, HPQ, BMY, ORLY)",2010-04-29 10:36:00-04:00,BMY,neutral
177833.0,"Stock Market News for April 29, 2010 - Market News",2010-04-29 09:30:00-04:00,BMY,neutral
177834.0,"Company News for April 29, 2010 - Corporate Summary",2010-04-29 09:30:00-04:00,BMY,neutral
177835.0,"Mad Money Lightning Round: Jim Thinks SD, NVDA, ORA, CVE Are Great Investments",2010-04-16 07:20:00-04:00,BMY,positive
177836.0,Top Stocks of New York,2010-04-14 12:45:00-04:00,BMY,positive
177837.0,"Stock Market News for March 24, 2010 - Market News",2010-03-24 09:45:00-04:00,BMY,neutral
177838.0,Before Jumping Into A Single Health Care Stock Consider This ETF,2010-03-23 23:22:00-04:00,BMY,positive
177839.0,Investors Flock To Healthcare ETFs On Historic Reform,2010-03-22 16:13:00-04:00,BMY,neutral
177840.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,BMY,positive
177841.0,This Healthcare ETF (XLV) Is Seeing Above Average Call Buying,2010-03-17 13:42:00-04:00,BMY,neutral
177842.0,New CEO Appointed For Bristol-Myers (BMY) To Deal With $11 Billion Loss ,2010-03-03 22:38:00-05:00,BMY,negative
177843.0,"Bristol-Myers Signs A Pact With Allergan Inc. (BMY, AGN)",2010-03-03 15:19:00-05:00,BMY,neutral
177844.0,Bristol Myers Squibb And Allergan Enters Into Global Agreement,2010-03-03 08:37:00-05:00,BMY,positive
177845.0,"COO Andreotti Is New Bristol-Myers CEO (BMY, SNY)",2010-03-02 18:47:00-05:00,BMY,neutral
177846.0,"Unusual Movements Expected In These Shares (BAC, BMY, DBRN, MDR, PCG)",2010-03-02 08:45:00-05:00,BMY,positive
177847.0,A Portfolio That Delivers,2010-02-15 21:46:00-05:00,BMY,neutral
177848.0,"Market Round-up (UBS, GOOG¸ AAPL, MOT¸ PG, PFE, MRK, LLY, CVS, WAG)",2010-02-05 14:08:00-05:00,BMY,neutral
177849.0,Merck (MRK) Is A Frontrunner Among Pharma Stocks,2010-02-04 05:25:00-05:00,BMY,neutral
177850.0,Eli Lilly (LLY) Has A Healthy Pipeline : CEO Tells CNBC,2010-01-29 08:09:00-05:00,BMY,positive
177851.0,"Bristol (BMY), Lilly (LLY) Up Sales And Settle Dispute",2010-01-28 11:50:00-05:00,BMY,negative
177852.0,"Company News for January 28, 2010 - Corporate Summary",2010-01-28 09:28:00-05:00,BMY,neutral
177853.0,"Stock Market News for January 28, 2010 - Market News",2010-01-28 09:23:00-05:00,BMY,neutral
177854.0,"Earnings Round-up For Companies Reporting Before The Markets Open (MOT, T, AMZN, MMM, MSFT, MO, BDX, AEP, AZN, BMY, CAH, CEL, C, D, EL)   ",2010-01-28 06:43:00-05:00,BMY,neutral
177855.0,"Jim Cramer Thinks It Is Time To Sell UNH, HUM, RHB",2010-01-23 13:21:00-05:00,BMY,neutral
177856.0,Big Pharma Will Trade On the Following Fundamentals:   Morningstar Says Big Pharma Well Positioned,2010-01-22 13:14:00-05:00,BMY,positive
177857.0,"Short Selling Bets Increased Against Citigroup (C), Apple (AAPL)",2010-01-13 10:04:00-05:00,BMY,positive
177858.0,"Mead Johnson’s Split From BMY Makes It An Attractive Buy (MJN, BMY, GS)",2010-01-05 11:44:00-05:00,BMY,positive
177859.0,BMY Has Cash To Buy Growth,2010-01-05 09:17:00-05:00,BMY,positive
177860.0,Bristol-Myers Squibb Co. (BMY) Gets A Hold Rating,2009-12-28 12:45:00-05:00,BMY,neutral
177861.0,"Stock Futures Point To A Higher Open After Spending Data (MU, RHT, BMY)",2009-12-23 10:28:00-05:00,BMY,neutral
177862.0,Bristol Myers Squibb Co. (NYSE: BMY) Lowers FY09 Guidance ,2009-12-23 09:37:00-05:00,BMY,negative
177863.0,"Company News for December 23, 2009 - Corporate Summary",2009-12-23 09:26:00-05:00,BMY,neutral
177864.0,Walmart (WMT) And Comcast (CMCSA) For 2010,2009-12-22 13:00:00-05:00,BMY,neutral
177865.0,Bristol-Myers (BMY) Replaces CFO Huet,2009-12-14 12:37:00-05:00,BMY,neutral
177866.0,"Benzinga’s News Roundup (C, JAVA, BMY, V, TRA)",2009-12-14 08:29:00-05:00,BMY,neutral
177867.0,"Jim Cramer Is Bullish On UBSI, TRA, NITE, PFE, THS, JPM, BMY",2009-12-10 14:59:00-05:00,BMY,neutral
177868.0,"Most Active Stock Options November 18, 2009 & Trading Activity",2009-11-18 16:01:00-05:00,BMY,positive
177869.0,$ Keystone Morning Quickie,2009-11-17 09:31:00-05:00,BMY,neutral
177870.0,"Company News for November 16, 2009 - Corporate Summary",2009-11-16 09:09:00-05:00,BMY,neutral
177871.0,"Cramer Talks About HLF, BMY, PFE, CELG",2009-11-11 07:46:00-05:00,BMY,neutral
177872.0,"Jim Cramer Names His Best Picks for Cancer Cures (BMY, IMGN, PFE, DNDN, EXEL)",2009-11-09 17:47:00-05:00,BMY,negative
177873.0,BRISTOL MYERS SQUIBB CO (BMY) calls for profit booking around $22-23  ,2009-10-01 08:52:00-04:00,BMY,positive
177874.0,"WallStSense.com Fundamental & Technical Coverage of CRM, TRH, ADP, CNQ, BMY and VLO",2009-08-14 06:45:00-04:00,BMY,neutral
